Rank,NCT Number,Title,Acronym,Status,Study Results,Conditions,Interventions,Outcome Measures,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Type,Study Designs,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents,URL
1,NCT03564964,Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease,SUVN-502,Available,No Results Available,Alzheimer Disease|Dementia|Cognition Disorders,Drug: SUVN-502,,Suven Life Sciences Limited,All,"50 Years to 85 Years   (Adult, Older Adult)",,null,Industry,"Expanded Access:Intermediate-size Population""",,EAP1502HT6,null,null,null,21-Jun-18,null,25-Jun-18,,,https://ClinicalTrials.gov/show/NCT03564964
2,NCT03561194,Omegaven Protocol:Intermediate Size Patient Population,,Available,No Results Available,Parenteral Nutrition Associated Liver Disease,Other: Omegaven,,Doctors Hospital at Renaissance,All,22 Weeks to 40 Weeks   (Child),,null,Other,"Expanded Access:Intermediate-size Population""",,2,null,null,null,19-Jun-18,null,19-Jun-18,,,https://ClinicalTrials.gov/show/NCT03561194
3,NCT03559686,Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA),,Available,No Results Available,Rheumatoid Arthritis,Drug: Certolizumab Pegol,,UCB Biopharma S.P.R.L.|UCB Pharma,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,RA0039,null,null,null,18-Jun-18,null,18-Jun-18,,,https://ClinicalTrials.gov/show/NCT03559686
4,NCT03559673,Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures,,Available,No Results Available,"Epilepsies, Partial",Drug: Lacosamide,,UCB Biopharma S.P.R.L.|UCB Pharma,All,"16 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,EP0072,null,null,null,18-Jun-18,null,18-Jun-18,,,https://ClinicalTrials.gov/show/NCT03559673
5,NCT03559660,CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD),,Available,No Results Available,Crohn's Disease,Drug: Certolizumab Pegol,,UCB Biopharma S.P.R.L.|UCB Pharma,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,C87092,null,null,null,18-Jun-18,null,18-Jun-18,,,https://ClinicalTrials.gov/show/NCT03559660
6,NCT03544060,Volanesorsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS),,Available,No Results Available,Familial Chylomicronemia,Drug: Volanesorsen,,"Akcea Therapeutics|CaligorRx, Inc.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry|Other,"Expanded Access:Individual Patients""",,ISIS 304801,null,null,null,1-Jun-18,null,1-Jun-18,,,https://ClinicalTrials.gov/show/NCT03544060
7,NCT03539393,Expanded Access Program for Patients With Migraine,,Available,No Results Available,Migraine|Cluster Headache,Drug: Fremanezumab,,"Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries",All,"18 Years to 70 Years   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,TV48125-CNS-80005,null,null,null,28-May-18,null,28-May-18,,,https://ClinicalTrials.gov/show/NCT03539393
8,NCT03539380,TRx0237 for the Treatment of Mild-Moderate Alzheimer's Disease,,Available,No Results Available,Alzheimer Disease,Drug: TRx0237,,TauRx Therapeutics Ltd,All,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,TRx-237-040,null,null,null,28-May-18,null,28-May-18,,,https://ClinicalTrials.gov/show/NCT03539380
9,NCT03537807,Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS),,Available,No Results Available,"Amyotrophic Lateral Sclerosis|ALS|Lou Gehrig Disease|Lou Gehrig's Disease|Lou-Gehrigs Disease|Motor Neuron Disease, Amyotrophic Lateral Sclerosis",Drug: Riluzole,,"Biohaven Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,BHV0223-401,null,null,null,25-May-18,null,7-Jun-18,,,https://ClinicalTrials.gov/show/NCT03537807
10,NCT03533361,Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil,,Approved for marketing,No Results Available,Thyroid Cancer,Drug: Lenvatinib,,Eisai Inc.,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,E7080-M001-603,null,null,null,23-May-18,null,23-May-18,"Hospital Sirio Libanes, Sao Paulo, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03533361
11,NCT03532516,Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy,,Available,No Results Available,Epilepsy,Drug: Brivaracetam,,UCB Biopharma S.P.R.L.|UCB Pharma,All,"16 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,N01317,null,null,null,22-May-18,null,22-May-18,,,https://ClinicalTrials.gov/show/NCT03532516
12,NCT03503890,Expanded Access to Rovalpituzumab Tesirine,,Available,No Results Available,Small Cell Lung Cancer,Drug: rovalpituzumab tesirine,,AbbVie,All,"18 Years to 99 Years   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients|Intermediate-size Population""",,C18-915,null,null,null,20-Apr-18,null,12-Jun-18,,,https://ClinicalTrials.gov/show/NCT03503890
13,NCT03501940,F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer,,Available,No Results Available,Prostate Adenocarcinoma|PSA Level Greater Than 0.2|PSA Level Greater Than or Equal to Two|PSA Progression|Recurrent Prostate Carcinoma,Procedure: Computed Tomography|Radiation: Fluorine F 18 DCFPyL|Other: Laboratory Biomarker Analysis|Procedure: Positron Emission Tomography,,Andrei Iagaru|Stanford University,All,"18 Years and older   (Adult, Older Adult)",,null,Other,"Expanded Access:Intermediate-size Population""",,PROS0083|NCI-2018-00479|IRB-42701,null,null,null,18-Apr-18,null,4-Jun-18,"Stanford Cancer Institute Palo Alto, Palo Alto, California, United States",,https://ClinicalTrials.gov/show/NCT03501940
14,NCT03501615,An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia,MOXE,Available,No Results Available,Relapsed/Refractory Hairy Cell Leukemia,Drug: Moxetumomab Pasudotox,,AstraZeneca,All,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,D3143R00002,null,null,null,18-Apr-18,null,18-Apr-18,,,https://ClinicalTrials.gov/show/NCT03501615
15,NCT03493165,"Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)",,Available,No Results Available,,Drug: Everolimus,,The University of Texas Health Science Center at San Antonio,Female,"18 Years and older   (Adult, Older Adult)",,null,Other,"Expanded Access:Individual Patients""",,CTMS# 18-0020,null,null,null,10-Apr-18,null,10-Apr-18,,,https://ClinicalTrials.gov/show/NCT03493165
16,NCT03493152,"Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)",,Available,No Results Available,Gastrointestinal Stromal Tumor,Drug: Everolimus,,The University of Texas Health Science Center at San Antonio,Female,"18 Years and older   (Adult, Older Adult)",,null,Other,"Expanded Access:Individual Patients""",,CTMS# 18-0019,null,null,null,10-Apr-18,null,10-Apr-18,,,https://ClinicalTrials.gov/show/NCT03493152
17,NCT03492489,Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma,,Available,No Results Available,Cutaneous Squamous Cell Carcinoma,Drug: cemiplimab,,Regeneron Pharmaceuticals|Sanofi,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Intermediate-size Population|Treatment IND/Protocol""",,R2810-ONC-17103,null,null,null,10-Apr-18,null,25-Apr-18,,,https://ClinicalTrials.gov/show/NCT03492489
18,NCT03462810,"GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV",,Available,No Results Available,"Infection, Human Immunodeficiency Virus","Drug: cabotegravir, CAB",,ViiV Healthcare,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,205741,null,null,null,13-Mar-18,null,13-Mar-18,"GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Bellaire, Texas, United States|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Colombes, France|GSK Investigational Site, Setúbal, Portugal|GSK Investigational Site, Zurich, Switzerland|GSK Investigational Site, Tooting, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT03462810
19,NCT03439475,AMG 714 Expanded Access Program,,Available,No Results Available,,Biological: AMG 714,,Amgen,null,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,AMG714 Expanded Access Program,null,null,null,20-Feb-18,null,22-Feb-18,,,https://ClinicalTrials.gov/show/NCT03439475
20,NCT03433807,Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD),,Available,No Results Available,Duchenne Muscular Dystrophy,Drug: Idebenone,,Santhera Pharmaceuticals,All,"10 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Intermediate-size Population""",,SNT-EAP-002,null,null,null,15-Feb-18,null,15-Feb-18,,,https://ClinicalTrials.gov/show/NCT03433807
21,NCT03433131,Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy,,Available,No Results Available,Narcolepsy Without Cataplexy|Narcolepsy With Cataplexy,Drug: Pitolisant,,"Harmony Biosciences, LLC",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,HBS-101-CL-001,null,null,null,14-Feb-18,null,9-May-18,"Sleep Disorders Center of Alabama, Birmingham, Alabama, United States|Sleep Medicine Specialists of California, San Ramon, California, United States|NeuroTrials Research Center, Atlanta, Georgia, United States|The Neurological Center of North Georgia, Gainesville, Georgia, United States|Montefiore Medical Center, Bronx, New York, United States|Ohio Sleep Medicine Institute, Dublin, Ohio, United States|Bogan Sleep Consultants, Columbia, South Carolina, United States|Sleep Medicine Associates of Texas, Dallas, Texas, United States|Houston Neurology & Sleep Center, Houston, Texas, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03433131
22,NCT03420430,Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care,,Available,No Results Available,Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)|Acute Myeloid Leukemia (6 Patients),Biological: GL-ONC1,,Genelux Corporation,All,"21 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,GL-ONC1-021,null,null,null,2-Feb-18,null,2-Feb-18,"Florida Hospital Cancer Institute, Orlando, Florida, United States",,https://ClinicalTrials.gov/show/NCT03420430
23,NCT03419949,Comparison of Oral Lamotrigine and Oral Pregabalin for Control of Acute and Chronic Pain,,Available,No Results Available,Acute and Chronic Pain Following Modified Radical Mastectomy,Drug: oral lamotrigine 100 mg|Drug: oral pregabalin 150 mg,,Assiut University,Female,18 Years to 60 Years   (Adult),,null,Other,"Expanded Access:Individual Patients""",,Comparison of oral lamotrigine,null,null,null,2-Feb-18,null,6-Feb-18,"Salma Komy, Assiut, Egypt",,https://ClinicalTrials.gov/show/NCT03419949
24,NCT03414489,Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®),,Available,No Results Available,"Cholangiocarcinoma|Cholangiocarcinoma Non-resectable|Cholangiocarcinoma, Perihilar|Cholangiocarcinoma, Extrahepatic|Cholangiocarcinoma, Intrahepatic",Drug: ABC294640,,RedHill Biopharma Limited,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,ABC-108-EA,null,null,null,30-Jan-18,null,30-Jan-18,,,https://ClinicalTrials.gov/show/NCT03414489
25,NCT03412539,Mechanism of Effectiveness of Neurosurgery Treatments for Durable Pain,,Available,No Results Available,Oncology Problem,,,Tel-Aviv Sourasky Medical Center|University of Haifa,All,"18 Years to 90 Years   (Adult, Older Adult)",,null,Other,"Expanded Access:Individual Patients""",,TASMC-0354-17-TLV,null,null,null,26-Jan-18,null,26-Jan-18,"Neurosurgery, Tel-Aviv Sourasky MC, Tel Aviv, Israel",,https://ClinicalTrials.gov/show/NCT03412539
26,NCT03409081,Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD),,Available,No Results Available,Acute Myeloid Leukemia (AML)|FMS-like Tyrosine Kinase-3 (FLT3) Mutations,Drug: gilteritinib,,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,2215-CL-9200,null,null,null,24-Jan-18,null,8-May-18,,,https://ClinicalTrials.gov/show/NCT03409081
27,NCT03400098,ATTR Expanded Access Program (EAP) by Ionis,,Available,No Results Available,"Amyloidosis, Hereditary",Drug: Inotersen,,"Ionis Pharmaceuticals, Inc.|Clinigen Group PLC",All,"18 Years and older   (Adult, Older Adult)",,null,Industry|Other,"Expanded Access:Treatment IND/Protocol""",,ISIS 420915-CS5,null,null,null,17-Jan-18,null,12-Jun-18,"Mayo Clinic Cancer Center, Scottsdale, Arizona, United States|University of California - Irvine, Irvine, California, United States|Cedars-Sinai, Los Angeles, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|SC3 Research - Pasadena, Pasadena, California, United States|University of California - San Francisco, San Francisco, California, United States|Mayo Clinic Cancer Center, Jacksonville, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Northwestern University, Evanston, Illinois, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|The Neurological Institute at Columbia University Medical Center, New York, New York, United States|University of North Carolina - Chapel Hill, Department of Neurology, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Oregon Health and Science University, Knight Cardiovascular Institute, Portland, Oregon, United States|Penn Presbyterian Medical Center - University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Physicians, Department of Neurology, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT03400098
28,NCT03395769,"Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic",,Available,No Results Available,,Biological: AB-SA01,,AmpliPhi Biosciences Corporation,null,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,AB-SA01-EAP01,null,null,null,10-Jan-18,null,10-Jan-18,,,https://ClinicalTrials.gov/show/NCT03395769
29,NCT03395743,"Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic",,Available,No Results Available,,Biological: AB-PA01,,AmpliPhi Biosciences Corporation,null,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,AB-PA01-EAP01,null,null,null,10-Jan-18,null,10-Jan-18,,,https://ClinicalTrials.gov/show/NCT03395743
30,NCT03386071,Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib,,Available,No Results Available,Progressive Metastatic Castrate Resistant Prostate Cancer,Drug: Trametinib 2 mg,,Jonsson Comprehensive Cancer Center|Novartis,Male,"18 Years and older   (Adult, Older Adult)",,null,Other|Industry,"Expanded Access:Individual Patients""",,17-001886|Compassionate Use Trametinib,null,null,null,29-Dec-17,null,4-Jan-18,,,https://ClinicalTrials.gov/show/NCT03386071
31,NCT03363334,Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP,,Approved for marketing,No Results Available,Immune Thrombocytopenic Purpura,Drug: Fostamatinib disodium 100 mg|Drug: Fostamatinib disodium 150 mg,,Rigel Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Intermediate-size Population""",,C-935788-055,null,null,null,6-Dec-17,null,21-Jun-18,,,https://ClinicalTrials.gov/show/NCT03363334
32,NCT03362736,An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease,,Available,No Results Available,Crohn Disease,Drug: Ustekinumab,,"Janssen Research & Development, LLC",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CR108395|CNTO1275CRD3006,null,null,null,5-Dec-17,null,19-Apr-18,"Hospital Nossa Senhora Das Gracas, Curitiba, Brazil|Endogastro Clínica de Gastroenterologia e Endoscopia Digestiva Lida, Juiz De Fora, Brazil|Instituto do Aparelho Digestivo, Porto Alegre, Brazil|Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo, Ribeirão Preto, Brazil|UFRJ-Hospital Universitário Clementino Fraga Filho, Rio De Janeiro, Brazil|Hospital Copa D'Or, Rio De Janeiro, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da USP, São Paulo, Brazil|Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein, São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT03362736
33,NCT03327467,Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries,,Available,No Results Available,"Autism Spectrum Disorder|Autism|Cerebral Palsy|Hydrocephalus|Apraxia of Speech|Hypoxia Ischemia, Cerebral|Drowning; Anoxia",Biological: Cord Blood Infusion,,"Joanne Kurtzberg, MD|Duke University",All,"up to 18 Years   (Child, Adult)",,null,Other,"Expanded Access:Treatment IND/Protocol""",,Pro00083888,null,null,null,31-Oct-17,null,16-Mar-18,,,https://ClinicalTrials.gov/show/NCT03327467
34,NCT03317366,Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies,,Available,No Results Available,Proteus Syndrome|PIK3CA-Related Overgrowth Spectrum (PROS)|Growth Disorders,Drug: ARQ 092,,ArQule,All,"2 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,ARQ 092 Expanded Access,null,null,null,23-Oct-17,null,23-Oct-17,,,https://ClinicalTrials.gov/show/NCT03317366
35,NCT03278314,Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis,,Available,No Results Available,Cystic Fibrosis,Drug: tezacaftor/ivacaftor,,Vertex Pharmaceuticals Incorporated,All,"12 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,VX17-661-901,null,null,null,11-Sep-17,null,11-Sep-17,,,https://ClinicalTrials.gov/show/NCT03278314
36,NCT03265171,A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous,,Available,No Results Available,Hypoplasminogenemia,Biological: Plasminogen (Human),,"ProMetic BioTherapeutics, Inc|Cedars-Sinai Medical Center|Vanderbilt University Medical Center",All,"16 Months and older   (Child, Adult, Older Adult)",,null,Industry|Other,"Expanded Access:Individual Patients""",,2002C013G,null,null,null,29-Aug-17,null,29-Aug-17,,,https://ClinicalTrials.gov/show/NCT03265171
37,NCT03259633,An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1,,Available,No Results Available,NF type1 With Inoperable Plexiform Neurofibromas,Drug: Selumetinib,,AstraZeneca,All,"2 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Intermediate-size Population""",,D1346R00002,null,null,null,24-Aug-17,null,8-Jun-18,"Research Site, Birmingham, Alabama, United States|Research Site, Sacramento, California, United States|Research Site, San Francisco, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Hartford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Indianapolis, Indiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Albany, New York, United States|Research Site, Bronx, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Memphis, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Madison, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT03259633
38,NCT03245528,Expanded Access for LJPC-501,,Approved for marketing,No Results Available,Catecholamine Resistant Hypotension (CRH)|Distributive Shock|High Output Shock|Sepsis|Vasodilatory Shock,Drug: LJPC-501,,La Jolla Pharmaceutical Company,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,LJ501-EAP01,null,null,null,10-Aug-17,null,8-Mar-18,,,https://ClinicalTrials.gov/show/NCT03245528
39,NCT03245424,Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation,,Available,No Results Available,Acute Myeloid Leukemia|Relapsed Adult AML|Relapsed Pediatric AML,Drug: ivosidenib (AG-120),,"Agios Pharmaceuticals, Inc.",All,"12 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,AG120-C-010,null,null,null,10-Aug-17,null,23-Feb-18,,,https://ClinicalTrials.gov/show/NCT03245424
40,NCT03206931,Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion,,Available,No Results Available,"Cancer|Neurotrophic Tyrosine Kinase, Receptor-related Proteins",Drug: LOXO-195,,"Loxo Oncology, Inc.|Bayer",All,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,LOXO-195 EAP,null,null,null,2-Jul-17,null,1-Mar-18,,,https://ClinicalTrials.gov/show/NCT03206931
41,NCT03196934,Expanded Use of Cannabidiol Oral Solution,,Available,No Results Available,Refractory Epilepsy,Drug: Cannabidiol oral solution,,Steven Phillips|MultiCare Health System Research Institute,All,"1 Year to 18 Years   (Child, Adult)",,null,Other,"Expanded Access:Intermediate-size Population""",,MulticareHSRI,null,null,null,23-Jun-17,null,23-Jun-17,,,https://ClinicalTrials.gov/show/NCT03196934
42,NCT03178071,Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive,,Available,No Results Available,Non Small Cell Lung Cancer ALK Positive or ROS1 Positive,Drug: Lorlatinib,,Pfizer,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,B7461020,null,null,null,6-Jun-17,null,19-Jun-18,"Arizona Oncology Associates, PC - HAL, Sedona, Arizona, United States|Arizona Oncology Associates, PC - NAHOA, Sedona, Arizona, United States|Pacific Shores Medical Group, Huntington Beach, California, United States|Pacific Shores Medical Group, Irvine, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Kaiser Permanente, Oakland Medical Center, Oakland, California, United States|Chao Comprehensive Cancer Center, University of California Irvine, Orange, California, United States|Chao Comprehensive Cancer Center, Orange, California, United States|Kaiser Permanente, South Sacramento Medical Center, Sacramento, California, United States|Kaiser Permanente, San Francisco Medical Center, San Francisco, California, United States|Kaiser Permanente, Vallejo Medical Center, Vallejo, California, United States|Memorial Healthcare System/Memorial Cancer, Pembroke Pines, Florida, United States|The University of Chicago Medicine, Chicago, Illinois, United States|University of Chicago Medical Center, CCD, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Lawrence and Idell Weisberg Cancer Treatment Center (Weisberg), Farmington Hills, Michigan, United States|Robert Wood Johnson University Hospital,, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of NJ, New Brunswick, New Jersey, United States|University of Rochester, Rochester, New York, United States|The Ohio State University, Columbus, Ohio, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03178071
43,NCT03177005,Expanded Access for Hereditary Angioedema (HAE),,Approved for marketing,No Results Available,,Biological: CSL830,,"Joshua S. Jacobs, MD|CSL Behring",null,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,CSL830,null,null,null,6-Jun-17,null,31-Jul-17,,,https://ClinicalTrials.gov/show/NCT03177005
44,NCT03172455,Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT),,Available,No Results Available,SR aGvHD|Acute-graft-versus-host Disease|Steroid Refractory Acute Graft Versus Host Disease|Graft-versus-host-disease|Graft Vs Host Disease|Alpha 1-Antitrypsin Deficiency|Alpha-1 Proteinase Inhibitor|Alpha-1 Protease Inhibitor Deficiency|Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant,Drug: Glassia,,"Impatients N.V. trading as myTomorrows|Kamada, Ltd.",All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,2017-AATGLAKAM-EU,null,null,null,1-Jun-17,null,1-Jun-17,,,https://ClinicalTrials.gov/show/NCT03172455
45,NCT03154437,An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors,,Approved for marketing,No Results Available,Hemophilia A,Biological: Emicizumab,,"Genentech, Inc.",All,"12 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,ML39356,null,null,null,16-May-17,null,29-Mar-18,"University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Rush Medical Center, Chicago, Illinois, United States|Tulane Medical Center; Investigational/Research Pharmacy, New Orleans, Louisiana, United States|Boston Childrens Hospital, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hosp Clinics, Kansas City, Missouri, United States|Barnabas Health Newark Beth Israel Medical Center - Pulmonary Hypertension & Lung Transplant Program, Newark, New Jersey, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|University of Texas Southwestern Medical Center - Children's Medical Center Dallas, Dallas, Texas, United States|University of Texas Medical School, Houston, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT03154437
46,NCT03153462,Axicabtagene Ciloleucel Expanded Access Study,ZUMA-9,Available,No Results Available,Relapsed/Refractory Diffuse Large B Cell Lymphoma|Relapsed/Refractory Primary Mediastinal B Cell Lymphoma|Relapsed/Refractory Transformed Follicular Lymphoma|Relapsed/Refractory High-Grade B-Cell Lymphoma,Biological: Axicabtagene Ciloleucel,,"Kite, A Gilead Company",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,KTE-C19-109,null,null,null,15-May-17,null,30-May-18,"Stanford Cancer Institute, Stanford, California, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT03153462
47,NCT03147742,An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant,,Available,No Results Available,Graft-versus-host Disease (GVHD),Drug: Ruxolitinib,,Incyte Corporation,All,"12 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Intermediate-size Population""",,INCB 18424-MA-GD-301,null,null,null,10-May-17,null,5-Jul-17,,,https://ClinicalTrials.gov/show/NCT03147742
48,NCT03145545,Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC,,Available,No Results Available,Leukemia|Bone Marrow Failure Syndrome|Immunodeficiencies,Device: Apha/beta T and CD19+ cell depletion using CliniMACS device,,Children's Hospital of Philadelphia,All,"1 Month and older   (Child, Adult, Older Adult)",,null,Other,"Expanded Access:Treatment IND/Protocol""",,16-013527,null,null,null,9-May-17,null,18-Jun-18,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT03145545
49,NCT03138629,Expanded Access to VAL-083,,Available,No Results Available,Cancer,Drug: VAL-083,,"DelMar Pharmaceuticals, Inc.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients|Intermediate-size Population""",,DLM-17-002,null,null,null,3-May-17,null,3-May-17,,,https://ClinicalTrials.gov/show/NCT03138629
50,NCT03133988,Margetuximab Expanded Access Program,,Available,No Results Available,HER2-positive Breast Cancer|Neoplasm Metastasis|HER2-positive Carcinoma,,,MacroGenics,null,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,MGAH22-EA,null,null,null,28-Apr-17,null,26-Jun-17,,,https://ClinicalTrials.gov/show/NCT03133988
51,NCT03127618,Lorlatinib - PF-06463922,,Available,No Results Available,,Drug: Lorlatinib,,Pfizer,null,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,B746,null,null,null,25-Apr-17,null,18-Jul-17,,,https://ClinicalTrials.gov/show/NCT03127618
52,NCT03127605,Inotuzumab Ozogamicin - PF-05208773,,Available,No Results Available,,Drug: Inotuzumab Ozogamicin,,Pfizer,null,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,B193,null,null,null,25-Apr-17,null,25-Apr-17,,,https://ClinicalTrials.gov/show/NCT03127605
53,NCT03126643,Expanded Access to Nivolumab (Opdivo),,Available,No Results Available,Pediatric Cancer,Biological: Nivolumab,,Bristol-Myers Squibb,All,up to 17 Years   (Child),,null,Industry,"Expanded Access:Individual Patients""",,EAP-01-CA209,null,null,null,24-Apr-17,null,20-Jun-18,,,https://ClinicalTrials.gov/show/NCT03126643
54,NCT03126617,Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma,,Available,No Results Available,Multiple Myeloma,Biological: Elotuzumab,,Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,EAP-01-CA204,null,null,null,24-Apr-17,null,27-Jun-18,,,https://ClinicalTrials.gov/show/NCT03126617
55,NCT03123965,Expanded Access to Glecaprevir/ Pibrentasvir,,Available,No Results Available,Hepatitis C Virus Infection,Drug: glecaprevir|Drug: pibrentasvir,,AbbVie,null,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,C16-563,null,null,null,21-Apr-17,null,14-Mar-18,,,https://ClinicalTrials.gov/show/NCT03123965
56,NCT03123952,Expanded Access to ABT-414,,Available,No Results Available,Cancer,Drug: ABT-414,,AbbVie,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients|Intermediate-size Population""",,C16-478,null,null,null,21-Apr-17,null,14-Mar-18,,,https://ClinicalTrials.gov/show/NCT03123952
57,NCT03123939,Expanded Treatment Protocol in Acute Lymphoblastic Leukemia,,Available,No Results Available,Acute Lymphoblastic Leukemia,Genetic: CTL019,,Novartis Pharmaceuticals|Novartis,All,"3 Years to 21 Years   (Child, Adult)",,null,Industry,Expanded Access,,CCTL019B2001X|2016-001991-31,null,null,null,21-Apr-17,null,3-Aug-17,"Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Esplugues de Llobregat, Barcelona, Spain",,https://ClinicalTrials.gov/show/NCT03123939
58,NCT03123211,Expanded Access to Veliparib,,Available,No Results Available,Cancer,Drug: Veliparib,,AbbVie,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients|Intermediate-size Population""",,C16-468,null,null,null,21-Apr-17,null,14-Mar-18,,,https://ClinicalTrials.gov/show/NCT03123211
59,NCT03123029,Expanded Access to Venetoclax,,Available,No Results Available,Chronic Lymphocytic Leukemia (CLL)|Multiple Myeloma|Acute Myeloid Leukemia (AML)|Non-Hodgkin's Lymphoma,Drug: Venetoclax,,AbbVie,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Individual Patients""",,C16-431,null,null,null,21-Apr-17,null,14-Mar-18,,,https://ClinicalTrials.gov/show/NCT03123029
60,NCT03089658,Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC),,Available,No Results Available,Metastatic Merkel Cell Carcinoma,Drug: Avelumab,,Merck KGaA|Pfizer,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,MS100070_0308,null,null,null,24-Mar-17,null,9-Aug-17,"Avelumab ATU Unit, Lyon, France",,https://ClinicalTrials.gov/show/NCT03089658
61,NCT03079687,"Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",,Approved for marketing,No Results Available,Ovarian Cancer,Drug: Olaparib tablets,,AstraZeneca|Parexel,Female,"18 Years to 120 Years   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,D0816R00014,null,null,null,14-Mar-17,null,25-Oct-17,"Research Site, Duarte, California, United States|Research Site, Newport Beach, California, United States|Research Site, Roseville, California, United States|Research Site, Gainesville, Florida, United States|Research Site, Scarborough, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rochester, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT03079687
62,NCT03072667,Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease,,Available,No Results Available,Cholestasis|Liver Diseases,Drug: Omegaven,,"Catherine Cibulskis, MD|St. Louis University",All,up to 1 Year   (Child),,null,Other,"Expanded Access:Individual Patients|Treatment IND/Protocol""",,16150,null,null,null,7-Mar-17,null,14-Mar-18,"SSM Health Cardinal Glennon Children's Hospital, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT03072667
63,NCT03070093,Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD),,Available,No Results Available,Acute Myeloid Leukemia (AML)|FMS-like Tyrosine Kinase-3 (FLT3) Mutations,Drug: gilteritinib,,"Astellas Pharma Global Development, Inc.|Astellas Pharma Inc",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,2215-CL-9100,null,null,null,3-Mar-17,null,21-Jun-18,"UCLA, Los Angeles, California, United States|Memorial Healthcare System, Pembroke Pines, Florida, United States|Georgia Cancer Center at Augusta University, Augusta, Georgia, United States|Northwestern University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Tulane University, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|West Michigan Regional Cancer Center, Kalamazoo, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Huntsman Cancer Institute University of Utah, Salt Lake City, Utah, United States|WVU Medicine Cancer, Morgantown, West Virginia, United States|Site CA15002, Halifax, Nova Scotia, Canada|Site CA15003, Toronto, Ontario, Canada|Site CA15001, Montreal, Quebec, Canada|Site JP81001, Naka-ku, Japan|Site JP81002, Tokyo, Japan",,https://ClinicalTrials.gov/show/NCT03070093
64,NCT03062631,"Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome",,Available,No Results Available,Congenital Myasthenic Syndrome|Lambert-Eaton Myasthenic Syndrome,"Drug: 3,4-Diaminopyridine",,"Ricardo Maselli|Jacobus Pharmaceutical|University of California, Davis",All,"3 Months to 75 Years   (Child, Adult, Older Adult)",,null,Other|Industry,"Expanded Access:Individual Patients|Treatment IND/Protocol""",,223019,null,null,null,23-Feb-17,null,23-May-18,"University of California, Davis Medical Center, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT03062631
65,NCT03029481,Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma,,Available,No Results Available,Ewing Sarcoma,Drug: Ganitumab,,"Jonsson Comprehensive Cancer Center|NantCell, Inc.",All,48 Years to 50 Years   (Adult),,null,Other|Industry,"Expanded Access:Individual Patients|Treatment IND/Protocol""",,17-000019|JCCCID738,null,null,null,24-Jan-17,null,22-Feb-18,,,https://ClinicalTrials.gov/show/NCT03029481
66,NCT03025867,Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer,,Approved for marketing,No Results Available,Recurrent Ovarian Cancer,Drug: Niraparib,,"Tesaro, Inc.",Female,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,3000-07-001,null,null,null,20-Jan-17,null,17-Apr-17,,,https://ClinicalTrials.gov/show/NCT03025867
67,NCT03025360,Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion,,Available,No Results Available,"Cancer|Neurotrophic Tyrosine Kinase, Receptor-related Proteins",Drug: larotrectinib,,"Loxo Oncology, Inc.|Bayer",All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,Larotrectinib (LOXO-101) EAP,null,null,null,19-Jan-17,null,28-Feb-18,,,https://ClinicalTrials.gov/show/NCT03025360
68,NCT03020810,Dupilumab Compassionate Use Study,,Approved for marketing,No Results Available,Asthma,Drug: Dupilumab,,Sally E. Wenzel MD|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,PRO16120334,null,null,null,13-Jan-17,null,7-Mar-18,,,https://ClinicalTrials.gov/show/NCT03020810
69,NCT03015844,A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma,,Available,No Results Available,Neuroblastoma|Pheochromocytoma,Drug: 131-I-meta-iodobenzylguanidine,,Northwell Health|Cohen Children's Medical Center,All,"365 Days to 29 Years   (Child, Adult)",,null,Other,Expanded Access,,CCMC1611,null,null,null,10-Jan-17,null,31-Jan-18,"Cohen Children's Medical Center, New Hyde Park, New York, United States",,https://ClinicalTrials.gov/show/NCT03015844
70,NCT02985658,Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,,Available,No Results Available,Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation|Triple-Negative Breast Cancer,Drug: Veliparib|Drug: Cisplatin|Drug: Vinorelbine,,University of Washington|AbbVie,Female,"18 Years and older   (Adult, Older Adult)",,null,Other|Industry,Expanded Access,,9763,null,null,null,7-Dec-16,null,26-Oct-17,"Seattle Cancer Care Allliance, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02985658
71,NCT02969174,Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.,,Approved for marketing,No Results Available,HDFN,"Other: zimin Lu,Guo Sa",,"Shanghai Tongji Hospital, Tongji University School of Medicine",All,12 Weeks to 38 Weeks   (Child),,null,Other,Expanded Access,,ShangjiTongjiHsxk,null,null,null,21-Nov-16,null,21-Nov-16,,,https://ClinicalTrials.gov/show/NCT02969174
72,NCT02963350,"A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease",,Approved for marketing,No Results Available,CLN2 Disease,"Drug: BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)",,BioMarin Pharmaceutical,All,"2 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,190-502,null,null,null,15-Nov-16,null,24-Jul-17,"Orange, California, United States|Columbus, Ohio, United States|Hamburg, Germany|Rome, Italy|London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02963350
73,NCT02961491,Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma,,Available,No Results Available,Pheochromocytoma|Paraganglioma,Drug: Ultratrace Iobenguane I131,,"Molecular Insight Pharmaceuticals, Inc.",All,"12 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,MIP-IB12B-EAP,null,null,null,11-Nov-16,null,5-Oct-17,"University of Iowa, Iowa City, Iowa, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02961491
74,NCT02960620,Therasphere for Unresectable Primary or Secondary Liver Neoplasia,,Available,No Results Available,Liver Cancer|Liver Neoplasms|HepatoCellular Carcinoma,Device: TheraSphere Treatment,,H. Lee Moffitt Cancer Center and Research Institute|Biocompatibles UK Ltd|BTG International Inc.,All,"18 Years and older   (Adult, Older Adult)",,null,Other|Industry,Expanded Access,,MCC-15789,null,null,null,9-Nov-16,null,27-Feb-18,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",,https://ClinicalTrials.gov/show/NCT02960620
75,NCT02939820,Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR),,Available,No Results Available,"TTR-mediated Amyloidosis|Amyloidosis, Hereditary|Amyloid Neuropathies, Familial|Familial Amyloid Polyneuropathies|Amyloid Neuropathies|Amyloidosis, Hereditary, Transthyretin-Related",Drug: patisiran (ALN-TTR02),,Alnylam Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,ALN-TTR02-007,null,null,null,20-Oct-16,null,6-Jun-18,"Kaiser Permanente, Oakland, California, United States|Stanford University, Stanford, California, United States|MedStar Washington Hospital, Washington, District of Columbia, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Northwestern University, Evanston, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Johns Hopkins Medical Center, Baltimore, Maryland, United States|Boston University Medical Center, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Seton Family of Hospitals, Austin, Texas, United States|Baylor, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02939820
76,NCT02937467,The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules,,Available,No Results Available,Thyroid Nodules,Device: SWE,,Beijing Cancer Hospital|Shanghai 10th People's Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,SHSY-IEC-3.0/15-78/01,Dec-16,Dec-17,Dec-18,18-Oct-16,null,18-Oct-16,,,https://ClinicalTrials.gov/show/NCT02937467
77,NCT02934282,HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option,,Available,No Results Available,Anemia,Drug: HBOC-201,,University of Miami,All,"18 Years to 80 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,20160819,null,null,null,14-Oct-16,null,18-Apr-18,,,https://ClinicalTrials.gov/show/NCT02934282
78,NCT02929303,Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD,,Available,No Results Available,Total Parenteral Nutrition-induced Cholestasis,Drug: Omegaven IV lipid emulsion,,Hector Hernandez|Advocate Health Care,All,up to 17 Years   (Child),,null,Other,Expanded Access,,K5900315,null,null,null,11-Oct-16,null,19-Feb-18,"Advocate Children's Hospital, Park Ridge, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02929303
79,NCT02925520,Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children,,Available,No Results Available,Parenteral Nutrition-Associated Liver Disease,Drug: Omegaven,,Cook Children's Health Care System,All,up to 5 Years   (Child),,null,Other,Expanded Access,,2016-059,null,null,null,6-Oct-16,null,21-Dec-17,"Cook Children's Medical Center, Fort Worth, Texas, United States",,https://ClinicalTrials.gov/show/NCT02925520
80,NCT02889445,A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers,,Available,No Results Available,Advanced Cancer,Drug: 4-Demethyl-4-cholesteryloxycarbonylpenclomedine,,"DEKK-TEC, Inc.",All,"15 Years to 39 Years   (Child, Adult)",,null,Industry,Expanded Access,,DTI-024,null,null,null,5-Sep-16,null,21-Nov-17,"Detroit Clinical Research Centers, Detroit, Michigan, United States",,https://ClinicalTrials.gov/show/NCT02889445
81,NCT02883309,Efficacy of an Intradialysis Combined Training Program on Disability Level and Physical Performance.,PTH-CKD0113,Approved for marketing,No Results Available,Chronic Renal Failure,Other: intradialytic physical training program,,Universidad Austral de Chile|Nephrocare Portugal,All,"50 Years to 80 Years   (Adult, Older Adult)",,null,Other|Industry,Expanded Access,,Universidad Austral de Chile|33-2013,Nov-13,Jan-14,Mar-14,30-Aug-16,null,30-Sep-16,,,https://ClinicalTrials.gov/show/NCT02883309
82,NCT02865109,Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA),,Available,No Results Available,Infantile-onset Spinal Muscular Atrophy,Drug: nusinersen,,Biogen,All,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,232-SM-901,null,null,null,12-Aug-16,null,19-Jun-18,"Sydney Children's Hospital, Randwick, New South Wales, Australia|Lady Cilento Children's Hospital, Brisbane, Queensland, Australia|The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia|Princess Margaret Hospital, Subiaco, Western Australia, Australia|Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan, Province OF China, China|National Taiwan University Hospital, Taipei, Taipei City, Taiwan, Province OF China, China|Kyungpook National University Chilgok Hospital, Daegu Metropolital City, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Hospital Infantil de Mexico Federico Gomez, Mexico city, Mexico|Apotheek - UMC Utrecht, Utrecht, Netherlands|Upper Silesian Child Health Centre, Katowice, Silesian, Poland|University Clinical Center in Gdansk, Gdansk, Poland|The Children's Memorial Health Institute, Warsaw, Poland|Doña Estefania Hospital, Lisbon, Lisboa, Portugal|Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal|Centro Hospitalar Lisboa Norte, Lisbon, Portugal|Centro Hospital do Porto, Porto, Portugal|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Ege Universitesi Tip Fakultesi Cocuk Sagligi, Izmir, Anatolia, Turkey|Erciyes University Hospital, Kayseri, Anatolia, Turkey|Hacettepe University, Ankara, Central Anatolia, Turkey|Marmara Uni. Research & Educational Hospital, Kadıköy, Istanbul, Turkey|Medipol University Hospital, Istanbul, Marmara, Turkey|Karadeniz Technical University, Trabzon, Turkey|Royal Victoria Hospital, Belfast City, Belfast, United Kingdom|Sheffield Children's Hospital, Sheffield, South Yorkshire, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, Staffordshire, United Kingdom|The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, Tyne And Wear, United Kingdom|The Leeds Teaching Hospitals, Leeds, Yorkshire, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Alder Hey Childrens Hospital, Liverpool, United Kingdom|Guy's & St Thomas' NHS FT, London, United Kingdom|Great Ormond Street Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02865109
83,NCT02856438,Early Patient Access Treatment Use Protocol CA204-220,,Available,No Results Available,Multiple Myeloma,Drug: Elotuzumab|Drug: Lenalidomide|Drug: Dexamethasone,,Bristol-Myers Squibb|AbbVie,All,"20 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CA204-220,null,null,null,4-Aug-16,null,13-Dec-17,"Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Shibukawa-shi, Gunma, Japan|Local Institution, Osaka-shi, Osaka, Japan",,https://ClinicalTrials.gov/show/NCT02856438
84,NCT02835131,Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia,,Available,No Results Available,Congenital Hyperinsulinism,Drug: Pasireotide,,Montefiore Medical Center,All,"18 Years to 90 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,2015-5564,null,null,null,15-Jul-16,null,3-May-18,"Montefiore Medical Center, Bronx, New York, United States",,https://ClinicalTrials.gov/show/NCT02835131
85,NCT02826395,C11 Sodium Acetate PET/CT Imaging of PCa,,Available,No Results Available,Prostate Cancer,Drug: Carbon-11 Sodium Acetate,,Jonsson Comprehensive Cancer Center,Male,"Child, Adult, Older Adult",,null,Other,Expanded Access,,ACETATE16-000260EA,null,null,null,11-Jul-16,null,16-Jan-18,"200 Medical Plaza, B114, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02826395
86,NCT02822495,Expanded Access Protocol for Tabelecleucel in Subjects With EBV-Associated Viremia or Malignancies,,Available,No Results Available,Epstein-Barr Virus-Associated Lymphoproliferative Disorder|Epstein-Barr Virus Lymphoma|Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorder|Epstein-Barr Virus-Associated Viremia,Biological: tabelecleucel,,Atara Biotherapeutics,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,EBV-CTL-201,null,null,null,4-Jul-16,null,12-Apr-18,"Stanford University Medical Center, Stanford, California, United States|Yale University, New Haven, Connecticut, United States|University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, School of Medicine, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|The Children's Hospital at Montefiore, Bronx, New York, United States|Weill Cornell Medical College, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Ohio State University - Arthur G. James Cancer Center Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02822495
87,NCT02792725,Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer,,Approved for marketing,No Results Available,Metastatic Breast Cancer,Drug: Abemaciclib,,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,16244|I3Y-MC-JPCD,null,null,null,7-Jun-16,null,31-Oct-17,"Pacific Cancer Care, Monterey, California, United States|UCLA Medical Center, Santa Monica, California, United States|Orlando Health, Inc, Orlando, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Minnesota Medical Center, Fairview Lakes, Wyoming, Minnesota, United States|Saint Luke's Cancer Institute, Kansas City, Missouri, United States|Memorial Sloan Kettering Cancer Center, Commack, New York, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|West Virginia University Hospital, Morgantown, West Virginia, United States",,https://ClinicalTrials.gov/show/NCT02792725
88,NCT02780193,Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury,,Available,No Results Available,Cholestasis|Total Parenteral Nutrition-induced Cholestasis,Drug: Omegaven,,Rush University Medical Center,All,"up to 18 Years   (Child, Adult)",,null,Other,Expanded Access,,14051906,null,null,null,23-May-16,null,3-Oct-17,"Rush University Medical Center, Chicago, Illinois, United States",,https://ClinicalTrials.gov/show/NCT02780193
89,NCT02778698,Compassionate Use of Omegaven,,Available,No Results Available,Cholestasis,Dietary Supplement: Omegaven,,Geisinger Clinic,All,up to 5 Years   (Child),,null,Other,Expanded Access,,OMEGAVEN,null,null,null,20-May-16,null,2-Aug-17,,,https://ClinicalTrials.gov/show/NCT02778698
90,NCT02764034,Effect of Low Level Laser Therapy on Endometrial Cells: An In Vitro Study,LLLT,Available,No Results Available,Infertility,Device: Low level Laser diode machine,,Cairo University,Female,20 Years to 38 Years   (Adult),,null,Other,Expanded Access,,effect of low level laser 001,null,null,null,6-May-16,null,25-Jul-17,"National Research Centre, Cairo, El Dokki, Egypt",,https://ClinicalTrials.gov/show/NCT02764034
91,NCT02762591,Expanded Access of Pimavanserin for Patients With PD Psychosis,,Approved for marketing,No Results Available,Parkinson's Disease Psychosis,Drug: Pimavanserin tartrate,,ACADIA Pharmaceuticals Inc.,All,"40 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,ACP-103-036,null,null,null,5-May-16,null,18-Apr-17,,,https://ClinicalTrials.gov/show/NCT02762591
92,NCT02722707,"Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX",,Available,No Results Available,Fecal Incontinence,Device: magnetic anal sphincter augmentation for fecal incontinence,,Mayo Clinic,Female,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,16-000150,null,null,null,30-Mar-16,null,23-Aug-17,"Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT02722707
93,NCT02715843,Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma,,Available,No Results Available,Non-Hodgkin's B-cell Lymphoma,Drug: MT-3724,,"Molecular Templates, Inc.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,MT-3724_NHL_001_EXT_US,null,null,null,22-Mar-16,null,20-Jun-18,"University of Arizona, Tucson, Arizona, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02715843
94,NCT02705313,"EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx",,Approved for marketing,No Results Available,Neuroendocrine Tumors,Drug: 177Lu-DOTA0-Tyr3-Octreotate,,Advanced Accelerator Applications,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,AAA-177Lu-03,null,null,null,10-Mar-16,null,9-Apr-18,"Banner M.D. Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|City of Hope (City of Hope Medical Center, City of Hope National Medical Center), Duarte, California, United States|University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Kaiser Permanente, Santa Clara Homestead, Santa Clara, California, United States|Stanford University Medical Center, Stanford, California, United States|University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Mayo Clinic, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|Cancer Treatment Center of America - Southeastern Regional Medical Center, Newnan, Georgia, United States|Northwestern Medicine, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Iowa Hospitals & Clinics (UIHC) including the Carver College of Medicine, Iowa City, Iowa, United States|Ochsner Medical Center, Kenner, Louisiana, United States|Johns Hopkins Outpatient Center, Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City Research Institute, Kansas City, Missouri, United States|Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States|CHI Health West Omaha Imaging Center, Omaha, Nebraska, United States|Montefiore Einstein Center for Cancer Care, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lenox Hill Hospital, New York, New York, United States|Stony Brook Cancer Center, Stony Brook, New York, United States|Duke University Hospital, Durham, North Carolina, United States|The Ohio State University James Cancer Center, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Medical Center, Pittsburgh, Pennsylvania, United States|Bon Secours Medical Group/ Saint Francis Hospital Cancer Center, Greenville, South Carolina, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States|Carilion Clinic, Roanoke, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|University of Washington, Department of Radiology, Division of Nuclear Medicine, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02705313
95,NCT02695030,Low-profile Visualized Intraluminal Support -HUD,,Available,No Results Available,Giant Wide Necked Aneurysms,Device: Low Profile Visualized Intraluminal Support Device,,New York University School of Medicine,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,14-01582|09-0222|H130005,null,null,null,1-Mar-16,null,5-Feb-18,"New York University School of Medicine, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02695030
96,NCT02686541,Athrectomy and Drug Eluting Balloon Therapy (ADEBT) on the Femoral Popliteal Arteries,ADEBT,Approved for marketing,No Results Available,Peripheral Arterial Disease,Device: Atherectomy followed by Drug Eluting Balloon (DEB),,Changi General Hospital,All,"21 Years to 90 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,CG12Aug02-12,Apr-15,Mar-17,null,19-Feb-16,null,23-Feb-16,"Changi General Hospital, Singapore, Singapore",,https://ClinicalTrials.gov/show/NCT02686541
97,NCT02684474,Expanded Access Protocol Using HBOC-201,,Available,No Results Available,Anemia,Biological: HBOC-201,,Johns Hopkins University,All,"18 Years to 80 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,IRB00090805,null,null,null,18-Feb-16,null,28-Aug-17,"The Johns Hopkins Hospital, Baltimore, Maryland, United States",,https://ClinicalTrials.gov/show/NCT02684474
98,NCT02673606,Impact of Estrogen on Fear Extinction,,Available,No Results Available,Healthy Naturally Cycling Women,Drug: Estradiol 2Mg Tablet,,Massachusetts General Hospital,Female,18 Years to 30 Years   (Adult),,null,Other,Expanded Access,,2007P000496,null,null,null,4-Feb-16,null,9-Jan-18,"Massachusetts General Hospital (149 13th Street - Charlestown Navy Yard), Charlestown, Massachusetts, United States",,https://ClinicalTrials.gov/show/NCT02673606
99,NCT02660255,Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy,CBD,Available,No Results Available,Epilepsy,Drug: Cannabidiol,,Deepak Madhavan MD|GW Pharmaceuticals Ltd.|University of Nebraska,All,"1 Year to 60 Years   (Child, Adult)",,null,Other|Industry,Expanded Access,,719-15-FB,Feb-16,May-18,May-18,21-Jan-16,null,3-May-17,,,https://ClinicalTrials.gov/show/NCT02660255
100,NCT02635841,Compassionate Use of Deferiprone in Patients With PKAN,,Available,No Results Available,Pantothenate Kinase-Associated Neurodegeneration,Drug: Deferiprone,,ApoPharma,All,"7 Years and older   (Child, Adult, Older Adult)",,null,Industry,"Expanded Access:Intermediate-size Population""",,TIRCON2012V1-COMP,null,null,null,21-Dec-15,null,28-Jun-17,,,https://ClinicalTrials.gov/show/NCT02635841
101,NCT02632994,Protocol for Continued Patient Access to Study Drug,,Available,No Results Available,Cancer,Drug: LY2503029,,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,16161|I8I-MC-JYAA,null,null,null,17-Dec-15,null,16-Jan-18,"Tennessee Oncology, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT02632994
102,NCT02624570,Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy,AMLFLT3,Available,No Results Available,"Acute Myeloid Leukemia (AML) With|FLT3 Mutation, Internal Tandem Duplication (ITD) or Tyrosine Kinase Domain (TKD)",Drug: Midostaurin,,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,CPKC412AUS56X,null,null,null,8-Dec-15,null,12-Jun-18,"Mayo Clinic Arizona, Phoenix, Arizona, United States|The Jordan Research and Education Center ABSMC Comprehensive Cancer Ctr, Berkeley, California, United States|City of Hope National Medical Center Department of Hematology & HCT, Duarte, California, United States|St. Judes Medical Center, Fullerton, California, United States|University of Calif Irvine Medical Center Family Comp Cancer Cntr, Orange, California, United States|Kaiser Permanente Northwest Kaiser, Denver, Colorado, United States|Poudre Valley Hospital Poudre Valley Hospital -U of C, Fort Collins, Colorado, United States|Memorial Healthcare System Memorial Healthcare System, Hollywood, Florida, United States|UF Health Cancer Center at Orlando Health Orlando Health, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute SC - 5, Tampa, Florida, United States|Augusta University Georgia Cancer Center Pharmacy, Augusta, Georgia, United States|Rush University Medical Center Dept.of Rush UniversityMedCtr., Chicago, Illinois, United States|University of Chicago Medical Center University of Chicago, Chicago, Illinois, United States|Indiana Blood and Marrow Institute Indiana Blood and Marrow Trans, Beech Grove, Indiana, United States|Ft. Wayne Medical Oncology & Hematology, Inc., Fort Wayne, Indiana, United States|Norton Cancer Institute Norton Cancer Institute, Louisville, Kentucky, United States|University of Louisville / James Graham Brown Cancer Center Louisville 529-539, Louisville, Kentucky, United States|Tulane University Medical Center, New Orleans, Louisiana, United States|Oschner Clinic Foundation, New Orleans, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Karmanos Cancer Institute Harper Hosp. Invest. Pharmacy, Detroit, Michigan, United States|Henry Ford Hospital SC, Detroit, Michigan, United States|Mayo Clinic Mayo Clinic, Rochester, Minnesota, United States|Nebraska Cancer Specialist/Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Healthcare Partners Medical Group, Las Vegas, Nevada, United States|Weill Cornell Medical College NY Presbyterian Hospital, New York, New York, United States|University of Rochester Medical Center Univ of Rochester (7), Rochester, New York, United States|Kaiser Permanente Northwest Kaiser Permanente Northwest, Clackamas, Oregon, United States|Penn State University / Milton S. Hershey Medical Center Penn State Cancer Institute, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center University of Pen/Abr Canc ctr, Philadelphia, Pennsylvania, United States|Medical University of South Carolina Hematology-Oncology Division, Charleston, South Carolina, United States|Erlanger Medical Center Erlanger Health System, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Clinical Trials Center Division Hematology/Oncology, Nashville, Tennessee, United States|University of Texas Medical Branch University of Texas MB, Galveston, Texas, United States|McGovern Medical School at the University of Texas Health, Houston, Texas, United States|Oncology Consultants Oncology Consultants, Houston, Texas, United States|Methodist Healthcare System San Antonio, San Antonio, Texas, United States|Intermountain Healthcare - Huntsman Cancer Clinics Intermountain Healthcare (2), Murray, Utah, United States|Huntsman Cancer Institute Univ. of Utah Hematology Clinic, Salt Lake City, Utah, United States|Virginia Oncology Associates Virginia Oncology Assoc. (6), Norfolk, Virginia, United States|Swedish Cancer Institute Cancer Institute, Seattle, Washington, United States|Veterans Affairs Puget Sound Health Care System VAMC Seattle, WA Divison, Seattle, Washington, United States|Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States|Cheyenne Regional Medical Center, Cheyenne, Wyoming, United States",,https://ClinicalTrials.gov/show/NCT02624570
103,NCT02596997,Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease,,Available,No Results Available,Adenovirus,Drug: Brincidofovir,,Chimerix,All,"2 Months and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,CMX001-351,null,null,null,4-Nov-15,null,24-May-18,"University of Arkansas Medical Center, Little Rock, Arkansas, United States|Children's Hospital LA, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Pediatric Stem Cell Transplantation Stanford University, Palo Alto, California, United States|Stanford University, Palo Alto, California, United States|UC San Diego Moores Cancer center, San Diego, California, United States|University of California San Francisco Benioff Children's Hospital, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|All Childrens Research Institute, Saint Petersburg, Florida, United States|All Children's Research Institute, Saint Petersburg, Florida, United States|Emory University-AFLAC Cancer and Blood Disorder Clinic, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Children's Mercy Hospital, Kansas City, Kansas, United States|University of Louisville-Kosair Childrens Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Brigham & Woman's Hospital/Boston, Boston, Massachusetts, United States|Michigan State/Spectrum Health, Grand Rapids, Michigan, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska, Omaha, Nebraska, United States|Hackensack University MC, Hackensack, New Jersey, United States|The Children's Hospital at Montefiore, Bronx, New York, United States|Weill Conrell Medical Center, New York, New York, United States|Morgan Stanley Children's Hospital, New York, New York, United States|Memorial Sloan Kettering, New York, New York, United States|New York Medical College-Maria Fareri Childrens hospital, New York, New York, United States|New York Medical College, Maria Fareri Children's Hospital, Valhalla, New York, United States|Levine Children's Hospital, Charlotte, North Carolina, United States|Duke University Medical System, Durham, North Carolina, United States|Cincinnatti Children's Hospital, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Childrens hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Methodist University Hospital-BMT program west clinic, Memphis, Tennessee, United States|St. Jude Research Hospital, Memphis, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Baylor College of Medicine-Infectious Disease, Houston, Texas, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Washington/ Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Wauwatosa, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02596997
104,NCT02592941,"Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy",,Approved for marketing,No Results Available,Duchenne Muscular Dystrophy,Drug: Deflazacort,,PTC Therapeutics|Parexel|Dohmen Life Science Services,All,"5 Years and older   (Child, Adult, Older Adult)",,null,Industry|Other,Expanded Access,,MP-104-CL-037,null,null,null,30-Oct-15,null,28-Feb-18,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|UCLA Health, Los Angeles, California, United States|Childrens Hospital of Orange County, Orange, California, United States|UC Davis Medical Center, Sacramento, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Clinical Research Center, Gainesville, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Shriner's Hospital for Children - Tampa, Tampa, Florida, United States|Children's Healthcare of Atlanta- Scottish Rite, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Shriner's Hospital for Children - Chicago, Chicago, Illinois, United States|Carle Foundation Hospital, Urbana, Illinois, United States|Riley Hospital for Children at IU Health, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Kennedy Krieger Institute, Baltimore, Maryland, United States|Boston Children's Hospital, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Wayne State University- Children's Hospital of Michigan, Detroit, Michigan, United States|Helen DeVos Children's Hospital Neurology Clinic, Grand Rapids, Michigan, United States|Gillette Children's Specialty Healthcare, Saint Paul, Minnesota, United States|Las Vegas Clinic, Las Vegas, Nevada, United States|Neurosciences Institute, Neurology-Charlotte, Charlotte, North Carolina, United States|Wake Forest School of Medicine, Winston-Salem, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Shriner's Hospital for Children, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Children's Medical Center, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States|University of Virginia Children's Hospital, Charlottesville, Virginia, United States|Children's Specialty Group, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02592941
105,NCT02589717,An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy,,Approved for marketing,No Results Available,Urothelial Carcinoma,Drug: Atezolizumab [TECENTRIQ],,"Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,ML29725,Nov-15,Aug-16,Aug-16,28-Oct-15,null,2-Nov-16,"Scottsdale, Arizona, United States|Tucson, Arizona, United States|Duarte, California, United States|Oakland, California, United States|Stanford, California, United States|Denver, Colorado, United States|New Haven, Connecticut, United States|West Hartford, Connecticut, United States|Miami Beach, Florida, United States|Tampa, Florida, United States|Harvey, Illinois, United States|Springfield, Illinois, United States|Goshen, Indiana, United States|Indianapolis, Indiana, United States|Sioux City, Iowa, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|St. Cloud, Minnesota, United States|Jackson, Mississippi, United States|Saint Louis, Missouri, United States|Albuquerque, New Mexico, United States|Abany, New York, United States|New York, New York, United States|Rochester, New York, United States|Columbus, Ohio, United States|Eugene, Oregon, United States|Easton, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Charleston, South Carolina, United States|Houston, Texas, United States|San Antonio, Texas, United States|Charlottesville, Virginia, United States|Norfolk, Virginia, United States|Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT02589717
106,NCT02577562,Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Continued Access Study,,Approved for marketing,No Results Available,Abdominal Aortic Aneurysms|Aorto-iliac Aneurysms|Juxtarenal Aneurysms,Device: Zenith® Fenestrated AAA Endovascular Graft,,Cook Group Incorporated,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,04-541 CA,null,null,null,16-Oct-15,null,24-Nov-17,"University of California, San Francisco, San Francisco, California, United States|Shands Hospital, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|The Indiana Heart Hospital, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|NYU Medical Center, New York, New York, United States|University of North Carolina Hospital, Chapel Hill, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Harborview Medical Center, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT02577562
107,NCT02568943,"An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma",,Available,No Results Available,Multiple Myeloma,Drug: Panobinostat,,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CLBH589D2001X,null,null,null,6-Oct-15,null,14-May-18,"Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Rankweil, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Mannheim, Baden-Württemberg, Germany|Novartis Investigative Site, Bad Saarow, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Karlsruhe, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Mutlangen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Winnenden, Germany|Novartis Investigative Site, Wurzburg, Germany|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Linköping, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Umea, Sweden",,https://ClinicalTrials.gov/show/NCT02568943
108,NCT02567175,Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders,,Available,No Results Available,"Refractory Gastroesophageal Reflux Disease With Upper Gastrointestinal (GI) Symptoms, Gastroparesis, and Chronic Constipation",Drug: Domperidone,,Kristin Fiorino|Children's Hospital of Philadelphia,All,"12 Years and older   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,14-010908,null,null,null,2-Oct-15,null,6-Nov-17,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02567175
109,NCT02533219,Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia,[18F]-DOPA,Available,No Results Available,"Hyperinsulinemic Hypoglycemia, Persistent|Congenital Hyperinsulinism|Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)",Drug: 18 F-DOPA,,Baylor College of Medicine|Texas Children's Hospital,All,"up to 64 Years   (Child, Adult)",,null,Other,Expanded Access,,H-32432,null,null,null,26-Aug-15,null,12-Oct-16,"Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02533219
110,NCT02533115,EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML,401,Approved for marketing,No Results Available,Secondary AML,Drug: CPX-351,,Jazz Pharmaceuticals,All,"60 Years to 75 Years   (Adult, Older Adult)",,null,Industry,Expanded Access,,CLTR0314-401,null,null,null,26-Aug-15,null,22-Aug-17,"UCLA Ronald Reagan Medical Center, Los Angeles, California, United States|Northside Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|The University of Kansas Hospital, Kansas City, Kansas, United States|Weill Cornell Medical College- NY Presbyterian Hospital, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02533115
111,NCT02531672,Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography,,Available,No Results Available,Prostate Cancer|Recurrent Prostate Cancer,Drug: 11C-choline|Device: PET/CT Scan,,Memorial Sloan Kettering Cancer Center,Male,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,15-117,null,null,null,24-Aug-15,null,20-Nov-17,"Memorioal Sloan Kettering Cancer Center, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02531672
112,NCT02496689,Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP),,Approved for marketing,No Results Available,Hypophosphatasia,Biological: asfotase alfa,,Alexion Pharma GmbH,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,AA-HPP-405,null,null,null,14-Jul-15,null,25-Oct-17,"Colorado Center for Bone Research, Lakewood, Colorado, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Hôpital Bicêtre, Le Kremlin-Bicêtre, France|Hôpital Necker - Enfants Malades, Paris, France|Hôpital des Enfants, Toulouse Cedex 9, France",,https://ClinicalTrials.gov/show/NCT02496689
113,NCT02494687,Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy,,Available,No Results Available,Oncology Patients With Gastroparesis,Drug: Oral Domperidone,,Eastern Regional Medical Center,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,EP2014022,null,null,null,10-Jul-15,null,6-Jul-17,"Eastern Regional Medical Center, Inc., Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02494687
114,NCT02477891,Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma,,Available,No Results Available,Multiple Myeloma,Drug: Daratumumab,,"Janssen Research & Development, LLC",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CR106626|54767414MMY3010,null,null,null,23-Jun-15,null,6-Jun-18,"Mayo Clinic Arizona, Phoenix, Arizona, United States|The University of Arkansas for Medical Sciences Myeloma Institute for Research and Therapy, Little Rock, Arkansas, United States|City of Hope, Duarte, California, United States|Compassionate Cancer Care, Fountain Valley, California, United States|PCRI, Gilroy, California, United States|Marin Cancer Center, Greenbrae, California, United States|SCORA Network, LLC, Los Angeles, California, United States|Institute for Myeloma & Bone Cancer Research, West Hollywood, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Mayo Clinic Cancer Center of Florida, Jacksonville, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Florida Cancer Specialists & Research Institute, West Palm Beach, Florida, United States|Winship Cancer Institute Emory University, Atlanta, Georgia, United States|Boise, Idaho, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Indiana University School of Medicine Division of Hematology and Oncology, Indianapolis, Indiana, United States|University of Iowa Hospital, Iowa City, Iowa, United States|St. Francis Health, Topeka, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Johns Hopkins University School of Medicine (JHUSOM), Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Clinic Cancer Care, Great Falls, Montana, United States|Nebraska Medical Center (NCI-CC), Omaha, Nebraska, United States|Hunterdon Hematology Oncology, Flemington, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Langone Medical Center, New York, New York, United States|Mt. Sinai School of Medicine, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Samaritan Hematology and Oncology Associates, Corvallis, Oregon, United States|Penn State Milton S. Hershey Medical Ctr., Hershey, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|St. Francis Hospital, Greenville, South Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Madison, Wisconsin, United States|HC Barretos, Barretos, Brazil|Universidade Federal da Paraíba - UFPB, Joao Pessoa, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Instituto Nacional do Cancer - INCA, Rio De Janeiro, Brazil|Federal University of Rio de Janeiro - UFRJ, Rio De Janeiro, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Rio De Janeiro, Brazil|Federal University of Bahia - UFBA, Salvador, Brazil|Hospital Das Clinicas Da Faculdade De Medicina Da Universidade De Sao Paulo, Sao Paulo, Brazil|Ospedali Riuniti Di Ancona, Ancona, Italy|Dipartimento di Medicina Interna e Oncologia Umana-Medicina Interna-G. Baccelli-Policlinico di Bari, Bari, Italy|U.O. Ematologia con Trapianto- AOU Policlinico di Bari, Bari, Italy|Seragnoli Institute, Hematology Department, Bologna, Italy|Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy|IRCCS Aor San Martino IST, Genova, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Division of Hematology, Cardarelli Hospital, Napoli, Italy|Dept.of Medicine, Hematology and Clinical Immunology, Padova, Italy|Policlinico San Matteo, Pavia, Italy|UO Ematologia, Ospedale S. Chiara, Pisa, Italy|IRCCS CROB Referral Cancer center of Basilicata, Rionero In Vulture, Italy|Dipartimento Di Biotecnologie Cellulari Ed Ematologia Università la Sapienza, Roma, Italy|S. C. di Ematologia, Presidio Molinette, Torino, Italy|UO Hematology Azienda Ospedaliera-Universitaria di Udine, Udine, Italy|Kobe City Medical Center General Hospital, Kobe-City, Japan|City Clinical Hospital No.52, Moscow, Russian Federation|Hematological Scientific center of RAS, Moscow, Russian Federation|City clinical hospital n.a. S.P.Botkin, Moscow, Russian Federation|Novosibirsk State Medical University, Novosibirsk, Russian Federation|Federal North-West Medical Research Centre, Saint-Petersburg, Russian Federation|City Hospital No.15, Saint-Petersburg, Russian Federation|Samara State Medical Univeristy, Samara, Russian Federation|Volgograd Regional Clinical Oncologic Dispensary No.1, Volgograd, Russian Federation|Inst. Cat. Doncologia-H Duran I Reynals, Barcelona, Spain|Hosp. Univ. Virgen de Las Nieves, Granada, Spain|Hosp. Univ. de Gran Canaria Dr. Negrin, Las Palmas De Gran Canaria, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hosp. Gral. Univ. Gregorio Maranon, Madrid, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Son Llatzer, Mallorca, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Hosp. Clinico Univ. de Salamanca, Salamanca, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Hosp. Clinico Univ. de Santiago, Santiago De Compostela, Spain|Hosp. Virgen de La Salud, Toledo, Spain|Hosp. Univ. Dr. Peset, Valencia, Spain|Hosp. Clinico Univ. de Valladolid, Valladolid, Spain|Hosp. Clinico Univ. Lozano Blesa, Zaragoza, Spain|Blackpool Victoria Hospital, Blackpool, United Kingdom|Royal Bournemouth Hospital, Bournemouth, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Beatson West Of Scotland Cancer Centre, Glasgow, United Kingdom|Maidstone Hospital, Kent, United Kingdom|St. James Hospital, Leeds, United Kingdom|Altnagelvin Hospital, Londonderry, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|University College Hospital, London, United Kingdom|Guy's Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Freeman Hospital, Newcastle, United Kingdom|Nottingham University Hospitals, Nottingham, United Kingdom|Royal Stoke University Hospital, Stoke On Trent, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,https://ClinicalTrials.gov/show/NCT02477891
115,NCT02475798,PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation,,Available,No Results Available,Aortoiliac Aneurysms|Iliac Aneurysms,"Device: Zenith® Branch Endovascular Graft-Iliac Bifurcation,",,Cook Research Incorporated|Cook Group Incorporated,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,05-625 CA-P2,null,null,null,19-Jun-15,null,8-May-18,"Mayo Foundation for Medical Education and Research, Phoenix, Arizona, United States|VA Palo Alto HCS, Palo Alto, California, United States|Stanford University Medical Center, Stanford, California, United States|Christine E. Lynn Heart and Vascular Institute, Boca Raton, Florida, United States|South Florida Medical Imaging, Fort Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|Emory University, Atlanta, Georgia, United States|St. Anthony's Medical Center, Rockford, Illinois, United States|Methodist Hospital of Indiana, Indianapolis, Indiana, United States|University of Kentucky Hospital, Lexington, Kentucky, United States|University of Massachusetts, Worcester, Massachusetts, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital East Communities, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Columbia University Medical Center, New York, New York, United States|Weill Cornell Medical Center, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|UT Southwestern, Dallas, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Aurora St. Luke's Hospital, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02475798
116,NCT02474121,Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access,MOBILE-CA,Available,No Results Available,Peripheral Arterial Disease|Peripheral Vascular Diseases|Critical Limb Ischemia,Device: Bone marrow concentration device,,Zimmer Biomet,All,"21 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,BB-IDE 13996 (CA),null,null,null,17-Jun-15,null,21-Jun-18,"Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|Piedmont Hospital, Atlanta, Georgia, United States|Indiana University, Indianapolis, Indiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|The Mount Sinai Hospital, New York, New York, United States|Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02474121
117,NCT02473497,Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients,,Available,No Results Available,Neoplasm,Drug: Crizotinib,,Pfizer,All,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,A8081056,null,null,null,16-Jun-15,null,1-Feb-18,"Children's Hospital of Philadelphia (Investigational Pharmacy), Philadelphia, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02473497
118,NCT02471781,Zenith® TX2® Low Profile TAA Endovascular Graft,,Approved for marketing,No Results Available,Aortic Aneurysm|Penetrating Ulcer|Vascular Disease,Device: Zenith TX2 Low Profile TAA Endovascular Graft,,Cook Group Incorporated,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,10-001 CA,Apr-13,Jan-16,Jan-21,15-Jun-15,null,7-Mar-17,"University of South Florida, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|Methodist Hospital of Indiana, Indianapolis, Indiana, United States|Indiana Heart Hospital, Indianapolis, Indiana, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Barnes-Jewish Hospital, St. Louis, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cooper University Hospital, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Mount Sinai Hospital, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT02471781
119,NCT02464943,Zenith® Dissection Endovascular System in the Treatment of Patients With Aortic Dissections,,Available,No Results Available,Aortic Dissection,Device: Endovascular Treatment (Zenith),,Cook Group Incorporated,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,11-007-CA,null,null,null,8-Jun-15,null,19-Jan-18,"Cooper University Hospital, Camden, New Jersey, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|University of Virginia Medical Center, Charlottesville, Virginia, United States",,https://ClinicalTrials.gov/show/NCT02464943
120,NCT02437019,Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL),,Approved for marketing,No Results Available,B-cell Chronic Lymphocytic Leukemia,Drug: PCI-32765 (Ibrutinib),,Janssen-Cilag Farmaceutica Ltda.,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CR106344|54179060CLL3005,null,null,null,7-May-15,null,20-Mar-17,"Barretos, Brazil|Florianopolis, Brazil|Fortaleza, Brazil|Porto Alegre, Brazil|Rio De Janeiro, Brazil|Sao Paulo, Brazil|São Paulo, Brazil",,https://ClinicalTrials.gov/show/NCT02437019
121,NCT02436044,HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC,,Available,No Results Available,"Hepatocellular Carcinoma|Injury; Blood Vessel, Hepatic, Artery",Procedure: HAIC using oxaliplatin plus fluorouracil/leucovorin|Drug: Oxaliplatin|Drug: Fluorouracil|Drug: Leucovorin,,Ming Zhao|Sun Yat-sen University,All,"18 Years to 75 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,2015-FXY-011,Apr-15,May-20,May-20,6-May-15,null,18-Jan-17,"Minimally Invasive Interventional Division, Medical Imaging Center, Sun Yat-sen University Cancer Center,, Guangzhou, Guangdong, China",,https://ClinicalTrials.gov/show/NCT02436044
122,NCT02431715,18F-FDOPA PET in Neuroendocrine Tumours,,Available,No Results Available,"Thyroid Cancer, Medullary|Carcinoid Tumor|Pheochromocytoma|Paraganglioma|Insulinoma|Neuroblastoma",Drug: [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA),,British Columbia Cancer Agency,All,"1 Month and older   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,H12-01795,Oct-12,Aug-17,Aug-18,1-May-15,null,30-Dec-16,"BC Cancer Agency, Vancouver, British Columbia, Canada",,https://ClinicalTrials.gov/show/NCT02431715
123,NCT02412566,SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury,SMOF,Available,No Results Available,Cholestasis|Growth Failure,Drug: SMOFlipid,,Baylor College of Medicine,All,up to 1 Year   (Child),,null,Other,Expanded Access,,H-34444,null,null,null,9-Apr-15,null,14-Feb-18,"Baylor College of Medicine / Texas Children's Hospital, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02412566
124,NCT02411604,Expanded Access Study for Renal Transplant Patients With Envarsus XR ™,,Approved for marketing,No Results Available,Renal Failure,Drug: Tacrolimus,,Veloxis Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,Envarsus® 3007,null,null,null,8-Apr-15,null,20-Jan-16,,,https://ClinicalTrials.gov/show/NCT02411604
125,NCT02397863,Epidiolex and Drug Resistant Epilepsy in Children,CBD,Available,No Results Available,Epilepsy,Drug: Cannabidiol (Epidiolex),,Augusta University|State of Georgia,All,"1 Year to 18 Years   (Child, Adult)",,null,Other,Expanded Access,,CBD02,Dec-14,Dec-19,Jan-20,25-Mar-15,null,24-Apr-15,"Georgia Regents University, Augusta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02397863
126,NCT02389933,Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF),,Available,No Results Available,Heart Failure With Reduced Ejection Fraction (HF-rEF),Drug: LCZ696,,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Intermediate-size Population""",,CLCZ696B2318M,null,null,null,17-Mar-15,null,20-Jun-18,"Novartis Investigative Site, Vero Beach, Florida, United States|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, North Ryde, New South Wales, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Krems, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, St. Poelten, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Varazdin, HRV, Croatia|Novartis Investigative Site, Limassol, Cyprus|Novartis Investigative Site, Nicosia, Cyprus|Novartis Investigative Site, Nicosia, Cyprus|Novartis Investigative Site, Nicosia, Cyprus|Novartis Investigative Site, Nicosia, Cyprus|Novartis Investigative Site, Nicosia, Cyprus|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, France|Novartis Investigative Site, Bron, Cedex, France|Novartis Investigative Site, Caen, Cedex, France|Novartis Investigative Site, Saint Denis, France / La Reunion, France|Novartis Investigative Site, Amiens cedex 1, France|Novartis Investigative Site, Amilly, France|Novartis Investigative Site, Angers Cedex 9, France|Novartis Investigative Site, Antibes, France|Novartis Investigative Site, Aressy, France|Novartis Investigative Site, Avignon Cedex 2, France|Novartis Investigative Site, Avignon, France|Novartis Investigative Site, Bayeux, France|Novartis Investigative Site, Beziers Cedex, France|Novartis Investigative Site, Bobigny, France|Novartis Investigative Site, Brest Armees, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Bron Cedex, France|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Caen, France|Novartis Investigative Site, Cambrai Cedex, France|Novartis Investigative Site, Cannes Cedex, France|Novartis Investigative Site, Chambéry cedex, France|Novartis Investigative Site, Chaumont Cedex, France|Novartis Investigative Site, Cherbourg Octeville, France|Novartis Investigative Site, Clamart, France|Novartis Investigative Site, Clermont-Ferrand cedex 1, France|Novartis Investigative Site, Compiègne cedex, France|Novartis Investigative Site, Contamine Sur Arve, France|Novartis Investigative Site, Corbeil Essonnes, France|Novartis Investigative Site, Cornebarrieu, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Eaubonne, France|Novartis Investigative Site, Honfleur Cedex, France|Novartis Investigative Site, Hyeres, France|Novartis Investigative Site, La Roche sur Yon Cedex, France|Novartis Investigative Site, La Seyne sur mer, France|Novartis Investigative Site, La Tronche, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Limoges, France|Novartis Investigative Site, Lyon CEDEX 04, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille Cedex 05, France|Novartis Investigative Site, Marseille Cedex 20, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Metz Cedex, France|Novartis Investigative Site, Metz-Tessy, France|Novartis Investigative Site, Monaco, France|Novartis Investigative Site, Montbeliard Cedex, France|Novartis Investigative Site, Montpellier Cedex, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Morlaix Cedex, France|Novartis Investigative Site, Moulins Cedex, France|Novartis Investigative Site, Mulhouse Cedex, France|Novartis Investigative Site, Mâcon Cedex, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Neuilly-sur-seine, France|Novartis Investigative Site, Nice Cedex 1, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Paris Cedex 14, France|Novartis Investigative Site, Pau Cedex, France|Novartis Investigative Site, Perpignan, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Pont L'Abbe, France|Novartis Investigative Site, Pontarlier Cedex, France|Novartis Investigative Site, Pontoise, France|Novartis Investigative Site, Rennes Cedex 9, France|Novartis Investigative Site, Rouen Cedex, France|Novartis Investigative Site, Rumilly, France|Novartis Investigative Site, Saint Denis, France|Novartis Investigative Site, Saint Denis, France|Novartis Investigative Site, Saint Etienne Cedex 2, France|Novartis Investigative Site, Saint Palais, France|Novartis Investigative Site, Saint-Germain-en-Laye, France|Novartis Investigative Site, St Jean, France|Novartis Investigative Site, St. Etienne, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Thonon Les Bains Cedex, France|Novartis Investigative Site, Toulouse Cedex, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Tours, France|Novartis Investigative Site, Valence Cedex 9, France|Novartis Investigative Site, Valenciennes Cedex, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Vichy, France|Novartis Investigative Site, Villefranche sur Saone, France|Novartis Investigative Site, Wattrelos, France|Novartis Investigative Site, Suderholz, OT Bartmannshagen, Germany|Novartis Investigative Site, Ahlen, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Bad Endbach, Germany|Novartis Investigative Site, Bad Homburg, Germany|Novartis Investigative Site, Bad Kreuznach, Germany|Novartis Investigative Site, Bad Krozingen, Germany|Novartis Investigative Site, Bad Oeynhausen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Cologne, Germany|Novartis Investigative Site, Dessau-Rosslau, Germany|Novartis Investigative Site, Diepholz, Germany|Novartis Investigative Site, Dinslaken, Germany|Novartis Investigative Site, Dortmund, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dusseldorf, Germany|Novartis Investigative Site, Eilenburg, Germany|Novartis Investigative Site, Eschwege, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Friedrichroda, Germany|Novartis Investigative Site, Goettingen, Germany|Novartis Investigative Site, Gronau, Germany|Novartis Investigative Site, Guenzburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Hassfurt, Germany|Novartis Investigative Site, Hassloch, Germany|Novartis Investigative Site, Hohenstein-Ernstthal, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Karlsruhe, Germany|Novartis Investigative Site, Kassel, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Köthen, Germany|Novartis Investigative Site, Lauchringen, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Marl, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Munchen, Germany|Novartis Investigative Site, Munster, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Pressath, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Weinheim, Germany|Novartis Investigative Site, Wildeshausen, Germany|Novartis Investigative Site, Wolfratshausen, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Alexandroupolis, Evros, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Larissa, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Tripoli, GR, Greece|Novartis Investigative Site, Voula, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Chaidari, Greece|Novartis Investigative Site, Chios, Greece|Novartis Investigative Site, Edessa, Greece|Novartis Investigative Site, Elefsina, Greece|Novartis Investigative Site, Glyfada, Greece|Novartis Investigative Site, Heraklion - Crete, Greece|Novartis Investigative Site, Heraklion, Greece|Novartis Investigative Site, Ioannina, Greece|Novartis Investigative Site, Kalamata, Greece|Novartis Investigative Site, Karditsa, Greece|Novartis Investigative Site, Katerini, Greece|Novartis Investigative Site, Kavala, Greece|Novartis Investigative Site, Kerkyra, Greece|Novartis Investigative Site, Kilkis, Greece|Novartis Investigative Site, Kozani, Greece|Novartis Investigative Site, Maroussi, Greece|Novartis Investigative Site, Piraeus, Greece|Novartis Investigative Site, Piraeus, Greece|Novartis Investigative Site, Rio Patra, Greece|Novartis Investigative Site, Thesaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Volos, Greece|Novartis Investigative Site, Co Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Tripoli, Lebanon|Novartis Investigative Site, Msida, Malta|Novartis Investigative Site, Panama City, Panama|Novartis Investigative Site, Panama, Panama|Novartis Investigative Site, Manila, Metro Manila, Philippines|Novartis Investigative Site, Makati City, Philippines|Novartis Investigative Site, Manila, Philippines|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Garanada, Andalucia, Spain|Novartis Investigative Site, Jerez de la Frontera, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Utrera, Andalucia, Spain|Novartis Investigative Site, Hospitalet de Llobregat, Barcelona, Spain|Novartis Investigative Site, Villamartin, Cadiz, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Torrelavega, Cantabria, Spain|Novartis Investigative Site, Lleida, Cataluna, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Salt, Cataluña, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, Pontevedra, Galicia, Spain|Novartis Investigative Site, Logrono, La Rioja, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, Las Palmas De G.C, Spain|Novartis Investigative Site, Majadahonda, Madrid, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, San Sebastian de los Reyes, Madrid, Spain|Novartis Investigative Site, Marbella, Malaga, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, Spain|Novartis Investigative Site, Galdakano, Pais Vasco, Spain|Novartis Investigative Site, Badalona, Spain|Novartis Investigative Site, Baleares, Spain|Novartis Investigative Site, El Palmar (Murcia), Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Luzern, LU, Switzerland|Novartis Investigative Site, Abu Dhabi, United Arab Emirates|Novartis Investigative Site, Ras Al Khaimah, United Arab Emirates",,https://ClinicalTrials.gov/show/NCT02389933
127,NCT02368301,Expanded Access Treatment Protocol CA204-143,,Approved for marketing,No Results Available,Multiple Myeloma,Drug: Elotuzumab in combination with Lenalidomide and Dexamethasone,,Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CA204-143,null,null,null,23-Feb-15,null,6-Oct-16,"Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Medical Associates of Brevard, Melbourne, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Stormont Vail Health Care, Topeka, Kansas, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|St. Louis Cancer Care LLP, Bridgeton, Missouri, United States|Billings Clinic, Billings, Montana, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Oncology Hematology West PC, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York Presbyterian Hospital - Weill-Cornell, New York, New York, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Northern Utah Associates, Ogden, Utah, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States|PR Hematology Oncology Group, Bayamon, Puerto Rico",,https://ClinicalTrials.gov/show/NCT02368301
128,NCT02355782,OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy,,Available,No Results Available,Thrombotic Microangiopathy,Biological: OMS721,,Michal Nowicki|Medical Universtity of Lodz,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,TMA-100,null,null,null,4-Feb-15,null,15-Apr-15,,,https://ClinicalTrials.gov/show/NCT02355782
129,NCT02355054,Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study,,Approved for marketing,No Results Available,Cancer of the Prostate,Drug: C-11 Choline PET Imaging,,Washington University School of Medicine,Male,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,201411142,null,null,null,4-Feb-15,null,20-Jan-17,"Washington University School of Medicine, Barnes-Jewish Hospital, Saint Louis, Missouri, United States",,https://ClinicalTrials.gov/show/NCT02355054
130,NCT02312037,Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy,AML,Available,No Results Available,CD33 Positive Acute Myelogenous Leukemia,Biological: Antibody Drug Conjugate Chemotherapeutic,,Pfizer,All,"3 Months and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,B1761026,null,null,null,9-Dec-14,null,31-Jan-18,"University of Alabama at Birmingham/Children's of Alabama, Birmingham, Alabama, United States|Alaska Oncology & Hematology, LLC, Anchorage, Alaska, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Providence Cancer Center, Anchorage, Alaska, United States|Banner Pediatric Specialists Hematology/Oncology Clinic, Mesa, Arizona, United States|Cardon Children's Medical Center., Mesa, Arizona, United States|Phoenix Children's Hospital, Phoenix, Arizona, United States|Children's Hospital Of Los Angeles - University Of Southern California School Of Medicine, Los Angeles, California, United States|Kaiser Permanente - Oakland Medical Center, Oakland, California, United States|Kaiser Permanente - Oakland, Oakland, California, United States|Children's Hospital of Orange County, Orange, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|UCSD/ Rady Children's Hospital, San Diego, California, United States|Kaiser Permanente - Santa Clara, Santa Clara, California, United States|c/o Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Smilow Cancer Center at Yale New Haven Hospital, New Haven, Connecticut, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Yale New-Haven Hospital & Smilow Cancer Center, New Haven, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Yale Medical Group, Trumbull, Connecticut, United States|Nemours - A.I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|JDCH pediatric Oncology and Hematology, Hollywood, Florida, United States|Joe Dimaggio Children's Hospital, Hollywood, Florida, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Baptist Medical Center/Wolfson Children's Hospital, Jacksonville, Florida, United States|Blood and Marrow Transplant Center, Orlando, Florida, United States|Cancer Institute of Florida, Orlando, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Memorial Cancer Institute at Memorial Hospital West, Pembroke Pines, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|Johns Hopkins All Children's Hospital IDS Pharmacy, Saint Petersburg, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Johns Hopkins All Children's Outpatient Care Pediatric Hematology/Oncology Department, Saint Petersburg, Florida, United States|H.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Children's Healthcare of Atlanta at Egleston, Atlanta, Georgia, United States|The Blood & Marrow Transplant Group Of Georgia, Atlanta, Georgia, United States|Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Investigational Drugs Service Pharmacy, Attn. Judy Pi, PharmD, Ami Patel, PharmD, Chicago, Illinois, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Cardinal Bernardin Cancer Center/Loyola University Medical Center, Maywood, Illinois, United States|Loyola University Chicago, performing research at Loyola University Medical Center, Maywood, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Riley Hospital for Children, Indianapolis, Indiana, United States|IU Health Pharmacy, Indianapolis, Indiana, United States|Indiana Blood and Marrow Transplantation - Administrative Offices, Indianapolis, Indiana, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States|St.Francis Hospital, Indianapolis, Indiana, United States|University of Kansas Hospital, Kansas City, Kansas, United States|The University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|The University of Kansas Cancer Center and Medical Pavillion, Westwood, Kansas, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|UK Healthcare Markey Cancer Center, Lexington, Kentucky, United States|Johns Hopkins University IDS Pharmacy, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|MassGeneral Hospital for Children, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|The West Clinic, P.C. dba West Cancer Center, Southaven, Mississippi, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Children's Mercy Hospital, Kansas City, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Infusion Center Pharmacy, Saint Louis, Missouri, United States|Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|North Shore Hematology Oncology Associates, P.C., East Setauket, New York, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College - New York-Presbyterian Hospital, New York, New York, United States|University of Rochester Cancer Center Pharmacy, Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Brody School of Medicine at ECU, Greenville, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|University Hospitals of Cleveland Rainbow Babies & Children's Hospital, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Milton Hershey Medical Center, Hershey, Pennsylvania, United States|The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Thomas Jefferson University (Tju) - Jefferson University Physicians (Jup), Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Investigative Drug Service, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office (Clinical), Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office (Regulatory), Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Cancer Institute, West Penn Hospital, Pittsburgh, Pennsylvania, United States|The West Clinic, P.C. dba West Cancer Center, Germantown, Tennessee, United States|East Tennessee Children's Hospital, Knoxville, Tennessee, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|The West Clinic, P.C. dba West Cancer Center, Memphis, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Sarah Cannon Center for Blood Cancer, Nashville, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology - Nashville, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Children's Hospital at TriStar Centennial, Nashville, Tennessee, United States|TriStar Centennial Medical Center/Sarah Cannon Cener for Blood Cancer, Nashville, Tennessee, United States|TriStar Centennial Medical Center, Nashville, Tennessee, United States|TriStar Medical Group Children's Specialist, Nashville, Tennessee, United States|VA Tennessee Valley Healthcare System - Nashville Campus, Nashville, Tennessee, United States|Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States|Vanderbilt University Medical Center - The Vanderbilt Clinic, Nashville, Tennessee, United States|Children's Blood and Cancer Center, Austin, Texas, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Dell Children's Medical Center, Austin, Texas, United States|El Paso Children's Hospital, El Paso, Texas, United States|Texas Tech University Health Sciences Center, El Paso, Texas, United States|Cook Children's Hematology/Oncology Center, Fort Worth, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Cook Children's Hematology/Oncology Center - Grapevine, Grapevine, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Texas Children's Hospital Attn: Investigational Pharmacy Services, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Houston Methodist Cancer Center, Houston, Texas, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Huntsman Cancer Institute-University of Utah, Salt Lake City, Utah, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|Cancer Center IDS Pharmacy Attn: Lauren Benusa, Pharm D., Charlottesville, Virginia, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|UVA Health System, Charlottesville, Virginia, United States|Virginia Oncology Associates, Hampton, Virginia, United States|Children's Hospital of the King's Daughters, Norfolk, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Swedish Medical Center First Hill, IDS Pharmacy, Seattle, Washington, United States|Seattle Children's IDS Pharmacy - Attn. Laura Winter, Seattle, Washington, United States|Seattle Children's, Seattle, Washington, United States|Lisa Nakatsu, RPh, Seattle, Washington, United States|Fox Valley Hematology & Oncology, SC, Appleton, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Fox Valley Hematology & Oncology, SC, Oshkosh, Wisconsin, United States|Aurora Health Care, Aurora Cancer Care, Wauwatosa, Wisconsin, United States|Aurora Health Care, Aurora Cancer Care, West Allis, Wisconsin, United States|Hospital Quiron de Zaragoza Servicio de Hematologia, Zaragoza, Spain",,https://ClinicalTrials.gov/show/NCT02312037
131,NCT02307578,Extended Access Program for Subjects Completing Perampanel StudyE2007-G000-332,,Available,No Results Available,Seizure Disorder Generalized Tonic Clonic,Drug: Perampanel,,Eisai Inc.,All,"12 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,E2007-G000-409,null,null,null,4-Dec-14,null,21-Sep-17,,,https://ClinicalTrials.gov/show/NCT02307578
132,NCT02286492,Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer,,Approved for marketing,No Results Available,Colorectal Cancer Metastatic,Drug: TAS-102,,"Taiho Oncology, Inc.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,TO-TAS-102-401,null,null,null,7-Nov-14,null,13-Jun-16,"Alabama Oncology, Birmingham, Alabama, United States|Mayo Clinic, Scottsdale, Arizona, United States|California Cancer Associates for Research and Excellence, Fresno, California, United States|Global Cancer Research Institute (GCRI), Inc., Gilroy, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Pacific Hematology Oncology Associates (PHOA), San Francisco, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|University of Florida Health Davis Cancer Center, Gainesville, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|The University of Chicago, Chicago, Illinois, United States|Illinois CancerCare, P.C., Peoria, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Hospital, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|University of Rochester, Rochester, New York, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|The Mark H. Zangmeister Center, Columbus, Ohio, United States|Hematology and Oncology Associates of Northeastern Pennsylvania, Dunmore, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Fox Valley Hematology & Oncology, Appleton, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02286492
133,NCT02274662,Expanded Access Protocol Thymus Transplantation,,Available,No Results Available,Poor Thymic Function|Immunodeficiency|Athymia|Immunoreconstitution|Thymus Transplantation|Low T Cell Numbers,Biological: Thymus Transplantation|Procedure: Blood Draw|Drug: Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus,,M. Louise Markert|Enzyvant Therapeutics GmbH|Duke University,All,"Child, Adult, Older Adult",,null,Other|Industry,Expanded Access,,Pro00051692,null,null,null,24-Oct-14,null,28-Jul-17,,,https://ClinicalTrials.gov/show/NCT02274662
134,NCT02258490,Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation,,Available,No Results Available,Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Acute Myeloid Leukemia,Biological: G-CSF mobilized CD34+ selected cells for transplantation,,Emory University,All,"17 Years to 75 Years   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,IRB00051037|EPIC-HPC001,null,null,null,7-Oct-14,null,5-Dec-17,"Emory University/Winship Cancer Institute, Atlanta, Georgia, United States",,https://ClinicalTrials.gov/show/NCT02258490
135,NCT02244788,Humanitarian Use of AVANTA Orthopaedics Proximal Interphalangeal Joint,,Available,No Results Available,Arthroplasty of the PIP Joint,Device: SR™ PIP,,"Hospital for Special Surgery, New York",All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,2013-059,null,null,null,19-Sep-14,null,30-Mar-17,"Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02244788
136,NCT02244775,"Use of Avanta Metacarpophalangeal (MCP) Joint Implant Finger Prosthesis, Humanitarian Use Device",,Approved for marketing,No Results Available,Arthroplasty of the MCP Joint,Device: SR™MCP,,"Hospital for Special Surgery, New York",All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,2013-090,null,null,null,19-Sep-14,null,19-Sep-14,"Hospital for Special Surgery, New York, New York, United States",,https://ClinicalTrials.gov/show/NCT02244775
137,NCT02239276,Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies,,Available,No Results Available,Dravet Syndrome|Epileptic Encephalopathies Associated With SCN1A Mutations,Drug: Stiripentol,,M. Scott Perry|Cook Children's Health Care System,All,"6 Months to 18 Years   (Child, Adult)",,null,Other,Expanded Access,,2014-047,null,null,null,12-Sep-14,null,25-Jan-18,"Cook Children's Medical Center, Fort Worth, Texas, United States",,https://ClinicalTrials.gov/show/NCT02239276
138,NCT02227927,Treatment Use of Domperidone for Gastroparesis,,Available,No Results Available,Gastroesophageal Reflux Disease|GERD|Gastroparesis,Drug: Domperidone,,The Cleveland Clinic,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,CCF-Domperidone,null,null,null,28-Aug-14,null,21-Nov-17,"Cleveland Clinic, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02227927
139,NCT02211222,An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer,,Approved for marketing,No Results Available,Differentiated Thyroid Cancer,Drug: Lenvatinib,,Eisai Inc.,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,E7080-G000-398,null,Aug-15,Jun-15,7-Aug-14,null,16-Mar-16,"La Jolla, California, United States|Stanford, California, United States|Torrance, California, United States|Washington, District of Columbia, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Lansing, Michigan, United States|Lebanon, New Hampshire, United States|Neptune, New Jersey, United States|Cleveland, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02211222
140,NCT02209441,Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer,,Available,No Results Available,Gastric Cancer.,Drug: Phase I Dose-finding Study of Sorafenib Study,,Chinese Academy of Medical Sciences,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,BAY43,null,null,null,6-Aug-14,null,6-Aug-14,,,https://ClinicalTrials.gov/show/NCT02209441
141,NCT02197650,Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase,EAP,Available,No Results Available,Acute Lymphoblastic Leukemia,Drug: suspension of erythrocytes encapsulating L-asparaginase,,ERYtech Pharma,All,"up to 55 Years   (Child, Adult)",,null,Industry,Expanded Access,,GRASPALL 2012-10-EAP,null,null,null,23-Jul-14,null,13-Jul-17,"Hôpital Jean Minjoz - Batiment MEMCP, Besançon, France|CHRU Lille - Hôpital Claude-Huriez, Lille, France|IHOP, Lyon, France|Hôpital de l'Archet 2, Nice, France|Hôpital Saint Louis, Paris, France|CHU Rouen - Hôpital des enfants, Rouen, France|CHU Saint Etienne Hôpital Nord, Saint-Étienne, France|Institut Universitaire du Cancer, Toulouse, France|Hôpital BRETONNEAU, Tours, France|Hôpital Brabois Enfants, Vandœuvre-lès-Nancy, France",,https://ClinicalTrials.gov/show/NCT02197650
142,NCT02189720,"Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients",EAP-001,Available,No Results Available,Lambert-Eaton Myasthenic Syndrome|Congenital Myasthenic Syndrome|Downbeat Nystagmus,Drug: Amifampridine Phosphate,,"Catalyst Pharmaceuticals, Inc.",All,"10 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,EAP-001,null,null,null,15-Jul-14,null,8-Jun-18,"UCLA, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02189720
143,NCT02187354,Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL,RIALTO,Available,No Results Available,Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia,Drug: Blinatumomab,,Amgen,All,up to 17 Years   (Child),,null,Industry,"Expanded Access:Treatment IND/Protocol""",,20130320|2014-001700-21,null,null,null,11-Jul-14,null,19-Dec-17,"Research Site, Aurora, Colorado, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Memphis, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Wien, Austria|Research Site, Marseille cedex 5, France|Research Site, Paris, France|Research Site, Berlin, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Kiel, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Tübingen, Germany|Research Site, Würzburg, Germany|Research Site, Monza (MB), Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Zuerich, Switzerland|Research Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT02187354
144,NCT02181868,Comparison of Biodegradable and Titanium Fixation Systems in Mandibular Symphysis or Parasymphysis Solitary Fractures,,Approved for marketing,No Results Available,Mandible Fracture|Rigid Internal Fixation|Three-dimensional Finite Element,Other: Biodegradable and titanium fixation used in mandibular fractures.,,Louqiang Zhang|Tianjin Medical University General Hospital,All,18 Years to 60 Years   (Adult),,null,Other,Expanded Access,,CBTF110,Jan-08,Dec-13,null,4-Jul-14,null,4-Jul-14,"Tianjin Medical University General Hospital, Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT02181868
145,NCT02174679,68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access),,Available,No Results Available,Carcinoid Cancer|Neuroendocrine Tumors|Medullary Thyroid Cancer|Cancers Expressing Somatostatin Receptors,Drug: 68Ga DOTATATE,,Jonsson Comprehensive Cancer Center,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,DOTATATE12-001920EA,null,null,null,25-Jun-14,null,28-Aug-17,"UCLA Hospital, Los Angeles, California, United States",,https://ClinicalTrials.gov/show/NCT02174679
146,NCT02171156,Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP),,Approved for marketing,No Results Available,Idiopathic Pulmonary Fibrosis,Drug: nintedanib,,Boehringer Ingelheim,All,"40 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,1199.177,null,null,null,24-Jun-14,null,8-May-17,"1199.177.1003 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States|1199.177.1012 Boehringer Ingelheim Investigational Site, Skokie, Illinois, United States|1199.177.1014 Boehringer Ingelheim Investigational Site, Muncie, Indiana, United States|1199.177.1002 Boehringer Ingelheim Investigational Site, Minneapolis, Minnesota, United States|1199.177.1011 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States|1199.177.1022 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States|1199.177.1067 Boehringer Ingelheim Investigational Site, Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT02171156
147,NCT02158767,"Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.",,Available,No Results Available,Hematopoietic/Lymphoid Cancer,Biological: Allogenic T cell-depleted hematopoietic stem cell transplantation,,"Paolo Caimi, MD|National Cancer Institute (NCI)|Case Comprehensive Cancer Center",All,"up to 80 Years   (Child, Adult, Older Adult)",,null,Other|NIH,Expanded Access,,CASE16Z13|NCI-2013-02383|P30CA043703,Dec-13,Dec-19,null,9-Jun-14,null,30-Sep-16,"University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",,https://ClinicalTrials.gov/show/NCT02158767
148,NCT02149732,Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation,,Available,No Results Available,Limbal Stem Cell Deficiency|Stevens-johnson Syndrome|Ocular Cicatricial Pemphigoid|Chemical Burn,Biological: cultivated oral mucosal epithelial sheet transplantation,,"Seoul National University Hospital|Ministry of Health & Welfare, Korea",All,"16 Years and older   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,COMET trial|MKKim,May-14,Dec-16,Dec-16,29-May-14,null,20-Apr-16,"Seoul National University Hospital, Seoul, Korea, Republic of|Seoul National Unversity Hospital, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT02149732
149,NCT02146066,Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221,DCVax-L EAP,Available,No Results Available,GBM|Glioblastoma Multiforme,Biological: DCVax-L,,Northwest Biotherapeutics,All,"18 Years to 70 Years   (Adult, Older Adult)",,null,Industry,Expanded Access,,0202EA,null,null,null,23-May-14,null,26-Feb-16,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|UCLA Medical Center, Los Angeles, California, United States|Hoag Memorial Hospital, Newport Beach, California, United States|St. Joseph Hospital of Orange, Orange, California, United States|University of California, Irvine Medical Center, Orange, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|University of Florida, Gainesville, Florida, United States|Memorial Healthcare System Memorial Cancer Institute, Hollywood, Florida, United States|Cadence Cancer Center at Warrenville, Warrenville, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Spectrum Health, Grand Rapids, Michigan, United States|John Nasseff Neuroscience Institute - Abott Northwestern Hospital, Minneapolis, Minnesota, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Capital Health, Trenton, New Jersey, United States|North Shore University Hospital, Manhasset, New York, United States|Columbia University Medical Center Neurological Institute of New York, New York, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Ohio State University, Columbus, Ohio, United States|University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Saint Thomas Research Institute, Nashville, Tennessee, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT02146066
150,NCT02141087,Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone,,Approved for marketing,No Results Available,Idiopathic Pulmonary Fibrosis,Drug: Pirfenidone,,"Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,PIPF-031,null,null,null,19-May-14,null,13-Jul-15,,,https://ClinicalTrials.gov/show/NCT02141087
151,NCT02136511,Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia,,Approved for marketing,No Results Available,Chronic Lymphocytic Leukemia (CLL),Drug: Idelalisib|Drug: Rituximab,,Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,GS-US-312-1325|2013-005343-82,null,null,null,13-May-14,null,28-Oct-14,"University of California, San Diego - Moores Cancer Center, La Jolla, California, United States|Georgetown University, Washington, District of Columbia, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Weill Cornell Medical College, New York, New York, United States|St. James University Hospital, Dublin, Ireland|Ospedale San Raffaele, Milano, Italy|A.S.O. Molinette S. Giovanni Battista, Turin, Italy|Hammersmith Hospital, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT02136511
152,NCT02121769,Omegaven Expanded Access Protocol,,Available,No Results Available,Parenteral Nutrition Associated Liver Disease,Drug: Omegaven,,"St. Luke’s Health System, Boise, Idaho",All,up to 17 Years   (Child),,null,Other,Expanded Access,,Omegaven Expanded Access,null,null,null,24-Apr-14,null,10-Oct-17,"St. Luke's Pediatric Gastroenterology, Boise, Idaho, United States",,https://ClinicalTrials.gov/show/NCT02121769
153,NCT02080767,Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure,,Available,No Results Available,Smallpox|Monkeypox,Drug: Tecovirimat,,U.S. Army Medical Research and Materiel Command,All,"Child, Adult, Older Adult",,null,U.S. Fed,Expanded Access,,M-10331|S-11-10,null,null,null,6-Mar-14,null,4-Dec-17,,,https://ClinicalTrials.gov/show/NCT02080767
154,NCT02075177,Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma,,Available,No Results Available,Recurrent Neuroblastoma|Neuroblastoma,Drug: Fenretinide Lym-X-Sorb Oral Powder|Drug: Ketoconazole,,South Plains Oncology Consortium,All,"Child, Adult, Older Adult",,null,Other,Expanded Access,,SPOC-2014-001,null,null,null,3-Mar-14,null,24-May-17,"University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Cook Children's Hospital, Fort Worth, Texas, United States",,https://ClinicalTrials.gov/show/NCT02075177
155,NCT02065674,"Therapeutic Efficacy of ""Abroma Agusta"" in HbA1c % in NIDDM",ABOMNIDDM,Available,No Results Available,Type II Diabetes Mellitus,Drug: Abroma Augusta Q (mother tincture),,Fr Muller Homoeopathic Medical College,All,"30 Years to 85 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,ABROAGUS01,Feb-14,Dec-14,Dec-14,19-Feb-14,null,9-Jun-15,",Father Muller Homoeopathic Medical College, Prasanth Nivas Ashram Nmpt Hospital, Mangalore, Karnataka, India",,https://ClinicalTrials.gov/show/NCT02065674
156,NCT02018302,Post Study Continuation of C7 for G1D,,Available,No Results Available,Glut1 Deficiency Syndrome|Glucose Transporter Type 1 Deficiency Syndrome,Drug: Triheptanoin,,Juan Pascual|University of Texas Southwestern Medical Center,All,"1 Month to 28 Years   (Child, Adult)",,null,Other,Expanded Access,,UTSW 082013-016,Jan-13,Dec-18,Dec-18,23-Dec-13,null,30-Dec-13,"UT Southwestern Medical Center, Dallas, Texas, United States",,https://ClinicalTrials.gov/show/NCT02018302
157,NCT02013895,Accuracy and Reliability of GSA for Remnant Liver Function,GSA,Available,No Results Available,Both Benign and Malignant Liver Mass,Device: 99mTc-GSA,,Kochi University,All,"Child, Adult, Older Adult",,null,Other,Expanded Access,,GSA-KHSC|GSA study,null,null,null,17-Dec-13,null,17-Dec-13,"Kochi Health Sciences Center, Kochi, Japan",,https://ClinicalTrials.gov/show/NCT02013895
158,NCT02012933,"3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)",,Available,No Results Available,Lambert-Eaton Myasthenic Syndrome (LEMS)|Congenital Myasthenia (CM),"Drug: 3,4-diaminopyridine",,Tessa L Marburger|Jacobus Pharmaceutical|Oregon Health and Science University,All,"2 Years and older   (Child, Adult, Older Adult)",,null,Other|Industry,Expanded Access,,Jacobus compassionate program,null,null,null,17-Dec-13,null,21-Apr-15,"Oregon Health & Science University, Portland, Oregon, United States",,https://ClinicalTrials.gov/show/NCT02012933
159,NCT01995734,"An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly",ACCESS,Approved for marketing,No Results Available,Acromegaly,Drug: Pasireotide long acting release formulation,,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CSOM230CUS33,null,null,null,27-Nov-13,null,29-Dec-15,"University of Alabama at Birmingham Univ. of Alabama Birmingham, Birmingham, Alabama, United States|Advanced Research, LLC Advanced Reserch (4), Peoria, Arizona, United States|St. Joseph's Hospital Medical Center St. Joseph's Hosp Med Ctr (2), Phoenix, Arizona, United States|San Diego Coastal Endocrinology Group, Chula Vista, California, United States|University of Southern California Keck School of Medicine, Los Angeles, California, United States|University of California at Los Angeles UCLA - Los Angeles, Los Angeles, California, United States|John Wayne Cancer Institute Saint John's Health Center, Santa Monica, California, United States|Harbor-UCLA Medical Center Center for Men's Health, Torrance, California, United States|George Washington University Medical Center Medical Faculty Associates Inc, Washington, District of Columbia, United States|Center for Diabetes & Endocrine Care Dept.of Ctr for Diab&Endoc - 2, Hollywood, Florida, United States|Central Florida Endocrine & Diabetes Consultants, Maitland, Florida, United States|Endocrine Assoc of FL, Ocoee, Florida, United States|Emory University School of Medicine/Winship Cancer Institute Emory University (5), Atlanta, Georgia, United States|Dr. Steven Leichter, Endocrine Consultant, Columbus, Georgia, United States|Northwestern University Endo, Metabolism and Molecular, Chicago, Illinois, United States|The Johns Hopkins University School of Medicine Johns Hopkins University, Baltimore, Maryland, United States|Sinai Hospital of Baltimore Sinai Hospital, Baltimore, Baltimore, Maryland, United States|Tufts Medical Center Tufts Medical Ctr, Boston, Massachusetts, United States|Mayo Clinic - Rochester Mayo Clinic (2), Rochester, Minnesota, United States|Washington University, St. Louis, Missouri, United States|PALM MEDICAL RESEARCH CENTER Palm Research Center, Inc, Las Vegas, Nevada, United States|Robert Wood Johnson Medical School Div. Endo, Meta & Nutrition, New Brunswick, New Jersey, United States|University of New Mexico School of Medicine Univ of NM, Albuquerque, New Mexico, United States|Stony Brook Internists PC, East Setauket, New York, United States|Mount Sinai School of Medicine Mt. Sinai Schoof of Med., New York, New York, United States|Columbia University Medical Center- New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Endocrine Associates of Long Island, P.C., Smithtown, New York, United States|Endocrinology Associates Inc, Columbus, Ohio, United States|Toledo Clinic Toledo Clinic, Inc., Toledo, Ohio, United States|Oregon Health & Sciences University Oregon Health & Sciences, Portland, Oregon, United States|Thomas Jefferson University Jefferson University Physician, Philadelphia, Pennsylvania, United States|Allegheny Endocrinology Associates Allegheny Endo Associates, Pittsburgh, Pennsylvania, United States|MidState Endocrine Associates, Nashville, Tennessee, United States|Vanderbilt University Medical Center Clinical Trials Center, Nashville, Tennessee, United States|Baylor College of Medicine Division of Endocrinology, Houston, Texas, United States|Virginia Endocrinology Research, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Neuroscience Institute, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01995734
160,NCT01995305,Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents,,Available,No Results Available,"Fanconi Anemia|Autosomal or Sex Linked Recessive Genetic Disease|Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases.|Hematopoiesis Maintainance.",Genetic: human whole exome|Genetic: whole genomic,,Xiaofan Zhu|Chinese Academy of Medical Sciences,All,"1 Month to 18 Years   (Child, Adult)",,null,Other,Expanded Access,,pumc001|zhm001,null,null,null,26-Nov-13,null,26-Nov-13,"Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China",,https://ClinicalTrials.gov/show/NCT01995305
161,NCT01983722,Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome,,Available,No Results Available,Dravet Syndrome,Drug: Stiripentol,,"Children's Hospital Medical Center, Cincinnati",All,"6 Months and older   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,2013-5518,null,null,null,14-Nov-13,null,23-Aug-17,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01983722
162,NCT01947608,Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,,Available,No Results Available,Non-small Cell Lung Cancer (NSCLC),Drug: LDK378,,Novartis Pharmaceuticals|Novartis,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,CLDK378A2402,null,null,null,20-Sep-13,null,26-Jun-18,"Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Caba, Argentina|Novartis Investigative Site, Córdoba, Cordoba, Argentina|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Hongkong, Hong Kong|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Seongnam, Gyeonggi, Korea, Republic of|Novartis Investigative Site, Gyeonggi-do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho-gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ciudad De Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico D F, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Taguig City, Metro Manila, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT01947608
163,NCT01931306,Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC),,Approved for marketing,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Afatinib,,Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,"Expanded Access:Treatment IND/Protocol""",,1200.193,null,null,null,29-Aug-13,null,5-Jun-18,"The Catholic University of Korea, Bucheon St.Mary's Hospital, Bucheon, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01931306
164,NCT01931085,Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program),,Available,No Results Available,Parasitic Disease,Drug: Triclabendazole,,"University of Colorado, Denver",All,"18 Years to 99 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,11-1438,null,null,null,29-Aug-13,null,31-Jan-18,,,https://ClinicalTrials.gov/show/NCT01931085
165,NCT01918514,The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain,,Available,No Results Available,Pain,Drug: Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain,,State University of New York - Upstate Medical University,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,455904-3,null,null,null,7-Aug-13,null,7-Aug-13,"Upstate Comprehensive Pain Medicine Center, East Syracuse, New York, United States",,https://ClinicalTrials.gov/show/NCT01918514
166,NCT01917396,Influence of Preoperative Enema Application on Return of Gastrointestinal Function After Elective Cesarean Section: A Randomized Controlled Study,,Approved for marketing,No Results Available,Postoperative Bowel Sounds|Bowel Gass Passage,Drug: Fleet enema,,Istanbul Bakirkoy Maternity and Children Diseases Hospital,Female,18 Years to 44 Years   (Adult),,null,Other,Expanded Access,,Aşıcıoğlu 04,Aug-13,Dec-13,Oct-14,6-Aug-13,null,20-Feb-15,"Tepecik Education and Research Hospital,, İzmir, Yenisehir, Turkey",,https://ClinicalTrials.gov/show/NCT01917396
167,NCT01916148,18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia,,Available,No Results Available,Congenital Hyperinsulinism|Beckwith-Wiedemann Syndrome|Insulinoma,Drug: 18F-DOPA,,Children's Hospital of Philadelphia,All,"Child, Adult, Older Adult",,null,Other,Expanded Access,,12-009528,null,null,null,5-Aug-13,null,16-Feb-18,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01916148
168,NCT01908985,Ocular Fluorophotometry for Glaucoma Treated With Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU).,,Available,No Results Available,Refractory Open Angle Glaucoma,Procedure: high intensity focused ultrasound for cyclodestruction in the eye,,EyeTechCare,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,EYEMUST-FLUO,null,null,null,26-Jul-13,null,16-Jun-15,,,https://ClinicalTrials.gov/show/NCT01908985
169,NCT01902563,Osteopathic Approach Into Neonatology Ward: the NE-O Model,,Available,No Results Available,The Focus of the Study is to Provide a Guideline on Osteopathic Approach in Treating Hospitalized Newborns.,Other: Osteopathic Manipulative Treatment,,European Institute for Evidence Based Osteopathic Medicine,All,29 Weeks to 40 Weeks   (Child),,null,Other,Expanded Access,,NE-O-prot,null,null,null,18-Jul-13,null,19-May-14,,,https://ClinicalTrials.gov/show/NCT01902563
170,NCT01897740,Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil,,Available,No Results Available,Pulmonary Arterial Hypertension,Drug: sildenafil,,Pfizer,All,"10 Years to 30 Years   (Child, Adult)",,null,Industry,"Expanded Access:Individual Patients""",,A1481307,null,null,null,12-Jul-13,null,1-Jun-18,"Moscow Research Institute of Pediatrics and Pediatric Surgery, Moscow, Russian Federation",,https://ClinicalTrials.gov/show/NCT01897740
171,NCT01881334,Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants,,Available,No Results Available,Hematologic Malignancies|Inborn Errors of Metabolism Disorders|Immune Deficiencies,Biological: CliniMACS CD34 Reagent System,,"Joanne Kurtzberg, MD|Duke University|Miltenyi Biotec, Inc.",All,"up to 65 Years   (Child, Adult, Older Adult)",,null,Other|Industry,Expanded Access,,Pro00045700,null,null,null,19-Jun-13,null,16-Mar-18,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01881334
172,NCT01871233,An Extended Access Program for Perampanel,,Available,No Results Available,Partial Onset Seizures,Drug: Perampanel,,Eisai Inc.,All,"12 Years to 70 Years   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,E2007-G000-401,null,null,null,6-Jun-13,null,21-Sep-17,"Buenos Aires, Argentina|Cordoba, Argentina|Rosario, Argentina|San José Guaymallén, Argentina|San Miguel de Tucumán, Argentina|Fitzroy, Australia|Heidelberg, Australia|Parkville, Australia|Victoria, Australia|Edegem, Belgium|Gent, Belgium|Ottignies, Belgium|Calgary, Canada|London, Ontario, Canada|Toronto, Canada|Puente Alto, Chile|Santiago, Chile|Valdivia, Chile|Brno, Czechia|Hradec Kralove, Czechia|Ostrava, Czechia|Prague, Czechia|Laagri, Estonia|Vantaa, Finland|Greece, Greece|Kwai Chung, Hong Kong|Budapest, Hungary|Haifa, Israel|Netanya, Israel|Napoli, Italy|Prague, Latvia|Riga, Latvia|Kaunas, Lithuania|Petaling Jaya, Malaysia|Haarlem, Netherlands|Heeze, Netherlands|Gdansk, Poland|Albacete, Spain|Granada, Spain|Madrid, Spain|Valencia, Spain|Tainan, Taiwan|Taiwan, Taiwan|Taoyuan, Taiwan|Bangplee, Thailand",,https://ClinicalTrials.gov/show/NCT01871233
173,NCT01869803,Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia,,Approved for marketing,No Results Available,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Promyelocytic Leukemia (M3)|Childhood Acute Promyelocytic Leukemia (M3)|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia,Drug: gemtuzumab ozogamicin|Other: laboratory biomarker analysis,,Wake Forest University Health Sciences|National Cancer Institute (NCI),All,"18 Years and older   (Adult, Older Adult)",,null,Other|NIH,"Expanded Access:Intermediate-size Population""",,CCCWFU# 99213|NCI-2013-00965|P30CA012197,null,null,null,5-Jun-13,null,2-Mar-18,"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01869803
174,NCT01861834,Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage,,Available,No Results Available,Cholestasis of Parenteral Nutrition,Drug: Omegaven 10%,,Georgetown University,All,"2 Months to 18 Years   (Child, Adult)",,null,Other,Expanded Access,,IND107300,null,null,null,24-May-13,null,7-Mar-18,"MedStar Georgetown Transplant Institute, Washington, District of Columbia, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States",,https://ClinicalTrials.gov/show/NCT01861834
175,NCT01858103,BMN 110 US Expanded Access Program,,Approved for marketing,No Results Available,Mucopolysaccharidosis IVA|Morquio A Syndrome|MPS IVA,Drug: BMN 110,,BioMarin Pharmaceutical,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,110-503,null,null,null,21-May-13,null,2-Apr-14,"Birmingham, Alabama, United States|Little Rock, Arkansas, United States|Oakland, California, United States|Orange, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Hollywood, Florida, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Minneapolis, Minnesota, United States|Paterson, New Jersey, United States|Manhasset, New York, United States|New York, New York, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Nashville, Tennessee, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Tacoma, Washington, United States|Santurce, Puerto Rico",,https://ClinicalTrials.gov/show/NCT01858103
176,NCT01838187,"Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma",,Available,No Results Available,Neuroblastoma|Pheochromocytoma|Paraganglioma,Radiation: I-131 MIBG,,"Children's Hospital Medical Center, Cincinnati",All,"12 Months and older   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,MIBG Expanded Access (NDP),null,null,null,23-Apr-13,null,21-Dec-17,"Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States",,https://ClinicalTrials.gov/show/NCT01838187
177,NCT01835314,Compassionate Use of Stiripentol in Dravet Syndrome,,Available,No Results Available,Dravet Syndrome,Drug: Stiripentol,,"University of Colorado, Denver",All,"1 Year to 21 Years   (Child, Adult)",,null,Other,Expanded Access,,12-0315,null,null,null,18-Apr-13,null,10-May-18,"Children's Hospital Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01835314
178,NCT01825395,"Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome",3 4-DAP,Available,No Results Available,Lambert Eaton Myasthenic Syndrome,"Drug: 3, 4-Diaminopyridine",,"University of Colorado, Denver",All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,04-0567,null,null,null,5-Apr-13,null,10-May-18,"University of Colorado, Aurora, Colorado, United States",,https://ClinicalTrials.gov/show/NCT01825395
179,NCT01787136,Dextromethorphan Added on for the Patients With ADHD,DAOFTPWA,Available,No Results Available,Attention Deficit Hyperactivity Disorder,Drug: Dextromethorphan,,Tri-Service General Hospital,All,"6 Years to 25 Years   (Child, Adult)",,null,Other,Expanded Access,,TSGH-C97-87,null,null,null,8-Feb-13,null,24-Apr-18,,,https://ClinicalTrials.gov/show/NCT01787136
180,NCT01786850,Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer,,Available,No Results Available,Pancreas|Cancer|Locally Advanced Pancreatic Cancer|Non-invasive Treatment,Procedure: Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS),,University of Roma La Sapienza,All,"18 Years to 90 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,Pancreafus-01,null,null,null,8-Feb-13,null,18-Jun-14,"Sapienza University of Rome, Policlinico Umberto I Hospital, Rome, Italy",,https://ClinicalTrials.gov/show/NCT01786850
181,NCT01779518,Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C,,Approved for marketing,No Results Available,Post-transplant Hepatitis C,Drug: Sofosbuvir|Drug: Ribavirin|Drug: Pegylated Interferon,,Gilead Sciences,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,GS-US-334-0139,null,null,null,30-Jan-13,null,16-Jan-14,,,https://ClinicalTrials.gov/show/NCT01779518
182,NCT01776450,Compassionate Use of the Incraft® AAA Stent Graft System,,Available,No Results Available,Abdominal Aortic Aneurysm,Device: Endovascular AAA repair,,Cordis Corporation,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,G120003/S4,Nov-12,Aug-18,Aug-18,28-Jan-13,null,1-Jan-15,"Cordis Corporation, Fremont, California, United States",,https://ClinicalTrials.gov/show/NCT01776450
183,NCT01765140,"Treatment Use of 3,4-Diaminopyridine",,Available,No Results Available,"Lambert Eaton Myasthenic Syndrome (LEMS)|Myasthenic Syndromes, Congenital","Drug: 3,4-diaminopyridine",,"Vern C. Juel, M.D.|Duke University",All,"Child, Adult, Older Adult",,null,Other,Expanded Access,,Pro00007811,null,null,null,10-Jan-13,null,6-Feb-18,"Duke University Hospital, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01765140
184,NCT01724580,Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes,,Available,No Results Available,Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature (CANDLE)|Juvenile Dermatomyositis (JDM)|Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset During Infancy (SAVI)|Aicardi-Goutières Syndrome (AGS),Drug: Baricitinib,,Eli Lilly and Company,All,"6 Months and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,14559|I4V-MC-JAGA,null,null,null,12-Nov-12,null,18-Apr-18,"(CANDLE and SAVI participants)Translational Autoinflammatory Disease Studies (TADS) National Institutes of Health, Bethesda, Maryland, United States|(JDM participants) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) Pediatric Clinical Trials Unit (PCTU), National Institutes of Health, Bethesda, Maryland, United States|(AGS participants) Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01724580
185,NCT01683110,Expanded Access of Cabozantinib in Medullary Thyroid Cancer,,Approved for marketing,No Results Available,Medullary Thyroid Cancer,Drug: cabozantinib,,Exelixis,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,XL184-209,null,null,null,11-Sep-12,null,16-Jan-13,"Stanford, California, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01683110
186,NCT01659515,Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria,,Available,No Results Available,Infection Due to Resistant Organism,Drug: Arbekacin Sulfate,,"U.S. Army Medical Research and Materiel Command|Meiji Seika Pharma Co., Ltd.|Uniformed Services University of the Health Sciences",All,"18 Years and older   (Adult, Older Adult)",,null,U.S. Fed|Industry,Expanded Access,,S-11-0001,null,null,null,7-Aug-12,null,16-Jan-18,"Walter Reed National Military Medical Center (WRNMMC), Bethesda, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01659515
187,NCT01649284,Afatinib Expanded Access Program,,Approved for marketing,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: afatinib,,Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,1200.45,Jul-12,Mar-14,Mar-14,25-Jul-12,null,30-Nov-16,"1200.45.004 Boehringer Ingelheim Investigational Site, Mobile, Alabama, United States|1200.45.116 Boehringer Ingelheim Investigational Site, Goodyear, Arizona, United States|1200.45.057 Boehringer Ingelheim Investigational Site, Hot Springs, Arkansas, United States|1200.45.078 Boehringer Ingelheim Investigational Site, Anaheim, California, United States|1200.45.114 Boehringer Ingelheim Investigational Site, Burbank, California, United States|1200.45.123 Boehringer Ingelheim Investigational Site, Glendale, California, United States|1200.45.115 Boehringer Ingelheim Investigational Site, Lakewood, California, United States|1200.45.117 Boehringer Ingelheim Investigational Site, Long Beach, California, United States|1200.45.102 Boehringer Ingelheim Investigational Site, Monterey, California, United States|1200.45.091 Boehringer Ingelheim Investigational Site, Pleasant Hill, California, United States|1200.45.098 Boehringer Ingelheim Investigational Site, Pleasant Hill, California, United States|1200.45.006 Boehringer Ingelheim Investigational Site, Ranco Cucamonga, California, United States|1200.45.003 Boehringer Ingelheim Investigational Site, Southington, Connecticut, United States|1200.45.007 Boehringer Ingelheim Investigational Site, Stamford, Connecticut, United States|1200.45.026 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States|1200.45.097 Boehringer Ingelheim Investigational Site, Hollywood, Florida, United States|1200.45.017 Boehringer Ingelheim Investigational Site, Jacksonville, Florida, United States|1200.45.058 Boehringer Ingelheim Investigational Site, Jacksonville, Florida, United States|1200.45.016 Boehringer Ingelheim Investigational Site, Lakeland, Florida, United States|1200.45.103 Boehringer Ingelheim Investigational Site, Miami Beach, Florida, United States|1200.45.037 Boehringer Ingelheim Investigational Site, Orlando, Florida, United States|1200.45.056 Boehringer Ingelheim Investigational Site, Port St. Lucie, Florida, United States|1200.45.119 Boehringer Ingelheim Investigational Site, Titusville, Florida, United States|1200.45.095 Boehringer Ingelheim Investigational Site, Alpharetta, Georgia, United States|1200.45.029 Boehringer Ingelheim Investigational Site, Athens, Georgia, United States|1200.45.042 Boehringer Ingelheim Investigational Site, Macon, Georgia, United States|1200.45.121 Boehringer Ingelheim Investigational Site, Valdosta, Georgia, United States|1200.45.024 Boehringer Ingelheim Investigational Site, Decatur, Illinois, United States|1200.45.009 Boehringer Ingelheim Investigational Site, Evanston, Illinois, United States|1200.45.099 Boehringer Ingelheim Investigational Site, Peoria, Illinois, United States|1200.45.040 Boehringer Ingelheim Investigational Site, Waterloo, Iowa, United States|1200.45.041 Boehringer Ingelheim Investigational Site, Wichita, Kansas, United States|1200.45.083 Boehringer Ingelheim Investigational Site, Marrero, Louisiana, United States|1200.45.087 Boehringer Ingelheim Investigational Site, Metairie, Louisiana, United States|1200.45.019 Boehringer Ingelheim Investigational Site, Columbia, Maryland, United States|1200.45.039 Boehringer Ingelheim Investigational Site, Rockville, Maryland, United States|1200.45.053 Boehringer Ingelheim Investigational Site, Ann Arbor, Michigan, United States|1200.45.046 Boehringer Ingelheim Investigational Site, Detroit, Michigan, United States|1200.45.100 Boehringer Ingelheim Investigational Site, Jackson, Mississippi, United States|1200.45.067 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States|1200.45.071 Boehringer Ingelheim Investigational Site, Billings, Montana, United States|1200.45.021 Boehringer Ingelheim Investigational Site, Omaha, Nebraska, United States|1200.45.066 Boehringer Ingelheim Investigational Site, Freehold, New Jersey, United States|1200.45.105 Boehringer Ingelheim Investigational Site, Albuquerque, New Mexico, United States|1200.45.080 Boehringer Ingelheim Investigational Site, Brooklyn, New York, United States|1200.45.068 Boehringer Ingelheim Investigational Site, Fresh Meadows, New York, United States|1200.45.051 Boehringer Ingelheim Investigational Site, New York, New York, United States|1200.45.092 Boehringer Ingelheim Investigational Site, New York, New York, United States|1200.45.001 Boehringer Ingelheim Investigational Site, Charlotte, North Carolina, United States|1200.45.086 Boehringer Ingelheim Investigational Site, Bismarck, North Dakota, United States|1200.45.048 Boehringer Ingelheim Investigational Site, Minot, North Dakota, United States|1200.45.090 Boehringer Ingelheim Investigational Site, Canton, Ohio, United States|1200.45.005 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States|1200.45.089 Boehringer Ingelheim Investigational Site, Tulsa, Oklahoma, United States|1200.45.094 Boehringer Ingelheim Investigational Site, Portland, Oregon, United States|1200.45.020 Boehringer Ingelheim Investigational Site, Hershey, Pennsylvania, United States|1200.45.096 Boehringer Ingelheim Investigational Site, Johnstown, Pennsylvania, United States|1200.45.060 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States|1200.45.085 Boehringer Ingelheim Investigational Site, Pottstown, Pennsylvania, United States|1200.45.120 Boehringer Ingelheim Investigational Site, Rapid City, South Dakota, United States|1200.45.049 Boehringer Ingelheim Investigational Site, Cookeville, Tennessee, United States|1200.45.113 Boehringer Ingelheim Investigational Site, El Paso, Texas, United States|1200.45.045 Boehringer Ingelheim Investigational Site, Fairfax, Virginia, United States|1200.45.076 Boehringer Ingelheim Investigational Site, Seattle, Washington, United States|1200.45.093 Boehringer Ingelheim Investigational Site, Charleston, West Virginia, United States|1200.45.125 Boehringer Ingelheim Investigational Site, Wausau, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT01649284
188,NCT01641796,Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis,,Available,No Results Available,"Leishmaniasis, Cutaneous",Drug: Paromomycin,,U.S. Army Medical Research and Materiel Command,All,"Child, Adult, Older Adult",,null,U.S. Fed,Expanded Access,,S-12-13|S-12-13/M-10337,null,null,null,17-Jul-12,null,12-Oct-17,"Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Military Treatment Facilities, Multiple Locations, Maryland, United States",,https://ClinicalTrials.gov/show/NCT01641796
189,NCT01632826,Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma,PEXIUS,Approved for marketing,No Results Available,Multiple Myeloma,Drug: Pomalidomide,,Celgene,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CC-4047-MM-009,null,null,null,3-Jul-12,null,25-Apr-17,"Celgene Study Site, Duarte, California, United States|Celgene Study Site, Greenbrae, California, United States|Celgene Study Site, Los Angeles, California, United States|Celgene Study Site, Denver, Colorado, United States|Celgene Study Site, West Palm Beach, Florida, United States|Celgene Study Site, Marietta, Georgia, United States|Celgene Study Site, Peoria, Illinois, United States|Celgene Study Site, Indianapolis, Indiana, United States|Celgene Study Site, Iowa City, Iowa, United States|Celgene Study Site, Baltimore, Maryland, United States|Celgene Study Site, Hyannis, Massachusetts, United States|Celgene Study Site, Saint Louis, Missouri, United States|Celgene Study Site, Omaha, Nebraska, United States|Celgene Study Site, Hackensack, New Jersey, United States|Celgene Study Site, New York, New York, United States|Celgene Study Site, New York, New York, United States|Celgene Study Site, Philadelphia, Pennsylvania, United States|Celgene Study Site, Sellersville, Pennsylvania, United States|Celgene Study Site, Greenville, South Carolina, United States|Celgene Study Site, Sioux Falls, South Dakota, United States|Celgene Study Site, Dallas, Texas, United States|Celgene Study Site, Houston, Texas, United States|Celgene Study Site, Salt Lake City, Utah, United States|Celgene Study Site, Morgantown, West Virginia, United States|Celgene Study Site, Milwaukee, Wisconsin, United States|Celgene Study Site, Calgary, Alberta, Canada|Celgene Study Site, Edmonton, Alberta, Canada|Celgene Study Site, Vancouver, British Columbia, Canada|Celgene Study Site, Victoria, British Columbia, Canada|Celgene Study Site, Winnipeg, Manitoba, Canada|Celgene Study Site, St. John's, Newfoundland and Labrador, Canada|Celgene Study Site, Halifax, Nova Scotia, Canada|Celgene Study Site, Hamilton, Ontario, Canada|Celgene Study Site, London, Ontario, Canada|Celgene Study Site, Ottawa, Ontario, Canada|Celgene Study Site, Toronto, Ontario, Canada|Celgene Study Site, Windsor, Ontario, Canada|Celgene Study Site, Montreal, Quebec, Canada|Celgene Study Site, Montreal, Quebec, Canada|Celgene Study Site, Montreal, Quebec, Canada|Celgene Study Site, Quebec City, Quebec, Canada|Celgene Study Site, Saskatoon, Saskatchewan, Canada",,https://ClinicalTrials.gov/show/NCT01632826
190,NCT01606982,Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy,,Approved for marketing,No Results Available,Metastatic Castration-Resistant Prostate Cancer,Drug: MDV3100,,"Astellas Pharma Global Development, Inc.|Medivation, Inc.|Astellas Pharma Inc",Male,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,9785-CL-0401,null,null,null,28-May-12,null,17-Feb-17,,,https://ClinicalTrials.gov/show/NCT01606982
191,NCT01606475,Islet Transplant for Type 1 or Surgical Diabetes,EXAX,Available,No Results Available,Type 1 Diabetes Mellitus|Hypoglycemia|Labile Diabetes|End-stage Renal Disease,Biological: Allogeneic islets of Langerhans,,University of Minnesota - Clinical and Translational Science Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,1108M03061,null,null,null,25-May-12,null,25-Jun-18,"University of Minnesota, Minneapolis, Minnesota, United States",,https://ClinicalTrials.gov/show/NCT01606475
192,NCT01592136,Expanded Access Program of Ponatinib,,Approved for marketing,No Results Available,Chronic Myeloid Leukemia (CML)|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL),Drug: ponatinib,,Ariad Pharmaceuticals|Takeda,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,AP24534-12-901,null,null,null,7-May-12,null,6-Feb-18,"Moores UCSD Cancer Center, Site #165, La Jolla, California, United States|Southern California Permanente Medical Group, Site #161, San Marcos, California, United States|Kaiser Permanente Medical Center, Site #158, Vallejo, California, United States|Smilow Cancer Hospital at Yale New Haven, Site #182, New Haven, Connecticut, United States|Cancer Institute of Florida, Site #187, Altamonte Springs, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Site #017, Tampa, Florida, United States|Emory University, Site # 058, Atlanta, Georgia, United States|University of Chicago Medical Center, Site #001, Chicago, Illinois, United States|Indiana Blood and Marrow Transplantation, Site #138, Indianapolis, Indiana, United States|Norton Cancer Institute, Site #142, Louisville, Kentucky, United States|University of Maryland, Site #040, Baltimore, Maryland, United States|Tufts Medical Center, Site #141, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Site 008, Boston, Massachusetts, United States|University of Massachusetts Worcester, Site #152, Worcester, Massachusetts, United States|University of Michigan Health System, Site #011, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Site #034, Detroit, Michigan, United States|Mayo Clinic, Site #044, Rochester, Minnesota, United States|Freeman Cancer Institute, Site #190, Joplin, Missouri, United States|Washington University School of Medicine, Site 007, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Site 128, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Site #029, Buffalo, New York, United States|Weill Cornell Medical College - New York Presbyterian Hospital, Site #006, New York, New York, United States|University of Rochester, Site 137, Rochester, New York, United States|Duke University Medical Center, Site 003, Durham, North Carolina, United States|Jewish Hospital, Site #175, Cincinnati, Ohio, United States|Oregon Health & Science University (OHSU), Site 048, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Site #013, Philadelphia, Pennsylvania, United States|Jeanes Hospital of TUHS, Site #127, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Site #148, Charleston, South Carolina, United States|Tennesse Oncology, PLLC, Site # 076, Nashville, Tennessee, United States|The University of Texas M.D. Anderson Cancer Center, Site #005, Houston, Texas, United States|Huntsman Cancer Institute at the University of Utah, Site #043, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Site #100, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01592136
193,NCT01590680,Expanded Access Protocol Using I131-MIBG,,Available,No Results Available,Neuroblastoma|Pheochromocytoma|Paraganglioma,Radiation: I-131 MIBG,,Jubilant DraxImage Inc.,All,"12 Months and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,JDI2007-01,null,null,null,3-May-12,null,27-Sep-16,,,https://ClinicalTrials.gov/show/NCT01590680
194,NCT01579890,Compassionate Use of Pennsaid Topical Lotion (Diclofenac) in Osteo or Rheumatoid Arthritis,,Approved for marketing,No Results Available,Osteoarthritis of the Hand,Drug: Diclofenac,,Mallinckrodt|Nuvo Research Inc.,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,105-95,null,null,null,18-Apr-12,null,19-Apr-12,,,https://ClinicalTrials.gov/show/NCT01579890
195,NCT01487044,A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema,GUARDIAN,Available,No Results Available,Diabetic Macular Edema,Drug: Macugen (Pegaptanib Sodium),,Retina Institute of Hawaii|Eyetech Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",,null,Other|Industry,Expanded Access,,RIH 1006,null,null,null,7-Dec-11,null,7-Dec-11,"Retina Institute of Hawaii, Honolulu, Hawaii, United States",,https://ClinicalTrials.gov/show/NCT01487044
196,NCT01476163,Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease,,Available,No Results Available,Fabry Disease,Drug: migalastat HCl,,Amicus Therapeutics,All,"16 Years to 74 Years   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,AT1001-188,null,null,null,22-Nov-11,null,3-May-18,"CHOC Children's Hospital Division of Metabolic Disease, Orange, California, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Kidney Care and Transplant Services of New England, Springfield, Massachusetts, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Royal Melbourne Hospital, Parkville, Victoria, Australia",,https://ClinicalTrials.gov/show/NCT01476163
197,NCT01464762,Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis,,Approved for marketing,No Results Available,Tuberculosis,Drug: TMC207,,Janssen Infectious Diseases BVBA,All,"18 Years to 99 Years   (Adult, Older Adult)",,null,Industry,Expanded Access,,CR017233|TMC207TBC3001|2010-021125-12,null,null,null,4-Nov-11,null,27-Nov-17,"Vilnius, Lithuania|Arkhangelsk, Russian Federation|Moscow, Russian Federation|Orel, Russian Federation|Saint-Petersburg, Russian Federation",,https://ClinicalTrials.gov/show/NCT01464762
198,NCT01461304,Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism,,Available,No Results Available,"Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency|Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2)|Mitochondrial Trifunctional Protein Deficiency|Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency|Glycogen Storage Disorders|Pyruvate Carboxylase Deficiency Disease|ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of|Barth Syndrome",Drug: triheptanoin,,"Gerard Vockley, MD, PhD|Ultragenyx Pharmaceutical Inc|University of Pittsburgh",All,"1 Month and older   (Child, Adult, Older Adult)",,null,Other|Industry,Expanded Access,,PRO08020019,null,null,null,28-Oct-11,null,3-May-18,"University of Pittsburgh Division of Medical Genetics, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01461304
199,NCT01432301,Uridine Triacetate as Antidote for Patients at Excess Risk of 5-FU Toxicity Due to Overdosage or Impaired Elimination,,Approved for marketing,No Results Available,Toxicity Due to Chemotherapy,Drug: uridine triacetate,,Wellstat Therapeutics,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,401.10.001,null,null,null,12-Sep-11,null,7-Mar-16,,,https://ClinicalTrials.gov/show/NCT01432301
200,NCT01410500,Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease,,Approved for marketing,No Results Available,Multiple Myeloma,Drug: Carfilzomib,,Amgen|Multiple Myeloma Research Foundation,All,"18 Years and older   (Adult, Older Adult)",,null,Industry|Other,Expanded Access,,2011-002,null,null,null,5-Aug-11,null,2-May-17,,,https://ClinicalTrials.gov/show/NCT01410500
201,NCT01381289,VX-770 Expanded Access Program,,Approved for marketing,No Results Available,Cystic Fibrosis,Drug: VX-770,,Vertex Pharmaceuticals Incorporated,All,"6 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,VX11-770-901,null,null,null,27-Jun-11,null,9-Feb-12,,,https://ClinicalTrials.gov/show/NCT01381289
202,NCT01377532,Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma,,Available,No Results Available,Pheochromocytoma|Paraganglioma,Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG),,"University of California, San Francisco",All,"2 Years and older   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,CompUse MIBG Pheo,null,null,null,21-Jun-11,null,13-Dec-17,"UCSF, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01377532
203,NCT01370330,131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol,,Available,No Results Available,Neuroblastoma,Drug: Metaiodobenzylguanidine (MIBG),,"University of California, San Francisco",All,"1 Year and older   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,CompUse MIBG,null,null,null,9-Jun-11,null,9-Nov-17,"University of California, San Francisco, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01370330
204,NCT01327742,Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft,,Approved for marketing,No Results Available,Thoracic Aortic Aneurysm|Penetrating Ulcers,Device: Relay Thoracic Stent-Graft,,Bolton Medical,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,IP-0004-06 rev I,null,null,null,4-Apr-11,null,19-Nov-12,"Arizona Heart Hospital, Phoenix, Arizona, United States|Washington Hospital Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Baptist Cardiac and Vascular Institute, Miami, Florida, United States|Indiana Heart Hospital, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|University of North Carolina, Chapel Hill, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Sentara Heart Hospital, Norfolk, Virginia, United States|University Washington, Seattle, Washington, United States",,https://ClinicalTrials.gov/show/NCT01327742
205,NCT01317953,Oral Green Tea Extract for Small Cell Lung Cancer,,Available,No Results Available,Small Cell Lung Carcinoma,Dietary Supplement: epigallocatechin gallate,,Shandong Cancer Hospital and Institute,All,"18 Years to 70 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,GTESCLC2011,null,null,null,18-Mar-11,null,15-Mar-18,"Shan Dong cancer hospital and institute, Jinan, Shandong, China",,https://ClinicalTrials.gov/show/NCT01317953
206,NCT01301664,Cartilage Tissue Engineering,,Available,No Results Available,Mesenchymal Stem Cells,Other: total knee / hip replacement,,Chin-Hung Chang|Far Eastern Memorial Hospital,All,"30 Years to 70 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,97022,null,null,null,23-Feb-11,null,7-Mar-13,,,https://ClinicalTrials.gov/show/NCT01301664
207,NCT01297933,Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease,Omegaven,Available,No Results Available,Cholestasis|Short Bowel Syndrome,Drug: Omegaven,,Children's Hospital of Philadelphia,All,"up to 21 Years   (Child, Adult)",,null,Other,Expanded Access,,10-007681,null,null,null,17-Feb-11,null,3-May-18,"Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01297933
208,NCT01277796,Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis,HECT,Available,No Results Available,Cutaneous Leishmaniasis,Device: Heat pack conduction-heat therapy,,Universidad Peruana Cayetano Heredia|Tulane University School of Medicine,All,"8 Years to 80 Years   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,032-08,null,null,null,17-Jan-11,null,17-Jan-11,,,https://ClinicalTrials.gov/show/NCT01277796
209,NCT01267461,Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells,,Available,No Results Available,Endometrial Cancer|Colon Cancer,Other: Tissue sample from tumor,,Meir Medical Center|Tel Aviv University,Female,"18 Years to 90 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,0015-10-MMC,null,null,null,28-Dec-10,null,10-Aug-12,,,https://ClinicalTrials.gov/show/NCT01267461
210,NCT01250808,Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy,,Available,No Results Available,Multiple Myeloma,Drug: Bortezomib/Dexamethasone/Melphalan,,Peking University,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,2008ZX09312-026,null,null,null,1-Dec-10,null,1-Dec-10,"Institute of Hematology,Peking University, Peking, China",,https://ClinicalTrials.gov/show/NCT01250808
211,NCT01242891,Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device Under a Continued Access Protocol,CAP,Approved for marketing,No Results Available,Heart Failure|Cardiomyopathies,Device: EXCOR® Pediatric Ventricular Assist Device,,"Berlin Heart, Inc",All,up to 16 Years   (Child),,null,Industry,Expanded Access,,EXCOR® Continued Access,null,null,null,17-Nov-10,null,6-Mar-12,,,https://ClinicalTrials.gov/show/NCT01242891
212,NCT01240421,"An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory",,Approved for marketing,No Results Available,Metastatic Breast Cancer,Drug: Eribulin Mesylate,,Eisai Inc.,Female,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,E7389-G000-398,Mar-11,Mar-15,Nov-14,15-Nov-10,null,22-May-15,"Brussels, Belgium|Edmonton, Canada|London, Canada|Moncton, Canada|Montreal, Canada|Ottawa, Canada|Quebec, Canada|Toronto, Canada|Vancouver, Canada|Besancon, France|Marseille Cedex 09, France|Paris Cedex 05, France|Saint-cloud, France|Toulouse cedex, France",,https://ClinicalTrials.gov/show/NCT01240421
213,NCT01236287,Special Access for the Use of Voclosporin for Kidney Transplantation,,Available,No Results Available,"Immunosuppression|Transplantation, Kidney",Drug: Voclosporin,,Weill Medical College of Cornell University,All,"18 Years to 65 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,904010380,null,null,null,8-Nov-10,null,28-Feb-18,,,https://ClinicalTrials.gov/show/NCT01236287
214,NCT01220531,Thymus Transplantation Safety-Efficacy,,Available,No Results Available,Complete DiGeorge Anomaly|DiGeorge Syndrome|DiGeorge Anomaly|Complete DiGeorge Syndrome,Biological: Thymus Tissue for Transplantation|Procedure: Blood Draw|Drug: Rabbit anti-thymocyte globulin|Drug: Cyclosporine|Drug: Tacrolimus|Drug: Methylprednisolone or Prednisolone|Drug: Basiliximab|Drug: Mycophenolate mofetil,,M. Louise Markert|National Institutes of Health (NIH)|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Enzyvant Therapeutics GmbH|Duke University,All,"Child, Adult, Older Adult",,null,Other|NIH|Industry,"Expanded Access:Intermediate-size Population|Treatment IND/Protocol""",,Pro00025966|2R01AI047040-11A2|5K12HD043494-09,null,null,null,14-Oct-10,null,21-May-18,"Duke University Medical Center, Durham, North Carolina, United States",,https://ClinicalTrials.gov/show/NCT01220531
215,NCT01217697,Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer,,Approved for marketing,No Results Available,"Prostate Neoplasms|Genital Neoplasms, Male|Urogenital Neoplasms|Genital Diseases, Male",Drug: Abiraterone Acetate|Drug: Prednisone\Prednisolone,,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",All,"18 Years to 99 Years   (Adult, Older Adult)",,null,Industry,Expanded Access,,CR017479|212082PCR3001|2010-021425-13,null,null,null,8-Oct-10,null,24-Mar-17,"Birmingham, Alabama, United States|Mobile, Alabama, United States|Chandler, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Bellflower, California, United States|Berkeley, California, United States|Beverly Hills, California, United States|Duarte, California, United States|Encinitas, California, United States|Glendale, California, United States|Greenbrae, California, United States|La Jolla, California, United States|Laguna Hills, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Marina Del Rey, California, United States|Rancho Mirage, California, United States|San Diego, California, United States|San Francisco, California, United States|Santa Rosa, California, United States|Stanford, California, United States|Aurora, Colorado, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Fort Collins, Colorado, United States|Littleton, Colorado, United States|Hartford, Connecticut, United States|Manchester, Connecticut, United States|New Britain, Connecticut, United States|Norwalk, Connecticut, United States|Norwich, Connecticut, United States|Southington, Connecticut, United States|Stamford, Connecticut, United States|Torrington, Connecticut, United States|Trumball, Connecticut, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Gainesville, Florida, United States|Miami, Florida, United States|Ocala, Florida, United States|Orlando, Florida, United States|Palm Beach Gardens, Florida, United States|Port Saint Lucie, Florida, United States|South Miami, Florida, United States|Atlanta, Georgia, United States|Savannah, Georgia, United States|Honolulu, Hawaii, United States|Post Falls, Idaho, United States|Chicago, Illinois, United States|Decatur, Illinois, United States|Harvey, Illinois, United States|Niles, Illinois, United States|Peoria, Illinois, United States|Urbana, Illinois, United States|Fort Wayne, Indiana, United States|Lafayette, Indiana, United States|Merrillville, Indiana, United States|Muncie, Indiana, United States|Bettendorf, Iowa, United States|Westwood, Kansas, United States|Lexington, Kentucky, United States|Louisville, Kentucky, United States|Marrero, Louisiana, United States|New Orleans, Louisiana, United States|Bangor, Maine, United States|Scarborough, Maine, United States|Easton, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Worcester, Massachusetts, United States|Dearborn, Michigan, United States|Detroit, Michigan, United States|Grand Rapids, Michigan, United States|Lansing, Michigan, United States|Rochester, Minnesota, United States|Saint Louis Park, Minnesota, United States|St. Joseph, Missouri, United States|Billings, Montana, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Hooksett, New Hampshire, United States|Portsmouth, New Hampshire, United States|Cherry Hill, New Jersey, United States|Hackensack, New Jersey, United States|Livingston, New Jersey, United States|Morristown, New Jersey, United States|New Brunswick, New Jersey, United States|Paramus, New Jersey, United States|Los Alamos, New Mexico, United States|Albany, New York, United States|Binghamton, New York, United States|Bronx, New York, United States|Brooklyn, New York, United States|Buffalo, New York, United States|Cooperstown, New York, United States|Dunkirk, New York, United States|East Setauket, New York, United States|East Syracuse, New York, United States|Fresh Meadows, New York, United States|Glens Falls, New York, United States|Mt. Kisco, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|Rochester, New York, United States|Stony Brook, New York, United States|Syracuse, New York, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Greenville, North Carolina, United States|Hendersonville, North Carolina, United States|High Point, North Carolina, United States|Huntersville, North Carolina, United States|Pinehurst, North Carolina, United States|Raleigh, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Elyria, Ohio, United States|Massillon, Ohio, United States|Middletown, Ohio, United States|Sandusky, Ohio, United States|Bethany, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|West Reading, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Greenville, South Carolina, United States|Myrtle Beach, South Carolina, United States|Bristol, Tennessee, United States|Chattanooga, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|Galveston, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|The Woodlands, Texas, United States|Salt Lake City, Utah, United States|Burlington, Vermont, United States|Hampton, Virginia, United States|Newport News, Virginia, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Milwaukee, Wisconsin, United States|Adelaide, Australia|Bedford Park, Australia|Box Hill, Australia|Camperdown, Australia|Footscray, Australia|Garran, Australia|Geelong, Australia|Heidelberg, Australia|Herston, Australia|Hobart, Australia|Kogarah, Australia|Kurralta Park, Australia|Liverpool, Australia|Nedlands, Australia|Port Macquarie, Australia|Randwick, Australia|South Brisbane, Australia|Southport Qld, Australia|Subiaco, Australia|Sydney, Australia|Tamworth, Australia|Wahroonga, Australia|Westmead, Australia|Wodonga, Australia|Woolloongabba, Australia|Belo Horizonte, Brazil|Curitiba, Brazil|Porto Alegre, Brazil|Recife, Brazil|Rio De Janeiro, Brazil|Salvador, Brazil|Sao Paulo, Brazil|São Paulo, Brazil|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Regina, Saskatchewan, Canada|Calgary, Canada|London, Canada|N/a N/a, Canada|Quebec, Canada|Bogota, Colombia|Floridablanca, Colombia|Medellin, Colombia|Monteria, Colombia|Pereira, Colombia|Valledupar, Colombia|Split, Croatia|Zagreb, Croatia|Brno, Czech Republic|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Praha 2, Czech Republic|Usti Nad Labem, Czech Republic|Aarhus, Denmark|Copenhagen Ø, Denmark|Köpenhamn Ö, Denmark|Athens Attica, Greece|Athens, Greece|Crete, Greece|Larisa, Greece|Patra, Greece|Thessalonikis, Greece|Hk, Hong Kong|Hong Kong, Hong Kong|New Territories, Hong Kong|Sha Tin, Hong Kong|Budapest N/A, Hungary|Budapest, Hungary|Zalaegerszeg-P Zva N/A, Hungary|Jakarta, Indonesia|Hwasun Gun, Korea, Republic of|Seongnam-Si, Gyeonggi-Do, Korea, Republic of|Seoul, Korea, Republic of|Jalan Cheras N/A, Malaysia|Kota Kinabalu, Malaysia|Kuala Lumpur N/A, Malaysia|Kuala Lumpur, Malaysia|Subang Jaya, Malaysia|Acapulco, Guerrero, Mexico|Aguascalientes, Mexico|Chihuahua, Mexico|Ciudad De Mexico, Mexico|Cuernavaca, Mexico|Distrito Federal, Mexico|Durango, Mexico|Guadalajara, Mexico|Leon, Mexico|Mexico City, Mexico|Mexico, D.F., Mexico|Monterrey, Mexico|Oaxaca, Mexico|Veracruz, Mexico|Zamora, Mexico|Christchurch, New Zealand|Grafton, New Zealand|Hamilton, New Zealand|Palmerston North, New Zealand|Wellington, New Zealand|Gdansk, Poland|Lodz, Poland|Opole, Poland|Otwock, Poland|Wroclaw, Poland|Ponce, Puerto Rico|San Juan, Puerto Rico|Brasov, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Iasi, Romania|Barnaul, Russian Federation|Ekaterinburg, Russian Federation|Kazan, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Obninsk, Russian Federation|Omsk, Russian Federation|Pyatigorsk, Russian Federation|Rostov-On-Don, Russian Federation|Saint-Petersburg, Russian Federation|St Petersburg, Russian Federation|St-Petersburg, Russian Federation|Stavropol, Russian Federation|Ufa, Russian Federation|Singapore, Singapore|Badajoz, Spain|Barakaldo Vizcaya, Spain|Barcelona, Spain|Cordoba, Spain|Hospitalet. Barcelona, Spain|La Coruña, Spain|Madrid, Spain|Palma De Mallorca, Spain|Salamanca, Spain|Santa Cruz De Tenerife, Spain|Sevilla, Spain|Toledo, Spain|Valencia, Spain|Kaohsiung County, Taiwan|Kaohsiung, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand",,https://ClinicalTrials.gov/show/NCT01217697
216,NCT01216124,Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients,,Available,No Results Available,Triple Negative Local Advanced Breast Cancer,Drug: docetaxel oxaliplatin,,Fudan University|Chinese Anti-Cancer Association,Female,"18 Years to 65 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,Fudan TNBC Neo CT,null,null,null,7-Oct-10,null,7-Oct-10,,,https://ClinicalTrials.gov/show/NCT01216124
217,NCT01216111,Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer,,Available,No Results Available,Triple Negative Breast Cancer,Drug: Paclitaxel Cisplatin,,Fudan University|Chinese Anti-Cancer Association,Female,"18 Years to 65 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,Fudan TNBC Adjuvant CT,null,null,null,7-Oct-10,null,7-Oct-10,,,https://ClinicalTrials.gov/show/NCT01216111
218,NCT01209650,LUX Lung Special Access Scheme Australia Named Patient Use (NPU),,Approved for marketing,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: BIBW 2992,,Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,1200.47,null,null,null,27-Sep-10,null,10-Nov-16,"1200.47.1 Boehringer Ingelheim Investigational Site, North Ryde, New South Wales, Australia",,https://ClinicalTrials.gov/show/NCT01209650
219,NCT01200017,Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant,,Available,No Results Available,Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Lymphomas|Bone Marrow Failure|Hemoglobinopathy|Immune Deficiency|Osteopetrosis|Cytopenias|Leukocyte Disorders|Anemia Due to Intrinsic Red Cell Abnormality,"Biological: CD34+ enriched, T Cell Depleted donor stem cell product",,"University of California, San Francisco",All,"2 Months to 30 Years   (Child, Adult)",,null,Other,Expanded Access,,UCSF-10082,null,null,null,13-Sep-10,null,27-Nov-17,"University of California, San Francisco (UCSF) Children's Hospital, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT01200017
220,NCT01198860,Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B,HBV,Available,No Results Available,CHRONIC HEPATITIS B,Drug: CTH Chronic Hepatitis B,,"Triệu, Nguyễn Thị, M.D.",All,18 Years to 60 Years   (Adult),,null,Other,Expanded Access,,HBsAg 07-10 - Private Clinic,null,null,null,10-Sep-10,null,11-Oct-17,"Private Clinic TRAN MINH DUC, Hồ Chí Minh, Ho Chi Minh City, Vietnam",,https://ClinicalTrials.gov/show/NCT01198860
221,NCT01196208,A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001,,Available,No Results Available,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell, Cutaneous",Drug: brentuximab vedotin,,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.",All,"6 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,SGN35-010|2010-020363-21,null,null,null,8-Sep-10,null,11-Sep-17,"Stanford Cancer Center, Stanford, California, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|Peter MacCallum Cancer Center, Melbourne, Australia|Leuven University Hospital, Leuven, Belgium|Specializirana bolnica aktivno lechenie detsa ohcohematologichni zabolyavania Hematologichno, Sofia, Bulgaria|Specializirana bolnica za aktivno lechenie na hematologichni zabolyavania, Sofia, Bulgaria|Hopital Saint-Louis/Service d'Hematologie, Paris, Cedex 10, France|South Lyon Hospital Center, Department of Dermatology, Lyon, France|Centre Henri Becquerel / Centre Regional de Lutte Contre le Cancer, Rouen, France|Johannes Wesling Hospital Minden, Department of Dermatology, Minden, Germany|Szent Istvan es Szent Laszlo Korhaz Rendelointezet Haematologiai es Ossejt-transzplantacios osztaly, Budapest, Hungary|Debreceni Egyetem Orvos és Egeszsegtudomanyi Centrum, III. sz. Belgyogyaszati Klinika, Debrecen, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikat Kozpont, Szeged, Hungary|Polyclinic S. Orsola-Malpighi, Institute of Hematology and Medical Oncology ""Lorenzo and Ariosto Seragnoli"", Bologna, Italy|IRCCS University Hospital San Martino, Genoa, Italy|Klinika Hematologii, Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Klinika Hematologii, Instytut Hematologii i Transfuzjologii, Warsaw, Poland|Centrum Onkologii Institut im. Marii Sklodowskiej-Curie, Warsaw, Poland|Spitalul Clinic Judetean de Urgenta Targu Mures, Sectia Clinica Hematologie si Transplant Medular, Targu Mures, judetul Mures, Romania|Fundeni Clinical Institute, Center for Hematology and Bone Marrow Transplantation, Bucharest, Romania|Institutul Clinic Fundeni, Centrul de Hematologie si Transplant Medular Stefan Berceanu, Bucharest, Romania|Rossijskij onkologicheskij nauchnyj centr im. N.N. Blokhina RAMN, Moscow, Russian Federation|Gematologicheskj nauchnyj centr RAMN, Moscow, Russian Federation|Research Institute of Clinical Immunology, Novosibirsk, Russian Federation|Sankt-Peterburgskij gosudarstvennyj medicinskij universitet im. akademika I. P. Pavlova, St. Petersburg, Russian Federation|Clinical Center of Serbia, Clinic of Hematology, Belgrade, Serbia|University Hospital 12 de Octubre, Department of Dermatology, Madrid, Spain|University Hospital Zurich, Department of Dermatology, Zurich, Switzerland|Queen Elizabeth Hospital, Birmingham, United Kingdom|St John's Institute of Dermatology, London, United Kingdom",,https://ClinicalTrials.gov/show/NCT01196208
222,NCT01180218,Complete Lesion Versus Culprit Lesion Revascularization,COCUA,Available,No Results Available,Myocardial Infarction,Procedure: complete revascularization|Procedure: Culprit revasularization,,Korea University Guro Hospital,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,KoreaUGuroH_1,Jul-11,Jul-16,Jul-16,12-Aug-10,null,25-Apr-17,"Seung Woon Rha, Seoul, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT01180218
223,NCT01163383,131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma,,Available,No Results Available,Neuroblastoma|Childhood Metastatic Pheochromocytoma|Paraganglioma,Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)|Drug: 131 I-MIBG,,Children's Hospital of Philadelphia,All,"1 Year and older   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,2005-02-4159|CHP-830,null,null,null,15-Jul-10,null,27-Jul-17,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT01163383
224,NCT01160250,A Study of Vismodegib (GDC-0449) in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma,,Approved for marketing,No Results Available,Basal Cell Carcinoma,Drug: vismodegib (GDC-0449),,"Genentech, Inc.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,SHH4811g,Jul-10,Apr-12,Apr-12,12-Jul-10,null,6-Aug-15,"Scottsdale, Arizona, United States|Scottsdale, Arizona, United States|Los Angeles, California, United States|Stanford, California, United States|Ormond Beach, Florida, United States|Detroit, Michigan, United States|New York, New York, United States|Columbus, Ohio, United States|Philadelphia, Pennsylvania, United States|Nashville, Tennessee, United States|Houston, Texas, United States",,https://ClinicalTrials.gov/show/NCT01160250
225,NCT01151930,Long-Term Compassionate Use Study for Continued Administration of SCB01A-01,,Available,No Results Available,Malignant Solid Tumour,Drug: SCB01A,,"SynCore Biotechnology Co., Ltd.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,SCB01A-01-B,null,null,null,29-Jun-10,null,19-Oct-17,,,https://ClinicalTrials.gov/show/NCT01151930
226,NCT01112332,Weight-bearing Measuring Device to Determine Normative Percentage Body-Weight/Weight-Bearing Values and Weight-bearing Gait Characteristics,SSW001,Available,No Results Available,Percentage Body-Weight|Weight-Bearing Values|Weight-bearing Gait Characteristics,Device: SmartStep insole,,Meir Medical Center,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,042-2010,Mar-10,null,null,28-Apr-10,null,10-Aug-12,"Jerusalem Sports Medicine Institute, Lerner Sports Center, Hebrew University of Jerusalem, Jerusalem, Israel",,https://ClinicalTrials.gov/show/NCT01112332
227,NCT01076517,A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma,,Available,No Results Available,Liver Cancer,Device: Therasphere,,Stanford University|BTG International Inc.,All,"Child, Adult, Older Adult",,null,Other,Expanded Access,,XHEP0016-NOT-RESEARCH|HEP0016|14324,null,null,null,26-Feb-10,null,18-Apr-18,"Stanford University School of Medicine, Stanford, California, United States",,https://ClinicalTrials.gov/show/NCT01076517
228,NCT00994916,"Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine",,Available,No Results Available,Lambert-Eaton Myasthenic Syndrome,"Drug: 3,4 diaminopyridine",,David Lacomis|Jacobus Pharmaceutical|University of Pittsburgh,All,"18 Years and older   (Adult, Older Adult)",,null,Other|Industry,Expanded Access,,IRB0410047,null,null,null,14-Oct-09,null,7-Nov-17,,,https://ClinicalTrials.gov/show/NCT00994916
229,NCT00989807,Expanded Access Program for Aztreonam Lysine for Inhalation in Canadian Patients With Cystic Fibrosis,EAP,Approved for marketing,No Results Available,Cystic Fibrosis|Pseudomonas Aeruginosa,Drug: Aztreonam lysine,,Gilead Sciences,All,"6 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,EA-US-205-0122,null,null,null,6-Oct-09,null,13-Dec-12,"University of Calgary, Adult CF Clinic, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada",,https://ClinicalTrials.gov/show/NCT00989807
230,NCT00965614,"To Validate the Specific Patterns of Magnetocardiography, a Non-invasive Non-contact Examination for Patients With Ischemic Heart Disease or Cardiac Arrhythmia",,Available,No Results Available,Arrhythmia,Other: MCG,,National Taiwan University Hospital,All,"18 Years to 80 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,34MD01,null,null,null,25-Aug-09,null,21-Dec-12,,,https://ClinicalTrials.gov/show/NCT00965614
231,NCT00965315,A Multicenter Randomized Parallel-group Study to Investigate the Efficacy of a Combination of Rosuvastatin and Fenofibrate in the Patients With Diabetes or Atherosclerotic Vascular Diseases With Metabolic Syndrome,,Available,No Results Available,Diabetes|CVD,"Drug: Rosuvastatin,SFC fenofibrate",,National Taiwan University Hospital,All,"20 Years to 79 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,200711014M,null,null,null,25-Aug-09,null,21-Dec-12,,,https://ClinicalTrials.gov/show/NCT00965315
232,NCT00954460,Treatment Protocol of Velaglucerase Alfa for Patients With Type 1 Gaucher Disease,,Approved for marketing,No Results Available,"Gaucher Disease, Type 1",Drug: velaglucerase alfa,,Shire,All,"3 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,HGT-GCB-058,null,null,null,7-Aug-09,null,21-Feb-14,"St Joseph's Hospital & Medical Center, Phoenix, Arizona, United States|Tower Hematology Oncology, Beverly Hills, California, United States|Rady's Children's Hospital of San Diego, La Jolla, California, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|The Permanente Medical Group, Sacramento, California, United States|Stanford University Medical Genetics, Stanford, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|University Research Foundation for Lysosomal Storage Diseases, Coral Springs, Florida, United States|Gainesville Hematology Oncology Associates, Gainesville, Florida, United States|Adventis Healthcare System dba Florida Hospital, Orlando, Florida, United States|East Lake Oncology, Palm Harbor, Florida, United States|Emory Genetics, Decatur, Georgia, United States|Children's Memorial Hospital, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Annapolis Oncology Center, Annapolis, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|University of Massachusetts, Shrewsbury, Massachusetts, United States|Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, United States|The University Research Foundation for Lysosomal Storage Diseases, Kansas City, Missouri, United States|St. Joseph's, Patterson, New Jersey, United States|Hemophilia Center of Western New York Incorporated, Buffalo, New York, United States|North Shore Hematology/Oncology - Manhasset, Manhasset, New York, United States|New York University School of Medicine, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Fullerton Genetic, Ashville, North Carolina, United States|Duke Medical Center, Durham, North Carolina, United States|Akron Children's Hospital, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|University of Virginia Health Systems, Charlottesville, Virginia, United States|O & O Alpan, LLC, Springfield, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00954460
233,NCT00948948,Mentor Adjunct Study for Silicone Gel-Filled Mammary Prosthesis,Adjunct,Approved for marketing,No Results Available,Breast Reconstruction,Device: Silicone Gel-Filled Mammary Prostheses,,"Mentor Worldwide, LLC",Female,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,5033,null,null,null,29-Jul-09,null,5-Apr-13,"Mentor Worldwide LLC, Santa Barbara, California, United States",,https://ClinicalTrials.gov/show/NCT00948948
234,NCT00934258,Effect of Genes on Rosuvastatin Therapy for Hyperlipidemia,,Available,No Results Available,Hyperlipidemia,"Drug: rosuvastatin,fenofibrate|Genetic: CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP",,National Taiwan University Hospital,All,"20 Years to 79 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,200812111R,null,null,null,8-Jul-09,null,21-Dec-12,,,https://ClinicalTrials.gov/show/NCT00934258
235,NCT00933205,An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.,,Approved for marketing,No Results Available,HIV Infections,Drug: Tipranavir,,Boehringer Ingelheim,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,1182.16,May-04,Jun-08,null,7-Jul-09,null,30-Nov-16,"1182.16.3202 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium|1182.16.3203 Boehringer Ingelheim Investigational Site, Brussel, Belgium|1182.16.3205 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1182.16.3206 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1182.16.3207 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1182.16.3211 Boehringer Ingelheim Investigational Site, Charleroi, Belgium|1182.16.3204 Boehringer Ingelheim Investigational Site, Gent, Belgium|1182.16.3201 Boehringer Ingelheim Investigational Site, Leuven, Belgium|1182.16.3208 Boehringer Ingelheim Investigational Site, Liège, Belgium|1182.16.3212 Boehringer Ingelheim Investigational Site, Liège, Belgium|1182.16.3209 Boehringer Ingelheim Investigational Site, Luxembourg, Belgium|1182.16.5511 Unidade de Pesquisa Clínica (UPC) - AIDS, Campinas - Sp, Brazil|1182.16.5505 Hospital São José de Doenças Infecciosas de Fortaleza, Fortaleza - Ce, Brazil|1182.16.5502 Hospital Nossa Senhora da Conceiç, Porto Alegre - Rs, Brazil|1182.16.5504 Hospital das Clínicas de Porto Alegre, Porto Alegre - Rs, Brazil|1182.16.5512 Ambulatório de DST/ AIDS - RS, Porto Alegre - Rs, Brazil|1182.16.5509, Rio de Janeiro - Rj, Brazil|1182.16.5513 Centro de Pesquisa Hospital Evandro Chagras, Rio de Janeiro, Brazil|1182.16.5510, Santos - Sp, Brazil|1182.16.5501 UNIFESP/ Hospital São Paulo- Univers. Federal de São Paulo, São Paulo - Sp, Brazil|1182.16.5506 Casa da AIDS da FMUSP, São Paulo - Sp, Brazil|1182.16.5507 Hospital do Servidor Público Estadual de São Paulo, São Paulo - Sp, Brazil|1182.16.5508, Vila Mariana, Brazil|1182.16.1118, Calgary, Alberta, Canada|1182.16.1104 University of Alberta H-Site, Edmonton, Alberta, Canada|1182.16.1101 St. Paul's Hospital, Vancouver, British Columbia, Canada|1182.16.1111 Downtown Infectious Diseases Clinic, Vancouver, British Columbia, Canada|1182.16.1125 St. Boniface General Hospital, Winnipeg, Manitoba, Canada|1182.16.1131 The Moncton Hospital, Moncton, New Brunswick, Canada|1182.16.1128 Centre for Clinical Research, Halifax, Nova Scotia, Canada|1182.16.1112 McMaster University Medical Centre, Hamilton, Ontario, Canada|1182.16.1126 HIV Care Programme, London, Ontario, Canada|1182.16.1132 Infectious Diseases Consultant, Oakville, Ontario, Canada|1182.16.1102 Canadian Immunodeficiency Research Collaborative Inc., Toronto, Ontario, Canada|1182.16.1107 Sunnybrook & Woman's College Health Science Centre, Toronto, Ontario, Canada|1182.16.1109 Infectious Diseases and HIV, Toronto, Ontario, Canada|1182.16.1110 Toronto East General Hospital, Toronto, Ontario, Canada|1182.16.1114 Toronto General Hospital, Toronto, Ontario, Canada|1182.16.1115, Toronto, Ontario, Canada|1182.16.1124, Toronto, Ontario, Canada|1182.16.1106 Positive Care Clinic, Whitby, Ontario, Canada|1182.16.1120 Metropolitan Campus, Windsor, Ontario, Canada|1182.16.1116 Immune Deficiency Treatment Centre, Monteal, Quebec, Canada|1182.16.1103 Hopital Notre Dame CHUM, Montreal, Quebec, Canada|1182.16.1113 Montreal Chest Institute, McGill University Health Centre, Montreal, Quebec, Canada|1182.16.1117 Clinique medicale l'Actuel, Montreal, Quebec, Canada|1182.16.1119, Montreal, Quebec, Canada|1182.16.1122 Infectious Diseases, Montreal, Quebec, Canada|1182.16.1130 Clinique Medicale LORI, Montreal, Quebec, Canada|1182.16.4501 Boehringer Ingelheim Investigational Site, Copenhagen, Denmark|1182.16.4502 Boehringer Ingelheim Investigational Site, Hvidovre, Denmark|1182.16.4504 Boehringer Ingelheim Investigational Site, Odense C, Denmark|1182.16.3491 Boehringer Ingelheim Investigational Site, Vic (Barcelona), El Salvador|1182.16.3464 Boehringer Ingelheim Investigational Site, Vizcaya, El Salvador|1182.16.3001 ""Andreas Syggros""Hospital of Dermatological & Veneral Diseas, Athens, Greece|1182.16.3002 ""Greek Red Cross"" Hospital, 3rd Internal Medicine Clinic, Athens, Greece|1182.16.3004 ""Attiko"" Hospital, 4th Internal Medicine Clinic, UOA, Athens, Greece|1182.16.3005 Laiko Hospital, 2nd District Blood Donation Center & Haemato, Athens, Greece|1182.16.3007 1st Social Insurance Foundation (IKA) Pentelis, Athens, Greece|1182.16.3010 University Hospital of Patras, Patras, Greece|1182.16.3008 ""Tzanio"" Hospital, Piraeus, Greece|1182.16.3009 AHEPA Hospital, Thessaloniki, Greece|1182.16.3932 Azienda Ospedaliera Umberto I, Ancona, Italy|1182.16.3923 Ospedale Santa Maria Annunziata, Antella (fi), Italy|1182.16.3952 Centro di riferimento oncologico, Aviano - PD, Italy|1182.16.3958 A.O. Ospedale Clinico Consorziale, Bari, Italy|1182.16.3920 Ospedali Riuniti di Bergamo, Bergamo, Italy|1182.16.3946 Ospedale Policlinico S. Orsola Bologna, Bologna, Italy|1182.16.3938 Ospedale Civile Regionale, Bolzano, Italy|1182.16.3901 Università di Brescia, Brescia, Italy|1182.16.3957 A.O. Spedali Civili di Brescia, Brescia, Italy|1182.16.3928 Azienda Ospedaliera, Busto Arsizio (va), Italy|1182.16.3964 Ospedale SS. Trinità, Cagliari, Italy|1182.16.3947 U.O. Malattie Infettive, Catania, Italy|1182.16.3961 Ospedale Pugliese, Catanzaro, Italy|1182.16.3954 Ospedale Civile, Cuggiono-MI, Italy|1182.16.3963 Azienda Ospedaliera Arcispedale S. Anna, Ferrara, Italy|1182.16.3924 Azienda Ospedaliera Careggi, Firenze, Italy|1182.16.3902 Ospedali Riuniti di Foggia, Foggia, Italy|1182.16.3911 U.O. di Malattie Infettive, Foggia, Italy|1182.16.3926 Azienda Ospedaliera, Genova, Italy|1182.16.3927 Azienda Ospedaliera, Genova, Italy|1182.16.3929 Malattie Infettive, Genova, Italy|1182.16.3912 Ospedale ""A. Manzoni"", Lecco, Italy|1182.16.3925 Azienda Ospedaliera Carlo Poma, Mantova, Italy|1182.16.3951 Ospedale Civile Umberto I, Mestre-VE, Italy|1182.16.3903 Ospedale L. Sacco, Milano, Italy|1182.16.3904 Ospedale Luigi Sacco, Milano, Italy|1182.16.3910 Ospedale Luigi Sacco, Milano, Italy|1182.16.3913 Fondazione Centro S. Raffaele del Monte Tabor, Milano, Italy|1182.16.3953 ospedale Niguarda, Milano, Italy|1182.16.3965 Ospedale Maggiore, Milano, Italy|1182.16.3968 Azienda Ospedaliera Policlinico, Modena, Italy|1182.16.3934 Azienda Ospedaliera D. Cotugno, Napoli, Italy|1182.16.3937 Azienda Ospedaliera D. Cotugno, Napoli, Italy|1182.16.3942 Azienda Ospedaliera di Padova, Padova, Italy|1182.16.3914 Presidio Ospedaliero di Verbania, PALLANZA (Verbania), Italy|1182.16.3948 U.O. Malattie Infettive ed Epatologia, Parma, Italy|1182.16.3909 I.R.C.C.S. Policlinico San Matteo, Pavia, Italy|1182.16.3921 IRCCS Policlinico San Matteo, Pavia, Italy|1182.16.3966 Policlinico Monteluce, Perugia, Italy|1182.16.3955 Ospedale San Salvatore, Pesaro, Italy|1182.16.3967 Ospedale Civile dello Spirito Santo, Pescara, Italy|1182.16.3944 Ospedale Cisanello, Pisa, Italy|1182.16.3931 Ospedale Santa Maria delle Croci, Ravenna, Italy|1182.16.3930 Arcispedale S. Maria Nuova, Reggio Emilia, Italy|1182.16.3905 IRCCS Lazzaro Spallanzani, Roma, Italy|1182.16.3906 IRCCS Lazzaro Spallanzani, Roma, Italy|1182.16.3907 IRCCS Lazzaro Spallanzani, Roma, Italy|1182.16.3908 IRCCS Lazzaro Spallanzani, Roma, Italy|1182.16.3915 Azienda Policlinico Umberto I, Roma, Italy|1182.16.3922 Università ""La Sapienza"", Roma, Italy|1182.16.3941 Istituto Nazionale per le Malattie Infettive, Roma, Italy|1182.16.3960 Università Cattolica del Sacro Cuore, Roma, Italy|1182.16.3945 Istituto Malattie Infettive Università Di Sassari, Sassari, Italy|1182.16.3970 Ospedale San Giuseppe Moscati, Statte (ta), Italy|1182.16.3917 Ospedale Amedeo di Savoia, Torino, Italy|1182.16.3918 Ospedale Amedeo di Savoia, Torino, Italy|1182.16.3919 Ospedale Amedeo di Savoia, Torino, Italy|1182.16.3933 Azienda Ospedaliera Umberto I, Torrette Di Ancona, Italy|1182.16.3939 Ospedale Regionale, Torrette Di Ancona, Italy|1182.16.3940 Presidio Ospedaliero Cà Foncello, Treviso, Italy|1182.16.3943 Policlinico Universitario di Udine, Udine, Italy|1182.16.3916 Ospedale di Circolo e Fondazione Macchi, Varese, Italy|1182.16.3950 Ospedale SS. Giovanni e Paolo, Venezia, Italy|1182.16.3949 Policlinico Rossi ""Borgo Roma"", Verona, Italy|1182.16.3959 Ospedale Civile di Vicenza - USSL 6, Vicenza, Italy|1182.16.3503 Centro Hospitalar de Lisboa, Lisboa, Portugal|1182.16.3502 Hospital São Francisco Xavier, Lisbon, Portugal|1182.16.3505 Hospital Santa Maria, Lisbon, Portugal|1182.16.3501 Unidade Local de Saúde de Matosinhos, Matosinhos, Portugal|1182.16.3504 Hospital Joaquim Urbano, Porto, Portugal|1182.16.3419 Boehringer Ingelheim Investigational Site, A Coruña, Spain|1182.16.3412 Boehringer Ingelheim Investigational Site, Alcalá de Henares (Madrid), Spain|1182.16.3432 Boehringer Ingelheim Investigational Site, Alicante, Spain|1182.16.3484 Boehringer Ingelheim Investigational Site, Almeria, Spain|1182.16.3487 Boehringer Ingelheim Investigational Site, Arrecife (Lanzarote), Spain|1182.16.3474 Boehringer Ingelheim Investigational Site, Aviles (Asturias), Spain|1182.16.3440, Badalona, Spain|1182.16.3454 Boehringer Ingelheim Investigational Site, Baracaldo (Vizcaya), Spain|1182.16.3438 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1182.16.3442 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1182.16.3448 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1182.16.3449 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1182.16.3463 Boehringer Ingelheim Investigational Site, Bilbao, Spain|1182.16.3476 Boehringer Ingelheim Investigational Site, Cadiz, Spain|1182.16.3430 Boehringer Ingelheim Investigational Site, Cartagena, Spain|1182.16.3462 Boehringer Ingelheim Investigational Site, Castellón, Spain|1182.16.3429 Boehringer Ingelheim Investigational Site, Cordoba, Spain|1182.16.3431 Boehringer Ingelheim Investigational Site, El Palmar (MURCIA), Spain|1182.16.3488 Boehringer Ingelheim Investigational Site, Gandia (Valencia), Spain|1182.16.3443 Boehringer Ingelheim Investigational Site, Gerona, Spain|1182.16.3411 Boehringer Ingelheim Investigational Site, Getafe (Madrid), Spain|1182.16.3418 Boehringer Ingelheim Investigational Site, Gijón (ASTURIAS), Spain|1182.16.3427 Boehringer Ingelheim Investigational Site, Granada, Spain|1182.16.3428 Boehringer Ingelheim Investigational Site, Granada, Spain|1182.16.3439 Boehringer Ingelheim Investigational Site, Granollers (Barcelona), Spain|1182.16.3477 Boehringer Ingelheim Investigational Site, Hospitalet de Llobregat (Barcelona), Spain|1182.16.3445 Boehringer Ingelheim Investigational Site, Hospitalet de Llobregat, Spain|1182.16.3480 Boehringer Ingelheim Investigational Site, Huelva, Spain|1182.16.3498 Boehringer Ingelheim Investigational Site, Ibiza, Spain|1182.16.3479 Boehringer Ingelheim Investigational Site, Jaen, Spain|1182.16.3423 Boehringer Ingelheim Investigational Site, Jerez de la Frontera, Spain|1182.16.3436 Boehringer Ingelheim Investigational Site, La Laguna (santa Cruz de Tenerife), Spain|1182.16.3437 Boehringer Ingelheim Investigational Site, Las Palmas de Gran Canarias, Spain|1182.16.3434 Boehringer Ingelheim Investigational Site, Las Palmas de Gran Canaria, Spain|1182.16.3470 Boehringer Ingelheim Investigational Site, Leganés (Madrid), Spain|1182.16.3441 Boehringer Ingelheim Investigational Site, Lleida, Spain|1182.16.3490 Boehringer Ingelheim Investigational Site, Logroño, Spain|1182.16.3401 Boehringer Ingelheim Investigational Site, Madrid, Spain|1182.16.3402 Boehringer Ingelheim Investigational Site, Madrid, Spain|1182.16.3404 Boehringer Ingelheim Investigational Site, Madrid, Spain|1182.16.3405 Boehringer Ingelheim Investigational Site, Madrid, Spain|1182.16.3406 Boehringer Ingelheim Investigational Site, Madrid, Spain|1182.16.3407 Boehringer Ingelheim Investigational Site, Madrid, Spain|1182.16.3408 Boehringer Ingelheim Investigational Site, Madrid, Spain|1182.16.3409 Boehringer Ingelheim Investigational Site, Madrid, Spain|1182.16.3413 Boehringer Ingelheim Investigational Site, Madrid, Spain|1182.16.3424 Boehringer Ingelheim Investigational Site, Malaga, Spain|1182.16.3494 Boehringer Ingelheim Investigational Site, Manresa (Barcelona), Spain|1182.16.3426 Boehringer Ingelheim Investigational Site, Marbella (Málaga), Spain|1182.16.3493 Boehringer Ingelheim Investigational Site, Mataro, Spain|1182.16.3492, Mataró (Barcelona), Spain|1182.16.3425 Boehringer Ingelheim Investigational Site, Málaga, Spain|1182.16.3410 Boehringer Ingelheim Investigational Site, Móstoles (Madrid), Spain|1182.16.3489 Boehringer Ingelheim Investigational Site, Navarra, Spain|1182.16.3472 Boehringer Ingelheim Investigational Site, Ourense, Spain|1182.16.3417 Boehringer Ingelheim Investigational Site, Oviedo (Asturias), Spain|1182.16.3496 Boehringer Ingelheim Investigational Site, Palma de Mallorca, Spain|1182.16.3450 Boehringer Ingelheim Investigational Site, Plama de Mallorca, Spain|1182.16.3497 Boehringer Ingelheim Investigational Site, Reus (Tarragona), Spain|1182.16.3446 Boehringer Ingelheim Investigational Site, Sabadell (Barcelona), Spain|1182.16.3453 Boehringer Ingelheim Investigational Site, San Sebastian, Spain|1182.16.3435 Boehringer Ingelheim Investigational Site, Santa Cruz de Tenerife, Spain|1182.16.3455 Boehringer Ingelheim Investigational Site, Santander, Spain|1182.16.3415 Boehringer Ingelheim Investigational Site, Santiago de Compostela, Spain|1182.16.3420 Boehringer Ingelheim Investigational Site, Sevilla, Spain|1182.16.3421 Boehringer Ingelheim Investigational Site, Sevilla, Spain|1182.16.3422 Boehringer Ingelheim Investigational Site, Sevilla, Spain|1182.16.3447 Boehringer Ingelheim Investigational Site, Tarragona, Spain|1182.16.3495 Boehringer Ingelheim Investigational Site, Tarragona, Spain|1182.16.3444 Boehringer Ingelheim Investigational Site, Terrassa, Spain|1182.16.3456 Boehringer Ingelheim Investigational Site, Valencia, Spain|1182.16.3457 Boehringer Ingelheim Investigational Site, Valencia, Spain|1182.16.3458 Boehringer Ingelheim Investigational Site, Valencia, Spain|1182.16.3460 Boehringer Ingelheim Investigational Site, Valencia, Spain|1182.16.3461 Boehringer Ingelheim Investigational Site, Valencia, Spain|1182.16.3403 Boehringer Ingelheim Investigational Site, Valladolid, Spain|1182.16.3467 Boehringer Ingelheim Investigational Site, Vigo (Pontevedra), Spain|1182.16.3416 Boehringer Ingelheim Investigational Site, Vigo, Spain|1182.16.3482 Boehringer Ingelheim Investigational Site, Villajoyosa (ALICANTE), Spain|1182.16.3483 Boehringer Ingelheim Investigational Site, Vitoria, Spain|1182.16.3471 Boehringer Ingelheim Investigational Site, Zamora, Spain|1182.16.3451 Boehringer Ingelheim Investigational Site, Zaragoza, Spain|1182.16.3452 Boehringer Ingelheim Investigational Site, zARAGOZA, Spain",,https://ClinicalTrials.gov/show/NCT00933205
236,NCT00918424,Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects,,Approved for marketing,No Results Available,Epilepsy,Drug: Oxcarbazepine Extended Release,,"Supernus Pharmaceuticals, Inc.",All,4 Years to 17 Years   (Child),,null,Industry,Expanded Access,,804P303,Jun-09,null,null,11-Jun-09,null,9-May-17,"Site 03, Loxahatchee Groves, Florida, United States|Palm Beach, Florida, United States|Site 02, Rockville, Maryland, United States|Site 05, Rochester, New York, United States|Kingsport, Tennessee, United States|Site 07, San Antonio, Texas, United States",,https://ClinicalTrials.gov/show/NCT00918424
237,NCT00905593,"Nilotinib in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase",ENACT,Approved for marketing,No Results Available,Chronic Myeloid Leukemia,Drug: Nilotinib,,Novartis Pharmaceuticals|Novartis,All,18 Years to 60 Years   (Adult),,null,Industry,Expanded Access,,CAMN107AMX01,Sep-08,Apr-11,null,20-May-09,null,18-Jul-12,"Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Mexico City, Mexico",,https://ClinicalTrials.gov/show/NCT00905593
238,NCT00889135,Long Term Treatment With L-DOPS,,Approved for marketing,No Results Available,Dopamine Beta Hydroxylase (DBH) Deficiency,Drug: droxidopa,,Vanderbilt University,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,41037,Sep-04,Jun-15,Jun-15,28-Apr-09,null,18-Oct-16,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00889135
239,NCT00866164,Prometra's Utilization in Mitigating Pain II,(PUMP 2),Approved for marketing,No Results Available,Intractable Pain|Back Pain|Leg Pain|Arm Pain|Trunk Pain,Device: Prometra Programmable Pump,,Flowonix Medical,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,G060192/S019,null,null,null,20-Mar-09,null,5-Mar-12,,,https://ClinicalTrials.gov/show/NCT00866164
240,NCT00854841,The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder,,Available,No Results Available,Chronic Myeloid Leukemia,Drug: Dasatinib and Imatinib,,Pusan National University Hospital,All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,CA180-257|KCML02,null,null,null,3-Mar-09,null,3-Mar-09,,,https://ClinicalTrials.gov/show/NCT00854841
241,NCT00815529,Clinical Research on the Efficacy of Acupuncture Treatment in Chronic Low Back Pain,,Available,No Results Available,Chronic Low Back Pain|Acupuncture,"Device: Acupuncture, Pak-sham needle",,Kyunghee University Medical Center|Korea Health Industry Development Institute,All,"18 Years to 65 Years   (Adult, Older Adult)",,null,Other,Expanded Access,,KyungHU,null,null,null,30-Dec-08,null,30-Dec-08,"East West Neo Medical Center, Kyung-hee university, Seoul, Gangdong-Gu, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00815529
242,NCT00811525,Post Approval Continued Access Study of the MENTOR® Contour Profile Gel Breast Implant,CPG-CA,Approved for marketing,No Results Available,Breast Augmentation|Breast Reconstruction|Breast Revision,Device: Mentor Siltex® Contour Profile Gel Mammary Prosthesis,,"Mentor Worldwide, LLC",Female,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,110390CA-0912-2,Aug-04,null,null,19-Dec-08,null,2-Dec-14,,,https://ClinicalTrials.gov/show/NCT00811525
243,NCT00786058,A Phase III Second Line Trial in Advanced Pancreatic Cancer CONKO 003,,Approved for marketing,No Results Available,Pancreatic Cancer,Drug: OFF in experimental arm,,CONKO-Studiengruppe|Sanofi|medac GmbH|Amgen,All,"18 Years and older   (Adult, Older Adult)",,null,Other|Industry,Expanded Access,,CONKO 003|CCT-NAPN-16751,null,null,null,5-Nov-08,null,15-Jun-09,,,https://ClinicalTrials.gov/show/NCT00786058
244,NCT00765557,"Randomized, Double-Blinded, Placebo-Controlled Trial of Laxatives for Children With Urge Syndrome",,Available,No Results Available,Urge Syndrome,Drug: Miralax,,University of Texas Southwestern Medical Center,All,"4 Years to 21 Years   (Child, Adult)",,null,Other,Expanded Access,,122004-038,null,null,null,3-Oct-08,null,3-Oct-08,,,https://ClinicalTrials.gov/show/NCT00765557
245,NCT00765531,Hypercalciuria and Calcium Stone Disease in Caucasian Patients,,Available,No Results Available,Hypercalciuria|Calcium Stone Disease,Radiation: Radiological testing|Genetic: Pediatric Urologic DNA and History Repository,,University of Texas Southwestern Medical Center,All,"4 Years to 20 Years   (Child, Adult)",,null,Other,Expanded Access,,1101-577,null,null,null,3-Oct-08,null,31-Oct-08,,,https://ClinicalTrials.gov/show/NCT00765531
246,NCT00764543,Ambulatory Blood Pressure Measurement in Children With Congenital Urine Flow Obstruction,,Available,No Results Available,Hydronephrosis|Multicystic-Dysplastic Kidney,Device: 24-hour ambulatory blood pressure monitor,,University of Texas Southwestern Medical Center,All,up to 24 Months   (Child),,null,Other,Expanded Access,,052005-008,null,null,null,2-Oct-08,null,2-Oct-08,,,https://ClinicalTrials.gov/show/NCT00764543
247,NCT00752349,To Evaluate Oral Phase Swallowing Function Using Submental Ultrasound,,Available,No Results Available,Dysphagia,Procedure: Ultrasound,,National Taiwan University Hospital,All,"20 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,200702029R,null,null,null,15-Sep-08,null,15-Sep-08,,,https://ClinicalTrials.gov/show/NCT00752349
248,NCT00733447,SynCardia Freedom Driver System Study,,Approved for marketing,No Results Available,Biventricular Failure,Device: CardioWest temporary Total Artificial Heart (TAH-t) System,,SynCardia Systems. LLC,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,RA-142|P030011,Mar-10,Aug-13,May-14,13-Aug-08,null,30-Jul-15,"Mayo Clinic Hospital, Phoenix, Arizona, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Virginia Commonwealth University Medical Center, Richmond, Virginia, United States",,https://ClinicalTrials.gov/show/NCT00733447
249,NCT00730444,Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma,,Approved for marketing,No Results Available,Neuroblastoma,Drug: Iobenguane I 123 Injection,,GE Healthcare,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,GE 122-008,null,null,null,8-Aug-08,null,9-Nov-09,"GE Healthcare, Princeton, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00730444
250,NCT00719225,A Belatacept Compassionate Use Study for Patients With a Kidney Transplant,,Approved for marketing,No Results Available,Renal Transplantation,Drug: Belatacept,,Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,IM103-056,null,null,null,21-Jul-08,null,14-Jul-11,"Scripps Green Hospital, La Jolla, California, United States|Office Of Dr. Allan Kirk, Atlanta, Georgia, United States|Local Institution, New Iberia, Louisiana, United States|Tulane Abdominal Transplant, New Orleans, Louisiana, United States|The Transplant Center Of The Lehigh Valley, Allentown, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00719225
251,NCT00704925,"Treatment of Lambert-Eaton Syndrome With 3,4 DAP",,Available,No Results Available,Lambert Eaton Myasthenic Syndrome,"Drug: 3, 4 DAP",,"David P. Richman, MD|Jacobus Pharmaceutical|University of California, Davis",All,"18 Years and older   (Adult, Older Adult)",,null,Other|Industry,Expanded Access,,200311036,null,null,null,25-Jun-08,null,21-May-18,"University of California, Davis, Sacramento, California, United States",,https://ClinicalTrials.gov/show/NCT00704925
252,NCT00650390,Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab,PROWD,Approved for marketing,No Results Available,Rheumatoid Arthritis,Biological: adalimumab,,Abbott,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,M02-532,null,null,null,1-Apr-08,null,1-Apr-08,,,https://ClinicalTrials.gov/show/NCT00650390
253,NCT00650026,Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis,ReAct,Approved for marketing,No Results Available,Rheumatoid Arthritis,Biological: adalimumab,,Abbott,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,M03-583,null,null,null,1-Apr-08,null,14-Apr-08,,,https://ClinicalTrials.gov/show/NCT00650026
254,NCT00649545,Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis,CanAct,Approved for marketing,No Results Available,Rheumatoid Arthritis,Biological: adalimumab,,Abbott,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,M02-574,null,null,null,1-Apr-08,null,1-Apr-08,,,https://ClinicalTrials.gov/show/NCT00649545
255,NCT00642057,Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements,TBZ,Available,No Results Available,Hyperkinetic Movement Disorders,Drug: tetrabenazine,,Christine Hunter|Baylor College of Medicine,All,"Child, Adult, Older Adult",,null,Other,Expanded Access,,H-721,Jun-89,Dec-09,Feb-13,24-Mar-08,null,27-Sep-16,,,https://ClinicalTrials.gov/show/NCT00642057
256,NCT00590382,Emergency/Compassionate Use - Muscular VSD Occluder,,Approved for marketing,No Results Available,Muscular|Ventricular|Septal|Defects|VSD,Device: AMPLATZER Muscular VSD Occluder,,St. Jude Medical,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,AGA-005 - E/C|G990289,null,null,null,10-Jan-08,null,29-Jan-15,,,https://ClinicalTrials.gov/show/NCT00590382
257,NCT00584064,Emergency/Compassionate Use PFO Occluder,,Available,No Results Available,Patent Foramen Ovale|PFO,Device: Device closure with the AMPLATZER PFO Occluder,,St. Jude Medical,All,18 Years to 60 Years   (Adult),,null,Industry,Expanded Access,,AGA-006 - E/C,null,null,null,2-Jan-08,null,21-Jul-16,,,https://ClinicalTrials.gov/show/NCT00584064
258,NCT00580658,Humanitarian Device Exemption,Dystonia IRB,Approved for marketing,No Results Available,Dystonia,Device: Medtronic Activa Gpi,,Vanderbilt University,All,"7 Years and older   (Child, Adult, Older Adult)",,null,Other,Expanded Access,,60155,May-06,null,May-20,27-Dec-07,null,13-May-16,"Vanderbilt University, Nashville, Tennessee, United States",,https://ClinicalTrials.gov/show/NCT00580658
259,NCT00575549,Prospective Analysis and Comparison of Stress Echo to Real-Time Myocardial Contrast Stress Echo,,Available,No Results Available,Evaluation of Troponin I Levels,Other: Dobutamine: Perflutren Lipid Microsphere,,University of Nebraska|Bristol-Myers Squibb,All,"19 Years and older   (Adult, Older Adult)",,null,Other|Industry,Expanded Access,,311-07-FB,null,null,null,18-Dec-07,null,23-Jul-12,"University of Nebraska Medical Center, Omaha, Nebraska, United States",,https://ClinicalTrials.gov/show/NCT00575549
260,NCT00528320,Clinical Evaluation of Cardiac Resynchronization Therapy (CRT) Using the Ovatio CRT Implantable Cardioverter-defibrillator (ICD) System,,Approved for marketing,No Results Available,Congestive Heart Failure (CHF),Device: Ovatio CRT,,"ELA Medical, Inc.",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,ITAC06,null,null,null,12-Sep-07,null,27-Nov-13,,,https://ClinicalTrials.gov/show/NCT00528320
261,NCT00520143,Alglucosidase Alfa Temporary Access Program,ATAP,Approved for marketing,No Results Available,Glycogen Storage Disease Type II (GSD-II)|Pompe Disease (Late-Onset)|Acid Maltase Deficiency Disease|Glycogenosis 2,Biological: alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA]),,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,AGLU03907,null,null,null,23-Aug-07,null,6-Feb-14,"Sheffield, Alabama, United States|Anchorage, Alaska, United States|Phoenix, Arizona, United States|Prescott, Arizona, United States|Scottsdale, Arizona, United States|Tucson, Arizona, United States|Bakersfield, California, United States|Beverly Hills, California, United States|Loma Linda, California, United States|Los Angeles, California, United States|Sacramento, California, United States|San Diego, California, United States|Stanford, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Bradenton, Florida, United States|Coral Springs, Florida, United States|Daytona Beach, Florida, United States|Gainsville, Florida, United States|St. Petersburg, Florida, United States|Decatur, Georgia, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Evansville, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Shreveport, Louisiana, United States|Augusta, Maine, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Springfield, Massachusetts, United States|Detroit, Michigan, United States|Grand Rapids, Michigan, United States|Lake Orion, Michigan, United States|Rochester Hills, Michigan, United States|St. Joseph, Michigan, United States|Minneapolis, Minnesota, United States|Missoula, Montana, United States|Omaha, Nebraska, United States|Midland Park, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Corning, New York, United States|Manhasset, New York, United States|New York, New York, United States|Asheville, North Carolina, United States|Durham, North Carolina, United States|Jacksonville, North Carolina, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Greenville, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Tulsa, Oklahoma, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Greenville, South Carolina, United States|West Colombia, South Carolina, United States|Houston, Texas, United States|San Antonio, Texas, United States|Waco, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Chesapeake, Virginia, United States|Newport News, Virginia, United States|Richmond, Virginia, United States|Winchester, Virginia, United States|Pullman, Washington, United States|Seattle, Washington, United States|Morgantown, West Virginia, United States|Green Bay, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00520143
262,NCT00508963,Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis,,Available,No Results Available,"Leishmaniasis, Cutaneous|Leishmaniasis, Mucocutaneous",Drug: sodium stibogluconate (Pentostam),,"University of California, San Francisco",All,"18 Years and older   (Adult, Older Adult)",,null,Other,Expanded Access,,UCSF Infectious Diseases,null,null,null,30-Jul-07,null,15-Dec-14,"University of CA at San Francisco Hospitals and Clinics, San Francisco, California, United States",,https://ClinicalTrials.gov/show/NCT00508963
263,NCT00499720,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection,,Approved for marketing,No Results Available,Cystic Fibrosis|Pseudomonas Aeruginosa Airway Infection,Drug: Aztreonam Lysine for Inhalation,,Gilead Sciences,All,"6 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,EA-US-205-0111,null,null,null,11-Jul-07,null,2-Aug-11,"Birmingham, Alabama, United States|Anchorage, Alaska, United States|Phoenix, Arizona, United States|Little Rock, Arkansas, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|San Francisco, California, United States|Denver, Colorado, United States|Denver, Colorado, United States|Hartford, Connecticut, United States|Hartford, Connecticut, United States|Ft, Meyers, Florida, United States|Gainesville, Florida, United States|Orlando, Florida, United States|St. Petersburg, Florida, United States|Tampa, Florida, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Maywood, Illinois, United States|Des Moines, Iowa, United States|Wichita, Kansas, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Kansas City, Missouri, United States|Great Falls, Montana, United States|Las Vegas, Nevada, United States|Long Branch, New Jersey, United States|New Brunswick, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Buffalo, New York, United States|New Hyde Park, New York, United States|New York, New York, United States|New York, New York, United States|Syracuse, New York, United States|Valhalla, New York, United States|Chapel Hill, North Carolina, United States|Akron, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Toledo, Ohio, United States|Oklahoma City, Oklahoma, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Sioux Falls, South Dakota, United States|Memphis, Tennessee, United States|Dallas, Texas, United States|Ft. Worth, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Portsmouth, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|San Juan, Puerto Rico",,https://ClinicalTrials.gov/show/NCT00499720
264,NCT00484991,Sapropterin Expanded Access Program,,Approved for marketing,No Results Available,Phenylketonuria,Drug: Sapropterin dihydrochloride,,BioMarin Pharmaceutical,All,"9 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,SEAP-001,null,null,null,12-Jun-07,null,15-Apr-08,"Los Angeles, California, United States|Orange, California, United States|San Diego, California, United States|Stanford, California, United States|Denver, Colorado, United States|Gainseville, Florida, United States|Tampa, Florida, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Bangor, Maine, United States|Boston, Massachusetts, United States|Minneapolis, Minnesota, United States|Columbia, Missouri, United States|Kansas City, Missouri, United States|St. Louis, Missouri, United States|Newark, New Jersey, United States|Manhasset, New York, United States|Rochester, New York, United States|Stony Brook, New York, United States|Valhalla, New York, United States|Akron, Ohio, United States|Columbus, Ohio, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Florence, South Carolina, United States|Sioux Falls, South Dakota, United States|Galveston, Texas, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Charlottesville, Virginia, United States|Norfolk, Virginia, United States|Madison, Wisconsin, United States|Milwakee, Wisconsin, United States",,https://ClinicalTrials.gov/show/NCT00484991
265,NCT00481559,Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity,,Approved for marketing,No Results Available,Neoplasms,Drug: Voraxaze (glucarpidase),,BTG International Inc.|CTI Clinical Trial and Consulting Services,All,"Child, Adult, Older Adult",,null,Other,Expanded Access,,PR001-CLN-pro016,null,null,null,1-Jun-07,null,17-Jan-14,,,https://ClinicalTrials.gov/show/NCT00481559
266,NCT00457548,Phone Intervention for Alcohol (ETOH) Use in Emergency Department Motor Vehicle Crash (ED MVC) Patients,DIAL,Available,No Results Available,Alcoholic Intoxication|Wounds and Injuries,Behavioral: Brief Telephone Counseling for risky aclohol use,,Rhode Island Hospital|Centers for Disease Control and Prevention,All,"18 Years and older   (Adult, Older Adult)",,null,Other|U.S. Fed,Expanded Access,,R49/CCR123228-03,null,null,null,6-Apr-07,null,30-Mar-11,,,https://ClinicalTrials.gov/show/NCT00457548
267,NCT00454753,Korean Early Access Program,,Approved for marketing,No Results Available,Leukemia,Drug: Dasatinib,,Bristol-Myers Squibb,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CA180-109,May-07,null,null,2-Apr-07,null,12-May-10,"Local Institution, Busan, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daejeon, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Incheon, Korea, Republic of|Local Institution, Jellanamdo, Korea, Republic of|Local Institution, Jeollabuk-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Ulsan, Korea, Republic of",,https://ClinicalTrials.gov/show/NCT00454753
268,NCT00438789,The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol,EMBRACE,Approved for marketing,No Results Available,"Hemoglobinuria, Paroxysmal",Drug: eculizumab,,Alexion Pharmaceuticals,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,C06-002,null,null,null,22-Feb-07,null,6-May-14,"Anthony Botti, Livingston, New Jersey, United States",,https://ClinicalTrials.gov/show/NCT00438789
269,NCT00377065,Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023),,Approved for marketing,No Results Available,HIV Infections,Drug: raltegravir,,Merck Sharp & Dohme Corp.,All,"16 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,0518-023|MK0518-023|2006_031,null,null,null,15-Sep-06,null,22-Apr-16,,,https://ClinicalTrials.gov/show/NCT00377065
270,NCT00338442,Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection,,Approved for marketing,No Results Available,Varicella,Drug: VariZIG™,,Cangene Corporation,All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,VZ-009,Feb-06,Dec-09,Dec-09,20-Jun-06,null,4-Apr-13,,,https://ClinicalTrials.gov/show/NCT00338442
271,NCT00338247,EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer,,Approved for marketing,No Results Available,"Neoplasms, Breast",Drug: lapatinib + capecitabine,,Novartis,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,EGF103659,Jul-06,Mar-15,Mar-15,20-Jun-06,null,6-Apr-16,"Novartis Investigative Site, Huntsville, Alabama, United States|Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Glendale, Arizona, United States|Novartis Investigative Site, Fayetteville, Arkansas, United States|Novartis Investigative Site, Little Rock, Arkansas, United States|Novartis Investigative Site, Bellflower, California, United States|Novartis Investigative Site, Burbank, California, United States|Novartis Investigative Site, Gilroy, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Long Beach, California, United States|Novartis Investigative Site, Newport Beach, California, United States|Novartis Investigative Site, San Diego, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Santa Rosa, California, United States|Novartis Investigative Site, Stockton, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Lafayette, Colorado, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, Manchester, Connecticut, United States|Novartis Investigative Site, New Havey, Connecticut, United States|Novartis Investigative Site, Norwich, Connecticut, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Fort Walton Beach, Florida, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Brunswick, Georgia, United States|Novartis Investigative Site, Macon, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Tucker, Georgia, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Decatur, Illinois, United States|Novartis Investigative Site, Galesburg, Illinois, United States|Novartis Investigative Site, Highland Park, Illinois, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Zion, Illinois, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Bettendorf, Iowa, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Council Bluffs, Iowa, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Metairie, Louisiana, United States|Novartis Investigative Site, Portland, Maine, United States|Novartis Investigative Site, Scarborough, Maine, United States|Novartis Investigative Site, Waterville, Maine, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Chevy Chase, Maryland, United States|Novartis Investigative Site, Frederick, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Fall River, Massachusetts, United States|Novartis Investigative Site, Peabody, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Royal Oak, Michigan, United States|Novartis Investigative Site, Troy, Michigan, United States|Novartis Investigative Site, Duluth, Minnesota, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Columbia, Missouri, United States|Novartis Investigative Site, Kalamazoo, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Billings, Montana, United States|Novartis Investigative Site, Great Falls, Montana, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, North Platte, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Exeter, New Hampshire, United States|Novartis Investigative Site, Flemington, New Jersey, United States|Novartis Investigative Site, Freehold, New Jersey, United States|Novartis Investigative Site, Little Silver, New Jersey, United States|Novartis Investigative Site, Livingston, New Jersey, United States|Novartis Investigative Site, Mountain Lakes, New Jersey, United States|Novartis Investigative Site, Newark, New Jersey, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, East Setauket, New York, United States|Novartis Investigative Site, East Syracuse, New York, United States|Novartis Investigative Site, Fresh Meadows, New York, United States|Novartis Investigative Site, Glens Falls, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Fayetteville, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Bismarck, North Dakota, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Sandusky, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Klamath Falls, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Drexel Hill, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Pottstown, Pennsylvania, United States|Novartis Investigative Site, Sayre, Pennsylvania, United States|Novartis Investigative Site, State College, Pennsylvania, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, Florence, South Carolina, United States|Novartis Investigative Site, Mt. Pleasant, South Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, El Paso, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Fairfax, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Kennewick, Washington, United States|Novartis Investigative Site, Mount Vernon, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Walla Walla, Washington, United States|Novartis Investigative Site, Morgantown, West Virginia, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, La Crosse, Wisconsin, United States|Novartis Investigative Site, Marshfield, Wisconsin, United States|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Port Macquarie, New South Wales, Australia|Novartis Investigative Site, Waratah, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Geelong, Victoria, Australia|Novartis Investigative Site, Wodonga, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Haine Saint Paul, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liège, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Salvador, Bahía, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Jau, São Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, São Paulo, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Winnipeg, Manitoba, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Oshawa, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Dalian, Liaoning, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Strovolos, Cyprus|Novartis Investigative Site, Brno, Czech Republic|Novartis Investigative Site, Olomouc, Czech Republic|Novartis Investigative Site, Praha, Czech Republic|Novartis Investigative Site, Praha, Czech Republic|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Roskilde, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Århus C, Denmark|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Hämeenlinna, Finland|Novartis Investigative Site, Kangasala, Finland|Novartis Investigative Site, Kuopio, Finland|Novartis Investigative Site, OYS, Finland|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuebingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Augsburg, Bayern, Germany|Novartis Investigative Site, Marburg, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Braunschweig, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Ibbenbueren, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Moenchengladbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Troisdorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Mainz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Luebeck, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion, Crete, Greece|Novartis Investigative Site, Maroussi, Greece|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Shatin, Hong Kong|Novartis Investigative Site, Reykjavik, Iceland|Novartis Investigative Site, Jakarta, Indonesia|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Tallaght, Dublin, Ireland|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Potenza, Basilicata, Italy|Novartis Investigative Site, Reggio Calabria, Calabria, Italy|Novartis Investigative Site, Napoli, Campania, Italy|Novartis Investigative Site, Forlì, Emilia-Romagna, Italy|Novartis Investigative Site, Modena, Emilia-Romagna, Italy|Novartis Investigative Site, Aviano (PN), Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Bergamo, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Candiolo (TO), Piemonte, Italy|Novartis Investigative Site, Torino, Piemonte, Italy|Novartis Investigative Site, Bari, Puglia, Italy|Novartis Investigative Site, San Giovanni Rotondo (FG), Puglia, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Pisa, Toscana, Italy|Novartis Investigative Site, Bolzano, Trentino-Alto Adige, Italy|Novartis Investigative Site, Perugia, Umbria, Italy|Novartis Investigative Site, Ancona, Italy|Novartis Investigative Site, Cagliari, Italy|Novartis Investigative Site, Chieti, Italy|Novartis Investigative Site, Macerata, Italy|Novartis Investigative Site, Padova, Italy|Novartis Investigative Site, Trieste, Italy|Novartis Investigative Site, Kyunggi-do, Korea, Republic of|Novartis Investigative Site, Pusan, Korea, Republic of|Novartis Investigative Site, seodaemun-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Luxembourg, Luxembourg|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Petaling Jaya Selangor, Malaysia|Novartis Investigative Site, Floriana, Malta|Novartis Investigative Site, Tijuana, Baja California Norte, Mexico|Novartis Investigative Site, Toluca, Edo Mex, Estado de México, Mexico|Novartis Investigative Site, Merida, Yucatán, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Dordrecht, Netherlands|Novartis Investigative Site, Enschede, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Christchurch, New Zealand|Novartis Investigative Site, Dunedin, New Zealand|Novartis Investigative Site, Newtown, Wellington, New Zealand|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Makati City, Philippines|Novartis Investigative Site, Pasay City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Sampaloc Manila, Philippines|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Elblag, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Evora, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Sibiu, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Irkutsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Banska Bystrica, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Poprad, Slovakia|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Maribor, Slovenia|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Basurto/Bilbao, Spain|Novartis Investigative Site, Burgos, Spain|Novartis Investigative Site, Caceres, Spain|Novartis Investigative Site, Elche, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Jaén, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Palencia, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, Pontevedra, Spain|Novartis Investigative Site, San Sebastián, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Santiago, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Jonkoping, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Umeå, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Chur, Switzerland|Novartis Investigative Site, Geneve, Switzerland|Novartis Investigative Site, Mendrisio, Switzerland|Novartis Investigative Site, Neuchatel, Switzerland|Novartis Investigative Site, St Gallen, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan County, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Pathumthani, Thailand|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Rovno, Ukraine|Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom|Novartis Investigative Site, Chelmsford, Essex, United Kingdom|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Edinburgh, Midlothian, United Kingdom|Novartis Investigative Site, Belfast, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Brighton, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, Cheltenham, United Kingdom|Novartis Investigative Site, Colchester, United Kingdom|Novartis Investigative Site, Cumbria, United Kingdom|Novartis Investigative Site, Denbighshire, United Kingdom|Novartis Investigative Site, Hartshill, Stoke-on-Trent, United Kingdom|Novartis Investigative Site, Lindley, huddersfield, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Peterborough, United Kingdom|Novartis Investigative Site, Poole, Dorset, United Kingdom|Novartis Investigative Site, Portsmouth, United Kingdom|Novartis Investigative Site, Shrewsbury, United Kingdom",,https://ClinicalTrials.gov/show/NCT00338247
272,NCT00293098,Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease,,Approved for marketing,No Results Available,Iron Overload,Drug: deferiprone,,Children's Hospital of Philadelphia|ApoPharma,All,"Child, Adult, Older Adult",,null,Other|Industry,Expanded Access,,2006-2-4700,Mar-06,null,null,17-Feb-06,null,9-Feb-12,"The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",,https://ClinicalTrials.gov/show/NCT00293098
273,NCT00291811,Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization,CUP,Approved for marketing,No Results Available,Autologous Stem Cell Transplant,Drug: AMD3100 + G-CSF,,"Genzyme, a Sanofi Company|Sanofi",All,"18 Years to 78 Years   (Adult, Older Adult)",,null,Industry,Expanded Access,,AMD3100-CUP001,Oct-03,null,null,15-Feb-06,null,11-Feb-14,,,https://ClinicalTrials.gov/show/NCT00291811
274,NCT00245739,"TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.",,Approved for marketing,No Results Available,HIV Infections,Drug: TMC-114,,"Tibotec Pharmaceuticals, Ireland",All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,CR006304|TMC114-C226,null,null,null,28-Oct-05,null,11-Apr-14,"Anniston, Alabama, United States|Birmingham, Alabama, United States|Mesa, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Bakersfield, California, United States|Baldwin Park, California, United States|Beverly Hills, California, United States|Carmichael, California, United States|Fontana, California, United States|Fountain Valley, California, United States|French Camp, California, United States|Glendale, California, United States|Harbor City, California, United States|Hayward, California, United States|Loma Linda, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Angles, California, United States|Newport Beach, California, United States|Oakland, California, United States|Palm Springs, California, United States|Palo Alto, California, United States|Panorama City, California, United States|Paramount, California, United States|Richmond, California, United States|Salinas, California, United States|San Diego, La Jolla, California, United States|San Diego, California, United States|San Francisco, California, United States|San Mateo, California, United States|San Rafael, California, United States|Santa Ana, California, United States|Santa Clara, California, United States|Santa Clarita, California, United States|Santa Rosa, California, United States|Stanford, California, United States|Sunnyvale, California, United States|Tarzana, California, United States|Ukiah, California, United States|West Hollywood, California, United States|Woodland Hills, California, United States|Denver, Colorado, United States|Glastonbury, Connecticut, United States|Hartford, Connecticut, United States|New Haven, Connecticut, United States|Norwalk, Connecticut, United States|Norwich, Connecticut, United States|Stanford, Connecticut, United States|Vernon Rockville, Connecticut, United States|Washington, District of Columbia, United States|Boynton Beach, Florida, United States|Brandon, Florida, United States|Fort Lauderdale, Florida, United States|Fort Laudersale, Florida, United States|Fort Myers, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Labelle, Florida, United States|Melbourne, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|N Miami Beach, Florida, United States|North Palm Beach, Florida, United States|Orlando, Florida, United States|Plantation, Florida, United States|Port St Lucie, Florida, United States|Safety Harbor, Florida, United States|Sarasota, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|West Palm Beach, Florida, United States|Winter Park, Florida, United States|Atlanta, Georgia, United States|Augusta, Georgia, United States|Austell, Georgia, United States|Decatur, Georgia, United States|Jessup, Georgia, United States|Macon, Georgia, United States|Marietta, Georgia, United States|Riverdale, Georgia, United States|Tucker, Georgia, United States|Honolulu, Hawaii, United States|Kahului, Hawaii, United States|Kapaa, Hawaii, United States|Boise, Idaho, United States|Chicago, Illinois, United States|Decatur, Illinois, United States|Granite City, Illinois, United States|Joliet, Illinois, United States|Rockford, Illinois, United States|Round Lake Beach, Illinois, United States|Springfield, Illinois, United States|Topeka, Kansas, United States|Henderson, Kentucky, United States|Paducah, Kentucky, United States|New Orleans, Louisiana, United States|Bangor, Maine, United States|Lewiston, Maine, United States|Monmouth, Maine, United States|Portland, Maine, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Elkton, Maryland, United States|Silver Spring, Maryland, United States|Boston, Massachusetts, United States|Cambridge, Massachusetts, United States|Springfield, Massachusetts, United States|Berkley, Michigan, United States|Detroit, Michigan, United States|Grosse Pointe Woods, Michigan, United States|Marquette, Michigan, United States|Minneapolis, Minnesota, United States|Greenwood, Mississippi, United States|Columbia, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|East Orange, New Jersey, United States|Galloway, New Jersey, United States|Hackensack, New Jersey, United States|Hamilton, New Jersey, United States|Hoboken, New Jersey, United States|Jersey City, New Jersey, United States|Long Branch, New Jersey, United States|Maplewood, New Jersey, United States|Neptune, New Jersey, United States|Newark, New Jersey, United States|Perth Amboy, New Jersey, United States|Somers Point, New Jersey, United States|Voorhees, New Jersey, United States|West Orange, New Jersey, United States|Westfield, New Jersey, United States|Albuquerque, New Mexico, United States|Albany, New York, United States|Briarcliff, New York, United States|Bronxville, New York, United States|Bronx, New York, United States|Brooklyn, New York, United States|Flushing, New York, United States|Harris, New York, United States|Manhasset, New York, United States|Mt. Vernon, New York, United States|New York, New York, United States|Rochester, New York, United States|Syracuse, New York, United States|Valhalla, New York, United States|Yonkers, New York, United States|Asheville, North Carolina, United States|Chapel Hill, North Carolina, United States|Greensboro, North Carolina, United States|Greenville, North Carolina, United States|Huntersville, North Carolina, United States|Wilmington, North Carolina, United States|Winston Salem, North Carolina, United States|Winston-Salem, North Carolina, United States|Akron, Ohio, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Dayton, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Allentown, Pennsylvania, United States|Easton, Pennsylvania, United States|Hershey, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Reading, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|West Columbia, South Carolina, United States|Hermitage, Tennessee, United States|Johnson City, Tennessee, United States|Knoxville, Tennessee, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Bryan, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Fort Worth, Texas, United States|Galveston, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|Lackland, Texas, United States|Longview, Texas, United States|San Antonio, Texas, United States|Annandale, Virginia, United States|Charlottesville, Virginia, United States|Fairfax, Virginia, United States|Hampton, Virginia, United States|Newport News, Virginia, United States|Norfolk, Virginia, United States|Portsmouth, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Eau Claire, Wisconsin, United States|Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Antwerpen, Belgium|Brugge, Belgium|Brussels, Belgium|Bruxelles, Belgium|Charleroi, Belgium|Gent, Belgium|Leuven, Belgium|Liège, Belgium|Yvoir, Belgium|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Vancouver, British Columbia, Canada|Winnipeg, Manitoba, Canada|Moncton, New Brunswick, Canada|Halifax, Nova Scotia, Canada|Hamilton, Ontario, Canada|Kingston, Ontario, Canada|London, Ontario, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Whitby, Ontario, Canada|Windsor, Ontario, Canada|Montreal, Quebec, Canada|Rouyn-Noranda, Quebec, Canada|Ste-Foy, Quebec, Canada|Vancouver British, Canada|Vancouver, Canada|Prague, Czech Republic|Aalborg, Denmark|Aarhus, Denmark|Copenhagen, Denmark|Hvidovre N/A, Denmark|Odense N/A, Denmark|Aachen, Germany|Berlin, Germany|Bochum, Germany|Bonn, Germany|Bremen, Germany|Chemnitz, Germany|Dortmund, Germany|Dresden, Germany|Duesseldorf, Germany|Düsseldorf, Germany|Erlangen, Germany|Essen, Germany|Frankfurt, Germany|Freiburg, Germany|Gießen, Germany|Hamburg, Germany|Hannover, Germany|Kiel, Germany|Koblenz, Germany|Konstanz, Germany|Köln, Germany|Kÿln, Germany|Leipzig, Germany|Mainz, Germany|Mannheim, Germany|Munich, Germany|München, Germany|Münster, Germany|Nürnberg, Germany|Osnabrück, Germany|Regensburg, Germany|Saarbrücken, Germany|Salzgitter, Germany|Stuttgart, Germany|Wuppertal, Germany|Würzburg, Germany|Athens, Greece|Piraeus, Greece|Thessalonikis, Greece|Budapest, Hungary|Luxembourg, Luxembourg|Ipoh, Malaysia|Kuala Lumpur, Malaysia|Pulau Pinang, Malaysia|Ciudad De Mexico, Mexico|Col Tacuba, Mexico|Guadalajara, Mexico|Mex Ctity, Mexico|Mexico, Mexico|Monterrey Nuevo León, Mexico|Oaxaca, Mexico|Puebla, Mexico|Veracruz, Mexico|Alkmaar, Netherlands|Amsterdam, Netherlands|Arnhem, Netherlands|Den Haag, Netherlands|Eindhoven, Netherlands|Enschede, Netherlands|Groningen, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Rotterdam, Netherlands|Tilburg, Netherlands|Ponce Pr, Puerto Rico|Rio Piedras Pr, Puerto Rico|San Juan, Puerto Rico|Ekaterinbourg, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Moscow N/A, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk Region, Russian Federation|Rostov-Na-Donu, Russian Federation|Saint-Petersburg, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|Tver, Russian Federation|Volgograd, Russian Federation|Voronezh, Russian Federation|Ljubljana, Slovenia|Alicante, Spain|Badajoz, Spain|Barakaldo Vizcaya S/N, Spain|Barcelona N/A, Spain|Barcelona, Spain|Bilbao, Spain|Caceres N/A, Spain|Calella (Barcelona), Spain|Castellon, Spain|Cordoba, Spain|Cuenca, Spain|Donostia Guipuzcoa, Spain|El Palmar Murcia N/A, Spain|Elche, Spain|Figueres, Spain|Fuenlabrada, Spain|Gijon Asturias, Spain|Girona, Spain|Granada, Spain|Guadalajara, Spain|Huelva N/A, Spain|Huelva, Spain|Huesca, Spain|Ibiza, Spain|Jérez, Spain|La Coruna, Spain|La Laguna, Spain|Las Palmas De Gran Canaria, Spain|Leon N/A, Spain|Lleida, Spain|Logrono, Spain|Madrid N/A, Spain|Madrid, Spain|Mahon Menorca, Spain|Malaga N/A, Spain|Malaga, Spain|Manresa, Spain|Murcia N/A, Spain|Murcia, Spain|Oviedo, Spain|Palma De Mallorca Illes Balear, Spain|Palma De Mallorca, Spain|Pamplona N/A, Spain|Puerto Real, Spain|Sabadell, Spain|Salamanca, Spain|Santander N/A, Spain|Santiago De Compostela, Spain|Sevilla N/A, Spain|Sevilla, Spain|Sta Cruz De Tenerife, Spain|Tarragona N/A, Spain|Tarragona, Spain|Terrassa, Spain|Valencia N/A, Spain|Valencia, Spain|Valladolid, Spain|Vic, Spain|Vigo, Spain|Villafranca Del Penedes, Spain|Vitoria-Gasteiz, Spain|Vizcaya N/A, Spain|Zamora N/A, Spain|Zaragoza, Spain|Göteborg N/A, Sweden|Göteborg, Sweden|Linköping, Sweden|Malmö, Sweden|Stockholm, Sweden|Uppsala, Sweden|Aarau, Switzerland|Basel, Switzerland|Bern, Switzerland|Bruderholz, Switzerland|Chur, Switzerland|Genève, Switzerland|Lausanne, Switzerland|Lugano N/A, Switzerland|St Gallen, Switzerland|Zurich N/A, Switzerland|Zurich Zh, Switzerland|Kaohsiung County, Taiwan|Kaohsiung, Taiwan|Taipei, Taiwan|Tao-Yuan, Taiwan|Bangkok, Thailand|Ankara, Turkey|Istanbul, Turkey|Caracas, Venezuela",,https://ClinicalTrials.gov/show/NCT00245739
275,NCT00244686,This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic,,Available,No Results Available,Hypereosinophilic Syndrome,Drug: Mepolizumab,,GlaxoSmithKline,All,"Child, Adult, Older Adult",,null,Industry,"Expanded Access:Individual Patients""",,MHE104317,null,null,null,27-Oct-05,null,13-Apr-18,"GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Anchorage, Alaska, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Port Saint Lucie, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Weston, Florida, United States|GSK Investigational Site, Athens, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Ames, Iowa, United States|GSK Investigational Site, Waterloo, Iowa, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Peabody, Massachusetts, United States|GSK Investigational Site, Grand Rapids, Michigan, United States|GSK Investigational Site, Southfield, Michigan, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Chesterfield, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Missoula, Montana, United States|GSK Investigational Site, Englewood, New Jersey, United States|GSK Investigational Site, Hackensack, New Jersey, United States|GSK Investigational Site, Ocean City, New Jersey, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, New Hyde Park, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Staten Island, New York, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Fargo, North Dakota, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Mayfield Heights, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Weatherford, Oklahoma, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Danville, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Lebanon, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Provo, Utah, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Burlington, Vermont, United States|GSK Investigational Site, Burlington, Vermont, United States|GSK Investigational Site, Colchester, Vermont, United States|GSK Investigational Site, Fairfax, Virginia, United States|GSK Investigational Site, Harrisonburg, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Charleston, West Virginia, United States|GSK Investigational Site, La Crosse, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Onalaska, Wisconsin, United States|GSK Investigational Site, Garran, Australian Capital Territory, Australia|GSK Investigational Site, Liverpool, New South Wales, Australia|GSK Investigational Site, Sydney, New South Wales, Australia|GSK Investigational Site, Tamworth, New South Wales, Australia|GSK Investigational Site, Westmead, New South Wales, Australia|GSK Investigational Site, Townsville, Queensland, Australia|GSK Investigational Site, Melbourne, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, West Perth, Western Australia, Australia|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Aurillac Cedex, France|GSK Investigational Site, Bastia Cedex, France|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Dijon, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Marseille cedex 20, France|GSK Investigational Site, Montpellier, France|GSK Investigational Site, Nice, France|GSK Investigational Site, Nîmes, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Pierre Benite, France|GSK Investigational Site, Saint-Etienne, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Suresnes, France|GSK Investigational Site, Toulouse Cedex 9, France|GSK Investigational Site, Kirchentellinsfurt, Baden-Wuerttemberg, Germany|GSK Investigational Site, Augsburg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Bad Bramstedt, Schleswig-Holstein, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Bremen, Germany|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Verona, Veneto, Italy|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Tromsø, Norway|GSK Investigational Site, Porto, Portugal|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Zurich, Switzerland|GSK Investigational Site, Zürich, Switzerland|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Sunderland, Tyne & Wear, United Kingdom|GSK Investigational Site, Abergavenny, Manmouthshire, United Kingdom|GSK Investigational Site, Aylesbury, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Cardiff, United Kingdom|GSK Investigational Site, Leicester, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle Upon Tyne, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",,https://ClinicalTrials.gov/show/NCT00244686
276,NCT00130897,Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma,,Approved for marketing,No Results Available,"Carcinoma, Renal Cell",Drug: Sutent,,Pfizer,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,A6181037,Jul-05,Nov-11,Nov-11,16-Aug-05,null,9-Mar-12,"Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Norwalk, Connecticut, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Maywood, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Council Bluffs, Iowa, United States|Pfizer Investigational Site, Covington, Louisiana, United States|Pfizer Investigational Site, Gretna, Louisiana, United States|Pfizer Investigational Site, Marrero, Louisiana, United States|Pfizer Investigational Site, Metairie, Louisiana, United States|Pfizer Investigational Site, Metairie, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Southaven, Mississippi, United States|Pfizer Investigational Site, Tupelo, Mississippi, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Norman, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Hershey, Pennsylvania, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Randwick, New South Wales, Australia|Pfizer Investigational Site, St Leonards, New South Wales, Australia|Pfizer Investigational Site, Westmead, New South Wales, Australia|Pfizer Investigational Site, South Brisbane, Queensland, Australia|Pfizer Investigational Site, Elizabeth Vale, South Australia, Australia|Pfizer Investigational Site, Woodville South, South Australia, Australia|Pfizer Investigational Site, East Melbourne, Victoria, Australia|Pfizer Investigational Site, Heidelburg, Victoria, Australia|Pfizer Investigational Site, Perth, Western Australia, Australia|Pfizer Investigational Site, Innsbruck, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Sarajevo, Bosnia and Herzegovina|Pfizer Investigational Site, Salvador, BA, Brazil|Pfizer Investigational Site, Belo Horizonte, MG, Brazil|Pfizer Investigational Site, Porto Alegre, Rio Grande do Sul, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Jau, SP, Brazil|Pfizer Investigational Site, Jaú, SP, Brazil|Pfizer Investigational Site, Jaú, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Winnnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Bogotá, Cundinamarca, Colombia|Pfizer Investigational Site, Cali, Colombia|Pfizer Investigational Site, Rijeka, Croatia|Pfizer Investigational Site, Split, Croatia|Pfizer Investigational Site, Brno, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Cairo, Egypt|Pfizer Investigational Site, Giza, Egypt|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, Lyon, Cedex 08, France|Pfizer Investigational Site, Saint Herblain, Cedex, France|Pfizer Investigational Site, Strasbourg, Cedex, France|Pfizer Investigational Site, Bordeaux, France|Pfizer Investigational Site, Clermont Ferand, France|Pfizer Investigational Site, Marseille Cedex 9, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Montpellier, France|Pfizer Investigational Site, Paris Cedex 13, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Reims, France|Pfizer Investigational Site, Rennes, France|Pfizer Investigational Site, Tours, France|Pfizer Investigational Site, Vandoeuvre les Nancy, France|Pfizer Investigational Site, Aachen, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Essen, Germany|Pfizer Investigational Site, Frankfurt, Germany|Pfizer Investigational Site, Freiburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hannover, Germany|Pfizer Investigational Site, Homburg/Saar, Germany|Pfizer Investigational Site, Jena, Germany|Pfizer Investigational Site, Kassel, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Rostock, Germany|Pfizer Investigational Site, Ulm, Germany|Pfizer Investigational Site, Athens, Attiki, Greece|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Patras, Greece|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Hong Hong, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, New Delhi, Delhi, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Parel, Mumbai, India|Pfizer Investigational Site, Jaipur, Rajasthan, India|Pfizer Investigational Site, New Delhi, India|Pfizer Investigational Site, Dublin 24, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Jerusalem, Israel|Pfizer Investigational Site, Tel Hashomer, Israel|Pfizer Investigational Site, Bergamo, Italy|Pfizer Investigational Site, Brescia, Italy|Pfizer Investigational Site, Cattolica (RN), Italy|Pfizer Investigational Site, Cuneo, Italy|Pfizer Investigational Site, Legnago, VR, Italy|Pfizer Investigational Site, Modena, Italy|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Padova, Italy|Pfizer Investigational Site, Parma, Italy|Pfizer Investigational Site, Pavia, Italy|Pfizer Investigational Site, Perugia, Italy|Pfizer Investigational Site, Pordenone, Italy|Pfizer Investigational Site, Rimini, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Beirut, Lebanon|Pfizer Investigational Site, Petaling Jaya, Selangor, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Toluca, Estado de Mexico, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Merida, Yucatan, Mexico|Pfizer Investigational Site, Chihuahua, Mexico|Pfizer Investigational Site, Puebla, Mexico|Pfizer Investigational Site, Groningen, GR, Netherlands|Pfizer Investigational Site, Amsterdam, NH, Netherlands|Pfizer Investigational Site, Amsterdam, Netherlands|Pfizer Investigational Site, Rotterdam, Netherlands|Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Panama, Panama|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Gdansk, Poland|Pfizer Investigational Site, Lodz, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Cluj-Napoca, Romania|Pfizer Investigational Site, Obninsk, Kaluga region, Russian Federation|Pfizer Investigational Site, Chelyabinsk, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Zilina, Slovakia|Pfizer Investigational Site, Ljubljana, Slovenia|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, L'hospitalet Del Llobregat, Barcelona, Spain|Pfizer Investigational Site, Pamplona, Navarra, Spain|Pfizer Investigational Site, Baracaldo, Vizcaya, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, La Coruña, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Salamanca, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Göteborg, Sweden|Pfizer Investigational Site, Lund, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Umeå, Sweden|Pfizer Investigational Site, Basel, Switzerland|Pfizer Investigational Site, Bellinzona, Switzerland|Pfizer Investigational Site, Bern, Switzerland|Pfizer Investigational Site, Biel, Switzerland|Pfizer Investigational Site, CH-4058 Basel, Switzerland|Pfizer Investigational Site, CH-4101 Bruderholz, Switzerland|Pfizer Investigational Site, CH-4410 Liesthal, Switzerland|Pfizer Investigational Site, Chur, Switzerland|Pfizer Investigational Site, Genève 14, Switzerland|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taoyun, Taiwan|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Istanbul, Capa, Turkey|Pfizer Investigational Site, Istanbul, Cerrahpasa, Turkey|Pfizer Investigational Site, Whitchurch, Cardiff, United Kingdom|Pfizer Investigational Site, London, Se1 9rt, United Kingdom|Pfizer Investigational Site, Sutton, Surrey, United Kingdom|Pfizer Investigational Site, Leeds, West Yorkshire, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Bristol, United Kingdom|Pfizer Investigational Site, Cottingham, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site, Guildford, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Northwood, United Kingdom|Pfizer Investigational Site, Nottingham, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom|Pfizer Investigational Site, Swansea, United Kingdom|Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela|Pfizer Investigational Site, Caracas, Estado Miranda, Venezuela",,https://ClinicalTrials.gov/show/NCT00130897
277,NCT00097799,Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection,,Approved for marketing,No Results Available,HIV Infections,Drug: Tipranavir|Drug: Ritonavir,,Boehringer Ingelheim,null,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,1182.7,Dec-04,Aug-05,null,1-Dec-04,null,30-Nov-16,"1182.70.127 Health Services Center, Inc., Anniston, Alabama, United States|1182.70.006 Spectrum Medical Group, Phoenix, Arizona, United States|1182.70.016 Health for Life Clinic, Little Rock, Arkansas, United States|1182.70.065, Anaheim, California, United States|1182.70.246, Baldwin Park, California, United States|1182.70.043, Fountain Valley, California, United States|1182.70.092, Fresno, California, United States|1182.70.057, Glendale, California, United States|1182.70.064, Harbor City, California, United States|1182.70.079, Long Beach, California, United States|1182.70.015, Los Angeles, California, United States|1182.70.053, Los Angeles, California, United States|1182.70.066, Los Angeles, California, United States|1182.70.071, Los Angeles, California, United States|1182.70.137, Los Angeles, California, United States|1182.70.198, Los Angeles, California, United States|1182.70.008, Newport Beach, California, United States|1182.70.081, Oakland, California, United States|1182.70.095, Oakland, California, United States|1182.70.067, Panorama City, California, United States|1182.70.033, San Diego, California, United States|1182.70.014, San Francisco, California, United States|1182.70.020, San Francisco, California, United States|1182.70.048, San Francisco, California, United States|1182.70.085, San Francisco, California, United States|1182.70.214, San Francisco, California, United States|1182.70.022, San Rafael, California, United States|1182.70.222, Stanford, California, United States|1182.70.005, Tarzana, California, United States|1182.70.030, Tarzana, California, United States|1182.70.068, Woodland Hills, California, United States|1182.70.218 Denver Infectious Disease Consultants, Denver, Colorado, United States|1182.70.281, Denver, Colorado, United States|1182.70.074, New Haven, Connecticut, United States|1182.70.073, Norwich, Connecticut, United States|1182.70.032, Washington, District of Columbia, United States|1182.70.042, Washington, District of Columbia, United States|1182.70.289 Dupont Circle Physicians Group, Washington, District of Columbia, United States|1182.70.003, Fort Lauderdale, Florida, United States|1182.70.013, Fort Lauderdale, Florida, United States|1182.70.049, Fort Lauderdale, Florida, United States|1182.70.096, Fort Lauderdale, Florida, United States|1182.70.045, Fort Myers, Florida, United States|1182.70.026, Hollywood, Florida, United States|1182.70.023, Miami, Florida, United States|1182.70.040, North Palm Beach, Florida, United States|1182.70.007, Orlando, Florida, United States|1182.70.117, Plantation, Florida, United States|1182.70.017, Pompano Beach, Florida, United States|1182.70.047, West Palm Beach, Florida, United States|1182.70.002, Atlanta, Georgia, United States|1182.70.046, Atlanta, Georgia, United States|1182.70.069, Atlanta, Georgia, United States|1182.70.037, Dactur, Georgia, United States|1182.70.058, Jesup, Georgia, United States|1182.70.174, Macon, Georgia, United States|1182.70.019, Chicago, Illinois, United States|1182.70.029 Dr. David Moore, Chicago, Illinois, United States|1182.70.194, Chicago, Illinois, United States|1182.70.010, Joliet, Illinois, United States|1182.70.167, Indianapolis, Indiana, United States|1182.70.192, Iowa City, Iowa, United States|1182.70.099, New Orleans, Louisiana, United States|1182.70.025 Chase Brexton Health Services, Inc, Baltimore, Maryland, United States|1182.70.082, Boston, Massachusetts, United States|1182.70.090, Boston, Massachusetts, United States|1182.70.004, Berkley, Michigan, United States|1182.70.084, Detroit, Michigan, United States|1182.70.035, St. Louis, Missouri, United States|1182.70.242, St. Louis, Missouri, United States|1182.70.093, Lincoln, Nebraska, United States|1182.70.021, Las Vegas, Nevada, United States|1182.70.288 Hackensack University Medical Center, Hackensack, New Jersey, United States|1182.70.075, Sommers Point, New Jersey, United States|1182.70.024, Briarcliff Manor, New York, United States|1182.70.105, Bronk, New York, United States|1182.70.250 Montefiore Medical Center, Bronx, New York, United States|1182.70.039, Kingston, New York, United States|1182.70.028, New York, New York, United States|1182.70.031, New York, New York, United States|1182.70.036, New York, New York, United States|1182.70.050, New York, New York, United States|1182.70.062, New York, New York, United States|1182.70.104, New York, New York, United States|1182.70.086 Boehringer Ingelheim Investigational Site, Rochester, New York, United States|1182.70.061, Asheville, North Carolina, United States|1182.70.100, Chapel Hill, North Carolina, United States|1182.70.136 Mecklenburg Medical Group, P.A., Charlotte, North Carolina, United States|1182.70.103, Durham, North Carolina, United States|1182.70.241 University of CIncinnati Medical Center, Cincinnati, Ohio, United States|1182.70.044, Portland, Oregon, United States|1182.70.059 Fanno Creek Clinic, Portland, Oregon, United States|1182.70.077 Kaiser Permanente-IDC, Portland, Oregon, United States|1182.70.051, Philadelphia, Pennsylvania, United States|1182.70.080, Philadelphia, Pennsylvania, United States|1182.70.072, Providence, Rhode Island, United States|1182.70.126, Charleston, South Carolina, United States|1182.70.271, Charleston, South Carolina, United States|1182.70.088, Columbia, South Carolina, United States|1182.70.165 Comprehensive Care Center, Nashville, Tennessee, United States|1182.70.018, Austin, Texas, United States|1182.70.038, Dallas, Texas, United States|1182.70.041, Dallas, Texas, United States|1182.70.055, Dallas, Texas, United States|1182.70.070, Dallas, Texas, United States|1182.70.060, El Paso, Texas, United States|1182.70.052, Houston, Texas, United States|1182.70.054, Houston, Texas, United States|1182.70.285, Houston, Texas, United States|1182.70.128 Olmos Park Medical Associates, San Antonio, Texas, United States|1182.70.011, Annadale, Virginia, United States|1182.70.217, Richmond, Virginia, United States|1182.70.097, Seattle, Washington, United States|1182.70.76, Seattle, Washington, United States|1182.70.083, Spokane, Washington, United States",,https://ClinicalTrials.gov/show/NCT00097799
278,NCT00094029,A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248,,Approved for marketing,No Results Available,Gastrointestinal Neoplasm,Drug: Sutent,,Pfizer,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,A6181036,Sep-04,Oct-11,Oct-11,11-Oct-04,null,9-Mar-12,"Pfizer Investigational Site, Duarte, California, United States|Pfizer Investigational Site, Pasadena, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Santa Monica, California, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Gainsville, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Niles, Illinois, United States|Pfizer Investigational Site, Park Ridge, Illinois, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, New Bedford, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Farmington Hills, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Rochester, Minnesota, United States|Pfizer Investigational Site, Creve Coeur, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Burnos Aires, Argentina|Pfizer Investigational Site, Camperdown, New South Wales, Australia|Pfizer Investigational Site, Randwick, New South Wales, Australia|Pfizer Investigational Site, Auchenflower, Queensland, Australia|Pfizer Investigational Site, Bedford Park, South Australia, Australia|Pfizer Investigational Site, East Melbourne, Victoria, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Ashford SA, Australia|Pfizer Investigational Site, Auchenflower QLD, Australia|Pfizer Investigational Site, Graz, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Brno, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Aarhus C, Denmark|Pfizer Investigational Site, Herlev, Denmark|Pfizer Investigational Site, Helsinki, Finland|Pfizer Investigational Site, Bordeaux Cedex, France|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Duesseldorf, Germany|Pfizer Investigational Site, Koeln, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Happy Valley, Hong Kong|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, New Delhi, Delhi, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Vellore, Tamil Nadu, India|Pfizer Investigational Site, Tel Hashomer, Israel|Pfizer Investigational Site, Tel-Aviv, Israel|Pfizer Investigational Site, Aviano (PN), Italy|Pfizer Investigational Site, Aviano, PN, Italy|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Candiolo (TO), Italy|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Groningen, Gr, Netherlands|Pfizer Investigational Site, Leiden, Netherlands|Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, L'Hospitalet de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Göteborg, Sweden|Pfizer Investigational Site, Lausanne, Switzerland|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Ratchatawi, Bangkok, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Inciralti / IZMIR, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Leeds, England, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Newcastle upon Tyne, United Kingdom|Pfizer Investigational Site, Newcastle-Upon-Tyne, United Kingdom|Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela",,https://ClinicalTrials.gov/show/NCT00094029
279,NCT00074919,Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Infantile-onset Pompe Disease,,Approved for marketing,No Results Available,Glycogen Storage Disease Type II|Glycogenosis 2,Biological: alglucosidase alfa,,"Genzyme, a Sanofi Company|Sanofi",All,"Child, Adult, Older Adult",,null,Industry,Expanded Access,,AGLU02203,Dec-03,Feb-07,Feb-07,25-Dec-03,null,5-Feb-14,,,https://ClinicalTrials.gov/show/NCT00074919
280,NCT00062660,"Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection",,Approved for marketing,No Results Available,HIV Infections,Drug: Tipranavir,,Boehringer Ingelheim,All,"2 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,1182.58,May-03,Apr-14,Apr-14,12-Jun-03,null,30-Nov-16,"1182.58.31, Scottsdale, Arizona, United States|1182.58.29, Los Angeles, California, United States|1182.58.34 Campus Code 696446, Los Angeles, California, United States|1182.58.42 Synergy Hematology/Oncology, Los Angeles, California, United States|1182.58.43, Los Angeles, California, United States|1182.58.03, San Francisco, California, United States|1182.58.33 Kaiser Permanente Medical Center, Clinical Trials Unit, San Francisco, California, United States|1182.58.37 AIDS Health Care Foundation, Los Angeles, Connecticut, United States|1182.58.41 Circle Medical, LLC, Norwalk, Connecticut, United States|1182.58.28, Washington, District of Columbia, United States|1182.58.38, Miami Beach, Florida, United States|1182.58.40 Drs. Raben and Feldman Research Associates, South Miami, Florida, United States|1182.58.23 Hillsborough County Health Department, Tampa, Florida, United States|1182.58.36 Suite 525, Atlanta, Georgia, United States|1182.58.08, Honolulu, Hawaii, United States|1182.58.22, Chicago, Illinois, United States|1182.58.32, New Orleans, Louisiana, United States|1182.58.15, Boston, Massachusetts, United States|1182.58.19 Henry Ford Hospital, Detroit, Michigan, United States|1182.58.04 Kansas City Free Health Clinic, Kansas City, Missouri, United States|1182.58.25 Wohl Clinic, St. Louis, Missouri, United States|1182.58.02 Wellness Center, Las Vegas, Nevada, United States|1182.58.09 Polari Medical Group, New York, New York, United States|1182.58.30, Chapel Hill, North Carolina, United States|1182.58.06 University of Cincinnati Medical Center, Infectious diseases, Cincinnati, Ohio, United States|1182.58.35, Portland, Oregon, United States|1182.58.14, Philadelphia, Pennsylvania, United States|1182.58.20 University of Pittsburgh, Pittsburgh, Pennsylvania, United States|1182.58.01 Boehringer Ingelheim Investigational Site, Columbia, South Carolina, United States|1182.58.10 Comprehensive Care Center, Nashville, Tennessee, United States|1182.58.18 University of Texas Southwest Medical Center at Dallas, Dallas, Texas, United States|1182.58.07, Houston, Texas, United States|1182.58.039 Olmos Park Medical Associates, San Antonio, Texas, United States|1182.58.11 Swedish Medical Center, Seattle, Washington, United States|1182.58.44 VW Hospital and Clinics, Madison, Wisconsin, United States|1182.58.61005 Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|1182.58.61008 St Vincents Hospital, Darlinghurst, New South Wales, Australia|1182.58.61011 St Vincents Hospital, Darlinghurst, New South Wales, Australia|1182.58.61014 St Vincents Hospital, Darlinghurst, New South Wales, Australia|1182.58.61007 407 Doctors Pty Ltd, Darlinghusrst, New South Wales, Australia|1182.58.61019 407 Bouke Street, Darlinghusrst, New South Wales, Australia|1182.58.61022 Sexual Health Clinic, Kingswood, New South Wales, Australia|1182.58.61012 Bigge Park Centre, Liverpool, New South Wales, Australia|1182.58.61003 The Prince of Wales Hospital, Randwick, New South Wales, Australia|1182.58.61002 Royal North Shore Hospital, St Leonards, New South Wales, Australia|1182.58.61006 Albion Street Clinic, Surry Hills, New South Wales, Australia|1182.58.61025 Immunology Department, Westmead, New South Wales, Australia|1182.58.61010 Biala Building, Brisbane, Queensland, Australia|1182.58.61009 Level 6, Herston, Queensland, Australia|1182.58.61024, Nambour, Queensland, Australia|1182.58.61016 Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|1182.58.61020, Adelaide, South Australia, Australia|1182.58.61015 Flinders Medical Centre, Bedford Park, South Australia, Australia|1182.58.61001 88 Rathdowne Street Carlton, Carlton, Victoria, Australia|1182.58.61018 Melbourne Sexual Health Clinic, Carlton, Victoria, Australia|1182.58.61017 Department of Infectious Diseases, Clayton, Victoria, Australia|1182.58.61013 Melbourne Sexual Health Clinic, Melbourne, Victoria, Australia|1182.58.61023, Melbourne, Victoria, Australia|1182.58.61021, South Yarra, Victoria, Australia|1182.58.61004 Royal Perth Hospital, Perth, Western Australia, Australia|1182.58.3201 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium|1182.58.3202 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1182.58.3203 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|1182.58.3204 Boehringer Ingelheim Investigational Site, Liège, Belgium|1182.58.4505 Aarhus Universitetshospital Skejby, Aarhus C, Denmark|1182.58.4501 Rigshospitalet, København Ø, Denmark|1182.58.4504 Odense Universitetshospital, Odense C, Denmark|1182.58.33029 Hôpital Aix, Aix en Provence cedex 1, France|1182.58.33001 Hôpital Saint Jacques, Besançon cedex, France|1182.58.33022 Hôpital Avicenne, Bobigny cedex, France|1182.58.33020 Hôpital Antoine Beclère, Clamart cedex, France|1182.58.33028 Hôpital Louis Mourier, Colombes, France|1182.58.33027 Hôpital, Dijon cedex, France|1182.58.33034 Hôpital Raymond Poincarré, Garches, France|1182.58.33006 Hôpital Bicêtre, Le Kremlin Bicêtre cedex, France|1182.58.33019 Hôpital de l'Hôtel Dieu, Lyon cedex 2, France|1182.58.33031 Hôpital edouard Herriot, Lyon cedex 3, France|1182.58.33009 Hôpital de la Conception, Marseille cedex 5, France|1182.58.33023 Hôpital Sainte Marguerite, Marseille cedex 9, France|1182.58.33030 Hôpital Saint Eloi, Montpellier, France|1182.58.33032 Hôpital Emile Muller, Mulhouse cedex 1, France|1182.58.33008 Hôpital Hôtel Dieu, Nantes cedex 1, France|1182.58.33003 Hôpital de l'Archet, Nice cedex 3, France|1182.58.33013 Hôpital Saint Louis, Paris cedex 10, France|1182.58.33014 Hôpital Cochin, Paris cedex 14, France|1182.58.33007 Hôpital Georges Pompidou, Paris cedex 15, France|1182.58.33005 Hôpital Bichat, Paris cedex 18, France|1182.58.33017 Hôpital Bichat Claude Bernard, Paris cedex 18, France|1182.58.33033 Hôpital Tenon, Paris cedex 20, France|1182.58.33018 Hôpital Saint Antoine, Paris, France|1182.58.33024 Hôpital Necker, Paris, France|1182.58.33035 Hôpital des Abîmes, Pointe A Pitre, France|1182.58.33012 Hôpital Robert Debré, Reims cedex, France|1182.58.33026 Hôpital Ponchaillou, Rennes cedex 9, France|1182.58.33015 Hôpital Civil, Strasbourg cedex, France|1182.58.33025 Hôpital Foch, Suresnes cedex, France|1182.58.33021 Hôpital Chalucet, Toulon cedex, France|1182.58.33002 Hôpital Purpan, Toulouse cedex 9, France|1182.58.33016, Tourcoing, France|1182.58.33010 Hôpital Brabois, Vandoeuvre Les Nancy, France|1182.58.33011 Hôpital Paul Brousse, Villejuif cedex, France|1182.58.3001, Athens, Greece|1182.58.44029 Our Lady For Sick Children, Dublin 12, Ireland|1182.58.44016 St James Hospital, Dept of Genito Urinary Medicine, Dublin, Ireland|1182.58.3903 Università di Brescia, Brescia, Italy|1182.58.3904 Ospedali Riuniti di Foggia, Foggia, Italy|1182.58.3901 Ospedale Luigi Sacco, Milano, Italy|1182.58.3902 Ospedale L. Sacco, Milano, Italy|1182.58.3907 Presidio Ospedaliero di Rimini, Rimini, Italy|1182.58.3905 Presidio Dalmati, S. Angelo Lodigiano (lo), Italy|1182.58.3906 Ospedale Infantile Regina Margherita, Torino, Italy|1182.58.3908 Centro Medicina Preventiva, Verona, Italy|1182.58.35102 Hospital Condes Castro Guimarães, Cascais, Portugal|1182.58.27095 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|1182.58.27098 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|1182.58.27099 Boehringer Ingelheim Investigational Site, Cape Town, South Africa|1182.58.27096 Boehringer Ingelheim Investigational Site, Durban, South Africa|1182.58.27097 Boehringer Ingelheim Investigational Site, Westville, Durban, South Africa|1182.58.4101 Boehringer Ingelheim Investigational Site, Basel, Switzerland|1182.58.4103 Boehringer Ingelheim Investigational Site, Bern, Switzerland|1182.58.4104 Boehringer Ingelheim Investigational Site, Genève, Switzerland|1182.58.4107 Boehringer Ingelheim Investigational Site, Genève, Switzerland|1182.58.4102 Boehringer Ingelheim Investigational Site, Zürich, Switzerland|1182.58.4105 Boehringer Ingelheim Investigational Site, Zürich, Switzerland|1182.58.44020 Beckenham Hospital, Beckenham, United Kingdom|1182.58.44004 Boehringer Ingelheim Investigational Site, Brighton, United Kingdom|1182.58.44002 Boehringer Ingelheim Investigational Site, Cardiff, United Kingdom|1182.58.44025 Boehringer Ingelheim Investigational Site, Chertsey, United Kingdom|1182.58.44019 Boehringer Ingelheim Investigational Site, Chichester, United Kingdom|1182.58.44009 Boehringer Ingelheim Investigational Site, Edinburgh, United Kingdom|1182.58.44023 Boehringer Ingelheim Investigational Site, Harrow, United Kingdom|1182.58.44024 Boehringer Ingelheim Investigational Site, Leeds, United Kingdom|1182.58.44003 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44005 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44008 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44010 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44014 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44017 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44018 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44026 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44027 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44028 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44031 Boehringer Ingelheim Investigational Site, London, United Kingdom|1182.58.44011 Boehringer Ingelheim Investigational Site, Peterborough, United Kingdom|1182.58.44022 Boehringer Ingelheim Investigational Site, Woolwich, United Kingdom|1182.58.44030 Boehringer Ingelheim Investigational Site, Woolwich, United Kingdom",,https://ClinicalTrials.gov/show/NCT00062660
281,NCT00042393,An Open-Label Program of Adefovir Dipivoxil in the Treatment of Patients With Lamivudine-Resistant Chronic Hepatitis B With Limited Treatment Options,,Approved for marketing,No Results Available,Chronic Hepatitis B,Drug: Adefovir Dipivoxil,,Gilead Sciences,All,"16 Years and older   (Child, Adult, Older Adult)",,null,Industry,Expanded Access,,GS-01-550,null,null,null,1-Aug-02,null,7-Jan-14,,,https://ClinicalTrials.gov/show/NCT00042393
282,NCT00040625,ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.,,Approved for marketing,No Results Available,Mesothelioma,Drug: Pemetrexed|Drug: Cisplatin,,Eli Lilly and Company,All,"18 Years and older   (Adult, Older Adult)",,null,Industry,Expanded Access,,6093|H3E-US-JMFE,null,null,null,4-Jul-02,null,15-Mar-07,"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Basking Ridge, New Jersey, United States|For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Porto Alegre, RS, Brazil|For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Sao Paulo, Brazil|""For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician."", Cairo, Egypt|For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Cairo, Egypt|For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician, Jeddah, Saudi Arabia",,https://ClinicalTrials.gov/show/NCT00040625
